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Sarcomas	are	rare	mesenchymal	tumors,	making	up	15%	of	all	childhood	and	1%	of	all	adult	
tumors.		They	account	for	a	disproportionate	share	of	mortality	in	young	adults,	and	if	left	
untreated,	are	highly	likely	to	metastasize.		However,	sarcoma	etiology	is	poorly	
understood,	and	having	numerous	histological	subtypes	has	complicated	elucidation.		To	
better	understand	factors	underlying	sarcomagenesis,	we	leveraged	two	rare	inherited	
cancer	predisposition	syndromes,	Li-Fraumeni	Syndrome	(LFS),	and	LFS-like	(LFSL),	both	
with	a	high	incidence	of	sarcomas.		LFS	is	caused	by	mutations	in	the	tumor	suppressor	gene	
TP53	(p53),	but	has	variable	and	incomplete	penetrance,	suggesting	additional	acquired	
somatic	mutations	are	necessary	for	tumorigenesis.		In	contrast,	LFSL	has	no	known	cause,	
although	a	10-Mb	region	in	1q23	has	been	mapped	by	linkage	analysis	as	a	putative	LFSL	
locus.		Therefore,	to	better	identify	genetic	variation	underlying	LFS	and	LFSL	we	utilized	a	
2-pronged	approach.		First,	we	evaluated	LFSL	families	for	rare,	co-segregating,	germline	
mutations,	which	identified	a	mutation	in	ARHGAP30	that	was	present	in	four	LFSL	families.		
Moreover,	this	mutation	impacted	both	proliferation	and	migration	when	overexpressed	in	
vitro.		Subsequent	analysis	of	publicly	available	data	indicates	a	potential	role	for	ARHGAP30	
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in	sporadic	cancers.		Secondly,	we	endeavored	to	identify	somatically	acquired	drivers	of	
sarcomagenesis.		In	cancer,	passenger	events	are	acquired	concomitantly	with	driver	
mutations,	and	distinguishing	them	remains	a	key	challenge.		To	best	address	this,	we	used	
a	comparative	genomics	approach,	leveraging	a	“humanized”	mouse	model	of	LFS	with	a	
hotspot	mutation,	Trp53R172H,	analogous	to	TP53R175H	in	humans.		Hypothesizing	that	
sarcoma	etiology	is	similar	in	humans	and	mice,	we	then	catalogued	recurrent	changes	in	
the	genome,	transcriptome,	and	methlyome.	We	found	little	overlap	in	any	of	the	omics	
approaches	across	the	human	tumors,	which	came	from	diverse	p53	mutations	and	
sarcoma	types,	but	found	strong	overlap	in	the	mouse	tumors	(fibrosarcomas	and	
osteosarcomas).		Recurrent	data	discovered	in	the	mouse	was	mirrored	in	some	human	
sporadic	mesenchymal	tumors,	including	novel	genes	like	MROH2A,	and	MIR219A2.		Our	
results	emphasize	the	utility	of	a	model	disorder	and	comparative	omics	to	uncover	genes	
with	relevance	for	both	inherited	and	sporadic	tumors.	
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1 Introduction	
1.1 Introduction	to	cancer	
Cancer	is	a	multifactorial	genetic	and	epigenetic	disease	characterized	by	abnormal,	
unchecked	 cell	 growth.	 	 Cells	 typically	 progress	 gradually	 through	 a	 series	 of	 steps,	 from	
hyperplasia,	to	dysplasia,	to	neoplasia,	and	sometimes	malignancy,	usually	driven	by	genetic	
changes,	 that	 disrupt	 core	 processes	 that	 normally	 help	 regulate	 cell	 growth.	 	 These	
processes	 have	 been	 categorized	 into	 ten	 distinct	 functions,	 known	 as	 “the	 Hallmarks	 of	
Cancer.”		Initially,	Hanahan	and	Weinberg	postulated	that	cancer	cells	might	have	additional	
capabilities	 across	 six	 different	 categories:	 sustained	 growth	 signaling,	 evasion	 of	 growth	
suppressors,	 resistance	 to	 cell	 death,	 induction	 of	 angiogenesis,	 enabling	 of	 replicative	
immortality,	and	activation	of	invasion	and	metastasis	(Figure	1)	(1).		
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Figure	1:	Hallmarks	of	Cancer.	 	Original	 six	 canonical	ways	 that	 cancer	 cells	have	added	
abilities	(2).		Used	with	permission:	Hanahan,	D.,	and	R.	A.	Weinberg.	2011.	Hallmarks	of	
cancer:	the	next	generation.	Cell	144:	646-674.	L/N	4294491470430.	
Subsequent	 research	 has	 strongly	 indicated	 two	 other	 hallmarks:	 deregulating	 cellular	
energetics,	 and	 avoiding	 immune	 destruction,	 and	 two	 enabling	 characteristics:	 genome	
instability	and	mutation,	and	tumor-prone	inflammation	(Figure	2)	(2).		
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Figure	2:	Hallmarks	of	Cancer,	updated.		In	2011,	the	hallmarks	were	updated	to	include	
two	new	emerging	hallmarks,	and	two	enabling	characteristics	(2).		Used	with	permission:	
Hanahan,	 D.,	 and	 R.	 A.	Weinberg.	 2011.	 Hallmarks	 of	 cancer:	 the	 next	 generation.	Cell	
144:	646-674.	L/N	4294491470430.	
These	 ideas	 provide	 a	 framework	 for	 understanding	 how	 tumors	might	 arise,	 and	 how	
they	differ	from	normal	cells.	
The	changes	necessary	 for	 tumorigenesis	 can	be	acquired	 in	a	 variety	of	ways.	 	 In	
cancer	 predisposition	 syndromes,	 germline	mutations	 can	 be	 inherited	 from	 the	 parents.	
Alternatively,	changes	in	the	genome	can	be	acquired	somatically,	either	from	errors	during	
cell	division,	or	from	exposure	to	environmental	mutagens	such	as	smoking	or	UV	rays.		For	
example,	 in	 microsatellite	 instability	 syndromes,	 such	 as	 Lynch	 Syndrome,	 during	
	 4	
replication,	defects	 in	mismatch	repair	genes	lead	to	DNA	polymerase	slippage,	frameshift	
mutations	and	non-functional	proteins	 (3).	However,	not	all	 such	changes	may	be	cancer-
causing;	some	alterations	that	are	acquired	may	instead	be	passengers,	with	limited	or	even	
no	 functional	 impact.	 	 Distinguishing	 cancer-causing	 driver	 mutations	 from	 passenger	
events	remains	a	key	challenge	in	understanding	cancer	etiology	(4).	
Beyond	 just	 looking	 for	 genetic	 changes	 in	 the	 genome,	we	 increasingly	 find	 that	
changes	in	the	transcriptome	and	epigenome	can	also	lead	to	disease,	including	cancer	(5-
7).	 	Moreover,	 this	makes	 integrative	 approaches	 that	 seek	 to	 completely	 profile	 tumors	
across	 the	 genome,	 transcriptome,	 and	 epigenome	 uniquely	 powerful	 to	 quantify,	 and	
evaluate	as	many	changes	as	possible	(7).	For	example,	pairing	whole	genome	sequencing	
(WGS)	and	profiling	by	RNA-seq	 in	breast	cancer	allows	scientists	 to	determine	 if	 somatic	
point	mutations	are	being	highly	expressed	(8).	Our	goal	is	to	identify	any	such	changes	that	
may	be	important	in	the	genesis	of	cancer,	and	in	sarcomas	in	particular,	in	the	hopes	that	
they	may	prove	useful	therapeutically.		
1.2 Introduction	to	Sarcomas	
Sarcomas	 are	 a	 relatively	 rare	 mesenchymal	 cancer,	 making	 up	 ~1%	 of	 all	 adult	
tumors	and	15%	of	all	childhood	tumors	(9-11).	They	are	most	often	found	in	the	arms	or	
legs	 (60%),	 and	 chest	 or	 abdomen	 (30%),	 but	 they	 can	 be	 either	 soft	 tissue	 or	 bone	
depending	on	the	location	(11).	
The	large	majority	of	soft	tissue	and	bone	sarcomas	do	not	have	a	known	causative	
factor.	 	 There	are	 some	 isolated	 reports	 that	 suggest	 that	 soft	 tissue	 sarcomas	may	arise	
near	 scar	 tissue,	or	at	 fracture	 sites,	or	 that	 sarcomas	of	 the	bone	may	be	more	 likely	 to	
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arise	from	bone	infarctions	or	radiation	injury,	but	these	appear	to	be	the	exception	rather	
than	the	norm.		The	foremost	known	causes	are	related	to	genetic	susceptibility	(which	still	
represent	a	relatively	small	number	of	tumors)	such	as	individuals	with	germline	TP53	(p53),	
RB1,	 or	 NF1	 mutations,	 but	 for	 the	 most	 part,	 the	 etiology	 of	 sarcomas,	 genetic	 or	
otherwise,	remains	a	relative	mystery	(11).	
1.2.1 Sarcomas	and	clinical	outcomes	
Treatment	for	patients	with	advanced-stage	sarcomas	has	not	changed	dramatically	
in	 the	 past	 30	 years	 (12).	 The	 primary	 options	 for	 treatment	 are	 surgery,	 radiation,	
chemotherapy,	 and	 targeted	 therapy.	 	 Surgery	 remains	 the	 most	 commonly	 accepted	
therapeutic	 option,	 but	 requires	 removal	 of	 healthy	 tissue	 with	margins	 as	 wide	 a	 1	 cm	
because	 even	 microscopically	 small	 portions	 have	 been	 associated	 with	 recurrence,	
metastasis	and	death	(11).	Under	ideal	conditions	with	low	grade	sarcomas,	and	removal	of	
all	 tumorigenic	 tissue,	 local	 control	 is	 about	 93%	 (9).	 Clinicians	 are	 still	 searching	 for	 a	
consensus	 as	 to	 the	 best	 chemotherapy	 and	 radiotherapy	 options	 (11),	 raising	 the	
possibility	 that	 better	 molecular	 profiling	 to	 inform	 treatment	 options	 could	 improve	
patient	outcomes.		
Without	 treatment,	 sarcomas	 are	 highly	 likely	 to	 metastasize	 and	 are	 considered	
highly	 aggressive,	 accounting	 for	 a	 disproportionate	 share	 of	 mortality	 in	 young	 adults.	
(SEER	 Cancer	 Statistics	 Review	 1975-2008;	
http://www.seer.cancer.gov/csr/1975_2008/)(11,	 13).	 	 In	 fact,	 the	mean	 age	 of	 onset	 for	
sarcomas,	 in	 part	 due	 to	 hereditary	 syndromes,	 is	 earlier	 than	 for	 many	 other	 types	 of	
cancer	(14).	Therefore,	identification	of	sarcoma-related	genes,	either	germline	variants,	or	
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acquired	 somatic	 variants,	 is	 considered	 vitally	 important	 for	 diagnostic	 testing	 to	 help	
identify	 at-risk	 individuals,	 and	 for	 uncovering	 and	 developing	 potential	 therapeutic	
avenues.			
1.2.2 Challenges	in	understanding	sarcoma	etiology	 	
One	distinct	challenge	in	identifying	drivers	of	sarcomagenesis	is	the	sheer	number	
of	histological	subtypes	of	sarcomas.	 	According	to	the	World	Health	Organization	(WHO),	
there	are	over	80	subtypes	of	soft	tissue	sarcomas,	and	over	60	subtypes	of	bone	sarcomas	
(11).	 	 Because	 sarcomas	 are	 both	 rarer	 tumor	 types,	 and	 because	 they	 comprise	 such	 a	
heterogeneous	 grouping	 of	 tumors,	 it	 is	 challenging	 to	 isolate	 enough	 tumors	 of	 similar	
subtyping	 to	 generate	 sufficient	 statistical	 power	 to	 identify	 drivers,	 often	 requiring	
extensive	collaborations.	 	Moreover,	 these	data	are	 further	complicated	because	not	only	
are	sarcomas	very	diverse	(numerous	subtypes),	but	also	each	sarcoma	is	heterogeneous	in	
composition.		Sarcomas	are	frequently	composed	of	bone,	cartilage,	and	fat	(13),	which	may	
further	 obfuscate	 and	 hinder	 identification	 of	 important	 genes	 for	 tumorigenesis,	
particularly	if	a	driver	gene	need	only	be	present	in	one	of	these	tissues.	
Two	prominent	papers	were	 recently	published	on	soft	 tissue	sarcomas	 (STS).	 In	a	
Cell	 paper,	 out	 of	 the	 Cancer	 Genome	 Atlas	 network	 (TCGA),	 the	 authors	 sequenced	 six	
types	 of	 soft	 tissue	 sarcomas,	 the	 majority	 of	 which	 are	 leiomyosarcomas	 (LMS)	 and	
liposarcomas	(LPS)	(10).	LMS	were	again	a	focus	in	the	second	paper,	from	Chudasma	et	al.	
and	 published	 in	Nature	 Communications	 (15).	 Both	 studies	 found	 that	 adult	 STSs	 have	
heterogeneous	 mutational	 profiles	 with	 copy	 number	 aberrations	 (CNA)	 consistent	 with	
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chromothripsis	 being	 a	 common	 occurrence.	 	 CNAs	 tended	 to	 be	 deletions,	 rather	 than	
amplifications,	and	the	authors	found	relatively	few	point	mutations	(10,	15).	
In	particular,	the	data	from	TCGA	suggested	that	some	alterations	may	be	sarcoma-
subtype	specific.		These	differentiating	features	can	range	anywhere	from	genomic	changes	
(e.g.	CNAs	and	point	mutations),	 to	 changes	 in	 the	 transcriptome,	methlyome,	or	protein	
levels.		For	example,	most	LMS	have	elevated	signaling	in	PI3K/AKT	signaling,	and	over	70%	
have	 at	 least	 shallow	 deletions	 in	 TP53,	 RB1,	 and	PTEN.	 	 The	majority	 of	 LMS	 also	 have	
elevated	miR-143,	and	miR-145.		However,	two	subtypes	of	LMS,	gynecologic	LMS	(ULMS),	
and	 soft-tissue	 LMS	 (STLMS)	 have	 distinct	 differences	 in	 the	 methylome	 and	 in	 reverse	
phase	protein	array	(RPPA)	analyses.	ULMS	showed	hypomethylation	of	ESR1	target	genes,	
something	 not	 seen	 in	 STLMS.	 	 RPPA	 showed	 that	 the	 DNA	 damage	 pathway	 was	more	
active	 in	ULMS	over	 STLMS,	 but	 that	 the	HIF1	 inflammation	 pathway	was	more	 active	 in	
STLMS	over	ULMS	(10).			
Taken	together,	these	data	implicate	CNAs	as	a	key	player	in	both	LMS	and	LPS,	and	
indicate	 sarcoma	 subtypes	 have	 distinct	 molecular	 profiles,	 which	may	 drive	 therapeutic	
approaches	for	clinicians	 in	the	future.	 	Ultimately,	 the	data	suggest	that	all	sarcomas	are	
not	 likely	 to	 share	 the	 same	 etiology	 and	 that	 sequencing	 of	 similar	 sarcomas	 may	 be	
necessary	to	avoid	confounding	from	multiple	types	of	sarcomas.	
However,	the	authors	do	note	a	role	for	point	mutations	in	soft	tissues	sarcomas.		In	
addition	 to	 CNAs	 frequently	 occurring	 somatically	 in	 the	 MDM2-p53	 and	 p16-CDK4-RB1	
pathways,	the	most	recurrently	mutated	genes	across	sarcoma	types	in	both	studies	were	a	
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triumvirate	 composed	 of	 TP53,	 ATRX,	 and	RB1,	 further	 suggesting	 that	 these	 genes	 (and	
their	pathways)	play	important	roles	in	sarcomagenesis	(10,	15).	
1.2.3 Sarcomas	and	multiple	germline	drivers	 	
The	thrust	of	the	previous	works	by	the	TCGA	(10)		and	Chudasama	et	al.	(15)	focus	
on	 acquired	 somatic	 changes.	 A	 third,	 slightly	 older	 study,	 by	 Ballinger	 et	 al.	 looked	 at	
germline	genetic	risk	factors	for	sarcomas	(16).		These	included	a	mix	of	both	sporadic	and	
familial	sarcomas,	across	a	broad	spectrum	of	sarcoma	types,	including	soft	tissue	and	bone	
sarcomas,	 with	 publically	 available	 Caucasian	 data	 used	 as	 controls	 to	 eliminate	
polymorphic	 alleles	 from	 consideration.	 	 Using	 targeted	 exon	 sequencing	 of	 72	 genes,	
selected	for	known	impact	 in	cancer,	Ballinger	et	al.	found	that	risk	generally	fell	 into	two	
groups:	classic	monogenic	variation	(~80%),	such	as	p53	(1%	of	all	sarcomas),	and	polygenic	
rare	 variation	 (~20%).	 	 Individuals	 classified	 as	 having	 polygenic	 rare	 variation	 had	
comparable	 tumor-free	 survival	 to	monogenic	p53	variants,	 suggesting	 that	 two	 so-called	
weaker	effects	can	make	up	for	one	big	one	(16).		
Given	the	limited	gene	set	from	targeted	sequencing,	Ballinger	et	al.	do	not	identify	
any	specifically	novel	genes,	but	do	observe	2%	of	sarcoma-patients	to	have	rare	germline	
mutations	predicted	to	be	damaging	in	ERCC2.		ERCC2	is	a	helicase	involved	in	base	excision	
repair;	 the	authors	 argue	 that	 it	 should	now	be	 considered	a	 sarcoma	 susceptibility	 gene	
(16).	Ultimately,	more	 than	half	 of	 the	 patients	 had	 variants	 predicted	 to	 be	 deleterious,	
and	40%	of	 these	 (one-fifth	 overall)	 had	mutations	with	 known	pathogenicity,	 suggesting	
that	additional	genetic	risk	factors	for	sarcomagenesis	have	yet	to	be	discovered.	
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1.3 Introduction	to	p53	
p53	is	arguably	the	most	important	tumor	suppressor	gene	and	has	been	called	the	
“guardian	of	the	genome”	(17),	and	more	recently,	the	“guardian	of	the	epigenome”	(18).	
Over	half	of	all	cancers	have	alterations	in	it,	and	it	is	considered	the	most	mutated	gene	in	
human	cancers	(19).	It	has	roles	in	numerous	cancer-related	processes,	including	cell-cycle	
arrest	 and	 apoptosis.	 Moreover,	 germline	 mutations	 and	 deletions	 in	 p53	 lead	 to	 Li-
Fraumeni	Syndrome	(LFS),	a	rare	cancer	predisposition	syndrome	that	has	a	high	incidence	
of	sarcomas,	suggesting	that	p53	may	play	a	role	 in	sarcomagenesis	 (20,	21).	 	Probably	 in	
part	 due	 to	 LFS,	 it	 is	 considered	 to	 be	 the	 strongest	monogenic	 driver	 of	 sarcomas	 (16).	
Conversely,	based	on	publicly	available	data	 from	cBio,	p53	alterations	are	present	 in	 less	
than	60%	of	sporadic	sarcomas,	and	as	low	as	20%,	(10,	15,	22-25)	implying	that	disrupted	
p53	 may	 not	 be	 required	 for	 their	 formation,	 and	 that	 sarcoma	 etiology	 may	 be	
considerably	 varied.	 More	 specifically,	 sarcomagenesis	 may	 occur	 by	 two	 divergent	
mechanisms,	one	that	is	p53-mediated,	and	one	that	is	p53-independent,	and	consideration	
of	 only	 one	of	 these	mechanisms,	 such	 as	 in	 LFS	 tumors,	with	 germline	p53	drivers,	may	
improve	 detection	 of	 additional	 sarcoma	 risk	 factors.	 	 Normally,	 p53	 abrogates	 tumor	
growth	in	part	by	helping	cells	to	sense	cellular	stresses	such	as	hypoxia	and	DNA	damage,	
and	 limit	 cell	 proliferation	 under	 conditions	 where	 genomic	 integrity	 is	 likely	 to	 be	
compromised.		However,	when	p53	is	lost,	the	loss	of	these	protective	aspects	can	lead	to	
the	accumulation	of	oncogenic	mutations,	as	well	as	unchecked	cell	proliferation,	leading	to	
a	 positive	 feedback	 loop	 where	 these	 populations	 expand	 more	 rapidly,	 resulting	 in	
tumorigenesis	(17,	26).	
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1.3.1 p53	and	MDM2	
p53	 is	 known	 to	 be	 regulated	 by	 a	 variety	 of	 regulators,	 including	 the	 negative-
regulator	 MDM2.	 	 MDM2	 is	 an	 E3-ubiquitin	 ligase	 that	 specifically	 ubiquitinates	 p53,	
exporting	it	out	of	nucleus,	and	marking	it	for	degradation	(27-29).	Moreover,	MDM2,	as	a	
p53-inducible	 gene,	 is	 closely	 correlated	 with	 p53	 levels	 in	 normal	 cells.	 	When	 working	
appropriately,	 these	 combine	 to	 form	 an	 auto-regulatory	 loop,	 designed	 to	maintain	 low	
levels	 of	p53	 in	 the	 absence	of	 stress.	On	 the	 flip-side,	 during	 periods	 of	 stress	 and	DNA	
damage,	p53	and	MDM2	 are	both	phosphorylated,	preventing	 their	 interaction	with	each	
other,	thus	stabilizing	p53	(30-34).		In	some	cases,	this	stabilization	has	been	shown	to	be	an	
important	step	in	tumorigenesis,	particularly	when	there	is	mutant	p53,	such	as	in	LFS	(35).	
In	 addition,	 work	 by	 several	 groups	 has	 implicated	 a	 polymorphism	 in	 MDM2	
(SNP309)	as	a	risk	factor	across	several	cancer	types,	including	colorectal,	breast,	lung,	and	
brain	 among	many	 others	 (36-39).	 	 In	 conjunction	with	 LFS	 or	 in	 sporadic	 sarcomas,	 the	
presence	of	the	MDM2	SNP309	polymorphism	appears	to	accelerate	tumor	formation	(37,	
40-42).	The	results	of	meta-analyses	have	only	continued	to	affirm	that	there	is	evidence	for	
association	 between	 MDM2	 SNP309	 and	 the	 p53	 R72P	 polymorphism,	 suggesting	 that	
MDM2	may	act	as	a	modifier	gene	for	tumorigenesis	(29,	37).			
1.3.2 p53	gain-of-function	mutations	
Although	the	majority	of	mutations	in	p53	are	loss-of-function	(LOF),	several	groups	
have	demonstrated	that,	contrary	to	expectation	based	on	other	tumor	suppressor	genes,	
which	only	have	LOF	mutations,	some	p53	mutations	result	 in	gain-of-function	(GOF)	(43).		
This	 idea	was	 first	 noted	when	 some	 tumors	with	 point	mutations	 in	p53	were	 found	 to	
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have	elevated	levels	of	p53	in	cancer	cells	relative	to	controls	(43,	44),	suggesting	that	p53	
must	 have	 acquired	 additional	 properties	 capable	 of	 aiding,	 rather	 than	 hindering	 tumor	
progression.		The	majority	of	results	have	been	established	by	overexpressing	mutant	p53	in	
p53-null	cells,	with	GOF	features	associated	with	elevated	resistance	to	apoptosis	 (45-48),	
cell	migration	and	invasion	(49,	50),	or	alternatively	with	cancer	 in	animal	models	(43,	51,	
52).	
1.3.3 p53	mutation	incidence	
The	majority	of	tumor-relevant	mutations	 in	p53	occur	 in	the	DNA	binding	domain	
(DBD),	 which	 comprises	 exons	 5-8	 of	 the	 gene.	 	 The	 World	 Health	 Organization	 (WHO)	
based	IARC	database,	which	collects	and	compiles	published	data	with	p53	mutations	at	the	
germline,	and	at	the	somatic	level,	show	several	hotspots	(53).			
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Figure	 3:	 Compilation	of	 published	data	 containing	p53	mutations,	 as	 generated	by	 the	
IARC	 database	 (53).	 Data	 on	 the	 left	 (A,B)	 composed	 of	 pedigrees	 with	 germline	 p53	
mutations.	Data	on	the	right	(C,	D)	represents	individuals	with	somatic	mutations	in	p53.		
Data	indicate	that	for	both	germline	and	somatic	variants,	most	occur	between	exons	5-8,	
and	appear	to	have	similar	hotspots	to	one	another.	
1.3.4 Hotspot	mutations	in	p53	
These	data	also	suggest	one	other	way	in	which	p53	differs	from	most	other	tumor	
suppressor	 genes.	 	 In	 general,	 the	mutational	 landscape	 for	 tumor	 suppressor	 genes	 and	
oncogenes	 are	 considered	 to	 be	 different;	 tumor	 suppressor	 genes	 tend	 to	 have	 flat	
mutational	profiles,	while	oncogenes	tend	to	have	profiles	with	distinct,	sharp	peaks,	known	
as	hotspot	mutations	(54).		For	example,	in	common	tumor	suppressor	genes	(TSG)	like	RB1	
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and	NF1,	the	profiles	are	relatively	flat	(Figure	4).		In	contrast,	for	oncogenes	such	as	BRAF,	
there	are	often	hotspot	mutations,	i.e.	nucleotides	that	are	frequently	mutated	(Figure	4).	
Thus,	these	data	do	not	rule	out	the	possibility	that	other	cancer	predisposing	TSG	will	not	
have	mutation	hot	spots	like	TP53,	or	that	some	of	these	variants	may	be	GOF	mutations.	
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Figure	4:	Lollipop	diagrams	 from	cBio	 (22)	depicting	 the	mutation	 frequency	across	 four	
genes.		Three	are	tumor	suppressors	(RB1,	NF1,	and	TP53)	and	one	is	an	oncogene	(BRAF).		
The	profiles	 for	 the	 first	 two	TSG	are	 representative	of	most	TSG.	 	The	 third	TSG,	TP53,	
appears	 to	 have	mutation	 hot	 spots	 that	 are	more	 consistent	with	 a	 classic	 oncogene,	
such	as	BRAF.		Note	that	the	scales	are	considerably	different	across	the	four	genes.	
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2 Li-Fraumeni	Syndrome	(LFS)	and	LFS-like	(LFSL)	
2.1 LFS	
In	 order	 to	 better	 understand	 the	 underlying	 genetics	 and	 epigenetics	 behind	
sarcomagenesis,	 we	 propose	 to	 use	 LFS	 as	 a	 model	 disorder.	 	 LFS	 is	 a	 rare,	 inherited,	
heterogeneous,	 cancer	 predisposing	 syndrome	 caused	 by	 mutations	 in	 the	 tumor	
suppressor	gene	p53	(70-80%	of	cases)	(55,	56)	with	a	high	prevalence	of	sarcomas	(20,	56,	
57,	58{,	59).	In	a	classic	LFS	pedigree	(Figure	5),	we	see	characteristic	patterns	of	autosomal	
dominant	 inheritance	 (cancer	 is	 observed	 in	 every	 generation)	 and	 anticipation	 (age	 of	
onset	for	cancer	gets	younger	for	each	generation,	ranging	from	a	lung	cancer	at	age	61	in	
the	oldest	generation,	 to	a	variety	of	 cancers	 from	roughly	30-50	years	old	 in	 the	 second	
generation,	 to	 sarcomas	 in	 the	 first	 two	 decades	 of	 life	 in	 the	 third	 generation).		
	
Figure	 5:	 Canonical	 LFS	 pedigree	 with	 a	 TP53	 M133T	 mutation.	 	 The	 pedigree	 shows	
characteristic	patterns	of	autosomal	dominant	 inheritance,	anticipations,	a	broad	tumor	
spectrum,	 and	 a	 high	 prevalence	 of	 sarcomas,	 including	 a	 soft	 tissue	 sarcoma	 in	 the	
proband,	denoted	by	an	arrow.	Shaded	circles	represent	cancer,	with	the	age	of	diagnosis	
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and	cancer	type	noted	below.	p53	mutation	carriers	are	denoted	by	a	“*”,	and	individuals	
with	WT	p53	are	denoted	by	an	“^”.			
LFS	is	further	identified	by	the	high	prevalence	of	sarcomas,	which	account	for	about	
25%	of	all	LFS-tumors	(Figure	6)	(53).		The	remainder	of	tumors	seen	in	LFS	covers	a	diverse	
spectrum,	 including	 breast	 cancer,	 brain	 cancer,	 lung	 cancer,	 and	 adrenocorticoid	 cancer	
(Figure	 6)	 (53,	56).	Given	 that	p53	 is	 considered	 to	be	 the	most	preeminent	cancer	gene	
(17,	19),	it	is	hardly	a	surprise	that	p53	germline	mutations	predispose	to	so	many	types	of	
cancer.			
	
Figure	6:	Tumor	 incidence	by	type	as	compiled	by	the	IARC	p53	database	for	 individuals	
with	germline	p53	mutations	(53).	
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2.1.1 Clinical	criteria	for	LFS	
Several	different	clinical	criteria	have	emerged	for	LFS	over	the	years.			
1. Classic	LFS,	first	defined	in	1988	(60),	requires	three	criteria	to	be	met:	
• Proband	with	a	sarcoma	before	the	age	of	45	
• First-degree	relative	with	cancer	before	the	age	of	45	
• Additional	 first	 degree	 relative	 with	 cancer	 before	 the	 age	 of	 45,	 or	 a	
sarcoma	at	any	age	
2. Chompret	LFS	(61,	62)	requires	one	of	the	following	to	be	met.		Unless	otherwise	
stated,	 tumors	 in	 the	 LFS	 spectrum	 are	 considered	 to	 be:	 soft	 tissue	 sarcoma,	
osteosarcoma,	 pre-menopausal	 breast	 cancer,	 brain	 tumor,	 adrenal	 cortical	
carcinoma,	leukemia,	or	lung	cancer	
• Tumor	belonging	to	LFS	spectrum	before	the	age	of	46	AND	at	least	one	first-
degree	or	second-degree	family	member	with	an	LFS-related	tumor	(except	
breast	 cancer	 if	 the	 individual	 has	 breast	 cancer),	 before	 the	 age	 of	 56,	 or	
with	multiple	tumors	
• A	 person	 with	multiple	 tumors,	 two	 of	 which	 belong	 to	 the	 LFS	 spectrum	
(excluding	multiple	breast	cancers),	the	first	of	which	occurs	before	the	age	
of	46.	
3. Eeles	definition	(63)	
• Two	first-degree	or	second-degree	relatives	LFS-related	tumors	at	any	age	
4. Birch	definition	(64)	requires	three	criteria	to	be	met:	
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• Proband	with	childhood	cancer,	sarcoma,	brain	tumor,	or	adrenal	cortical	tumor	
before	the	age	of	45	
• First-	or	second-degree	relative	with	a	tumor	in	the	LFS	spectrum	at	any	age	
• First-	or	second	degree	relative	with	any	cancer	before	the	age	of	60	
Individuals	and	 families	meeting	 these	criteria	 turn	out	 to	have	genetic	alterations	 in	p53	
(p53-LFS)	in	about	70-80%	of	cases	(55).	
2.2 Evidence	for	a	Li-Fraumeni	Syndrome-like	disorder	
However,	 several	 families	 that	 meet	 the	 clinical	 criteria	 for	 LFS	 appear	 to	 lack	
mutations	or	alterations	in	p53	(56,	65),	suggesting	the	presence	of	one	or	more	additional	
cancer/sarcoma-predisposition	gene(s).		Families	meeting	the	LFS	criteria	are	tested	across	
a	barrage	of	tests	to	definitively	rule	out	alterations	in	p53,	including	sequencing	and	testing	
for	 copy	 number	 aberrations.	 	 Notably,	 despite	 phenotypic	 similarities,	 the	 general	
consensus	seems	to	be	that	by	definition	LFS	and	LFSL	should	be	considered	distinct	from	
one	another,	that	is,	LFS-carriers	must	contain	a	p53	mutation	(56,	66).		
2.3 Alternative	risk	factors	for	LFS/LFSL	
2.3.1 CHEK2	
To	 date,	 no	 other	 mutations	 have	 been	 definitively	 associated	 with	 LFSL	 (56).	 In	
1999,	 Bell	 et	 al.	 advanced	 the	 idea	 that	 CHEK2	 could	 be	 a	 second	 LFS	 gene	 (67).	 	 They	
identified	a	specific	CHEK2	mutation	(CHEK2	1100delC)	that	co-segregated	with	disease	in	a	
family	that	met	the	criteria	for	classical	LFS,	but	lacked	a	p53	mutation,	as	well	as	two	other	
families	with	different	alterations	in	CHEK2	(67).	Moreover,	CHEK2	was	known	to	be	a	cell	
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cycle	 checkpoint	 kinase	 that	 interacted	with,	 and	 stabilized	 p53,	 and	 the	mutation	 itself,	
which	resulted	in	a	premature	stop	codon,	was	found	to	abolish	the	kinase	function	of	the	
CHEK2.		Combined,	these	initial	data	argued	strongly	for	the	probability	that	CHEK2	could	be	
an	LFSL	cancer	predisposition	gene.	
However,	 subsequent	 data	 accumulation	 on	 LFSL	 families	 did	 not	 find	 CHEK2	
1100delC	 to	 be	 a	 common	 cause	 of	 LFSL	 (68).	 Sequencing	 of	 additional	 LFSL	 families	
revealed	few	families	with	CHEK2	alterations	anywhere	in	the	gene	(69).	Additional	studies	
failed	to	detect	any	mutations	in	CHEK2	 in	LFSL	families	across	48	total	families	(70,	71).	A	
fourth	study,	by	Lee	et	al.	in	2001	found	three	missense	variants	across	10	LFS	and	49	LFSL	
pedigrees,	 including	 a	 polymorphism	 (Ile157Thr),	 and	 two	 that	 were	 somewhat	 rarer	
(Arg145Trp	 in	 a	patient	with	breast	 cancer	 and	a	 sarcoma,	 and	Arg3Trp	 in	 a	patient	with	
brain	cancer)	(72).	Sodha	et	al.	found	CHEK2	variants	in	3	of	26	families,	but	these	included	
a	synonymous	variant,	an	intronic	variant	which	does	not	appear	to	impact	splice	sites,	and	
a	 3-bp	 deletion	 in	 exon	 3,	 thus	 continuing	 to	 suggest	CHEK2	may	 not	 be	 an	 LFSL	 cancer	
predisposition	gene	(69).	
Expanding	the	pedigrees	tested	beyond	LFS/LFSL	for	CHEK2	mutations,	 including	 in	
familial	 breast	 cancer	 cohorts,	 did	 find	 excess	 risk	 for	 several	 cancers,	 including	 prostate	
(73),	colon	(74),	kidney	(73),	and	breast	cancer	(74,	75),	of	which	only	breast	is	a	canonical	
LFS/LFSL	 tumor	 (56).	 	However,	 they	did	not	 find	 similar	upticks	 in	 sarcomas	and	adrenal	
cortical	tumors	(73).		The	variant	is	fairly	common	in	the	general	population	(MAF	is	about	
1%),	and	therefore	present	 in	some	unaffected	women,	 leading	to	the	premise	that	 it	 is	a	
low-penetrance	 breast	 cancer	 risk	 allele.	 	 Moreover,	 the	 deletion	 is	 enriched	 in	 breast	
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cancer	families	that	are	BRCA1/BRCA2-negative	(74).	Therefore,	despite	some	ambiguity	in	
the	 literature,	 the	 general	 consensus	 has	 emerged	 that	 CHEK2	 should	 no	 longer	 be	
considered	a	cause	of	LFS/LFSL	(76).		
2.3.2 p53	UTR	
The	 majority	 of	 LFS-related	 research	 has	 focused	 on	 coding	 mutations	 in	 p53.		
However,	 recently,	Macedo	 et	 al.	 reported	 a	 rare	 germline	mutation	 (rs78378222)	 in	 the	
3’UTR	of	TP53	that	was	found	in	7	LFSL	probands	(5.4%)	and	was	correlated	with	reduced	
expression	of	p53	(77).	
2.3.3 Linkage	indicates	1q23	contains	an	LFSL	locus	
An	 additional	 locus	 for	 LFSL	 was	 mapped	 by	 linkage	 to	 1q23	 (65).	 	 In	 this	 study,	
linkage	 analysis	 using	 microsatellite	 markers	 was	 completed	 across	 62	 constitutive	 DNA	
samples	over	 four	 LFSL	pedigrees,	and	mapped	a	10-Mb	region	with	a	 significant	positive	
LOD	score	(Figure	7).		Moreover,	although	the	authors	assumed	that	these	four	families	did	
not	necessarily	have	the	same	predisposing,	 locus,	a	heterogeneity	LOD	score,	the	highest	
seen	across	 the	genome,	 suggested	 that	 two	 families	 (STS200	and	STS027)	 contributed	 in	
this	 region,	 with	 the	 STS200	 family	 showing	 stronger	 linkage.	 As	 of	 December	 2017,	
according	to	the	UCSC	genome	browser	 (hg19)	 (78),	 this	 region	contains	148	genes	and	5	
miRNAs.	
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Figure	7:	Linkage	map	showing	a	high	heterogeneity	LOD	(HLOD)	score	with	contribution	
from	 both	 STS200	 and	 STS027	 in	 the	 region.	 	 Used	 with	 permission	 from	 Dr.	 Linda	
Bachinski.	
3 Results	
3.1 Quality	Control	and	Choosing	a	Sequencing	Platform	
3.1.1 Sanger	sequencing	of	functional	positional	candidate	genes	
	
To	best	identify	putative	germline	cancer	predisposition	genes,	we	first	used	Sanger	
sequencing	 to	 look	 for	 single	 nucleotide	 variants	 (SNVs)	 and	 splicing	 variants	 across	 29	
functional	positional	candidate	genes:	AIM2,	ATF6,	C1orf226,	CADM3,	CD48,	CD244,	CREG1,	
DCAF8,	DDR2,	DEDD,	DUSP12,	DUSP23,	ESR1,	FCRL5,	 IFI16,	KLDHC9,	MNDA,	NHLH1,	NIT1,	
NUF2,	PEA15,	PRKAR1A,	PYHIN1,	SDHC,	SH2D1B,	TAGLN2,	UHMK1,	USP21,	VANGL2.		Genes	
were	 selected	 relative	 to	 known	 function	 and	 potential	 relevance	 to	 cancer.	 	 Sanger	
sequencing	 was	 performed	 across	 four	 primary	 individuals:	 STS200-000,	 STS200-017,	
Bachinski	et	al.,	2005 
STS200	=3.455		HLOD=3.573	
STS027=2.056	
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STS200-032,	 each	 of	 whom	 had	 cancer,	 as	 well	 as	 a	 fourth,	 STS200-009,	 a	 married-in	
founder,	which	served	as	a	negative	control	(Figure	8).	
	
Figure	 8:	 Non-p53	 LFS	 pedigree	 with	 linkage	 in	 1q23.	 	 Initial	 Sanger	 sequencing	 was	
performed	 on	 three	 individuals	 in	 the	 latest	 generation,	 all	 with	 cancer	 (STS200-032,	
STS200-017,	and	the	proband,	STS200-000),	plus	a	married-in	control	(STS200-009).			
To	analyze	Sanger	data,	we	used	a	program	called	“Mutation	Surveyor”	(79),	which	
automatically	 identifies	 variants	 using	 the	 chromatogram	 traces.	 	 To	best	 ensure	 that	we	
were	 not	 missing	 anything,	 we	 ran	 the	 program	 with	 both	 a	 stringent,	 normal	 set	 of	
parameters,	as	well	as	with	a	more	relaxed	set	of	criteria	designed	to	limit	false	negatives.		
Appropriate	 criteria	 were	 discussed	 with	 SoftGenetics	 after	 we	 discovered	 some	
inconsistencies	in	their	algorithms.		
After	 manual	 verification	 using	 the	 chromatograms	 for	 clean,	 double	 peaks,	 we	
identified	 61	 unique	 heterozygous	 variants	 across	 the	 three	 individuals	 (STS200-000,	
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STS200-017,	 and	 STS200-032).	 	 However,	 none	 of	 the	 variants	 appeared	 to	 co-segregate	
within	these	three	individuals.	
When	no	co-segregating	mutations	were	observed	in	the	Sanger	data,	we	then	used	
454	sequencing	data	of	these	same	four	individuals	to	do	longer,	targeted	sequencing	of	the	
region.	 	 Robust	 analysis	 was	 complicated	 by	 an	 intrinsic	 drawback	 of	 454-related	 data	 –	
difficulty	in	interpreting	homopolymers	–	and	no	strong	candidates	were	identified.	
3.1.2 Whole	genome	sequencing	to	identify	putative	mutations	
	
To	 best	 identify	 putative	 germline	 cancer	 predisposition	 mutations,	 we	 chose	 to	
employ	next	generation	sequencing	(NGS).		Given	the	lack	of	strong	candidates	discovered	
through	both	Sanger	sequencing	and	454-sequencing,	we	chose	to	leverage	whole	genome	
sequencing	(WGS)	over	whole	exome	sequencing	(WES),	because	of	the	ability	to	evaluate	
non-coding	 regions	 in	 addition	 to	 coding	 regions.	 	 Moreover,	WGS	 offered	 an	 improved	
ability	to	test	for	copy-number	changes.			
3.1.3 Establishment	of	a	Sequencing	Analysis	Pipeline	for	STS200	
	
Initially,	 we	 sequenced	 two	 individuals,	 STS032-011,	 and	 STS200-017	 across	 both	 the	
Illumina	 (GAIIX)	 and	 Complete	 Genomics	 (CGI,	 v.	 2.0)	 pipelines	 to	 determine	 which	
sequencing	technology	we	wanted	to	move	forward	with.		Subsequently,	we	sequenced	one	
individual	 on	 HS2000	 (STS200-000),	 and	 five	 additional	 individuals	 from	 STS200	 (STS200-
001,	STS200-008,	STS200-009,	STS200-019,	and	STS200-032)	via	Illumina	(H4000).	
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3.1.3.1 Illumina	Data	
	
For	 Illumina-based	 data,	 we	 implemented	 an	 in-house	 pipeline	 consistent	 with	 best	
practices	according	to	GATK	(80).	
	
Figure	9:	Final	pipeline	for	WGS	analysis,	modeled	after	best	practices	according	to	GATK.	
Briefly,	for	GAIIX,	HS2000	data,	we	wrote	some	custom	scripts	to	separate	out	FASTQ	files	
by	 lane.	Once	 separated,	 by	machine	 and	 lane,	 fastq	 files	were	 aligned	 using	 BWA-MEM	
(81).	 	 The	 resulting	 SAM	 files	 were	 cleaned	 and	 marked	 for	 duplicates	 using	 Picard	 to	
mitigate	potential	biases	introduced	during	amplification.		Samples	were	then	realigned	to	
adjust	for	potential	issues	near	indels,	followed	by	base-recalibration	using	GATK	(80).		For	
the	 initial	 comparative	 analysis	 between	 the	 two	 pipelines,	 variant	 calls	 were	 made	 via	
UnifiedGenotyper	(82),	but	the	most	recent	and	relevant	analysis	leverages	HaploCaller	and	
joint	genotyping	to	generate	gvcf	files	(80).	
	 25	
3.1.3.2 Complete	Genomics	Data	
	
For	CGI	data,	we	used	their	pipeline.			The	CGI	chemistry	was	unique	in	that	it	used	
adaptor	 ligation	 technologies	 that	 introduced	 known	 2-bp	 gaps	 into	 the	 sequence	 reads.		
Because	most	existing	tools	were	designed	around	Illumina’s	more	contiguous	sequencing	
and	 without	 explicit	 gaps,	 adaptation	 of	 existing	 tools	 to	 CG	 data	 was	 problematic	 and	
would	have	 likely	 yielded	 less	 accurate	 results.	 	 The	pipeline	 for	Complete	Genomics	was	
more	of	a	black	box,	and	tools	to	re-run	the	data	ourselves	were	not	provided.		Therefore,	
we	used	the	variant	calls	generated	by	their	internal	algorithms.		
3.1.3.3 Illumina	vs.	Complete	Genomics	
	
In	 order	 to	 determine	 which	 platform	 we	 wanted	 to	 move	 forward	 with,	 we	
compared	 across	 a	 variety	 of	metrics,	 including	 overall	 data	 quality,	 and	 ability	 to	 detect	
known	 positives,	 including	 the	 p53-mutation,	 and	 the	 Sanger	 sequencing	 data,	 where	
relevant.	Preliminary	analysis	of	the	Illumina-based	STS200-017	revealed	that	this	data	was	
of	poorer	quality	and	established	the	importance	of	checking	QC	data.	
3.1.3.3.1 Quality	Control,	GATK,	Picard	
	
All	samples	were	examined	across	several	quality	control	metrics	to	ensure	the	data	
could	be	used	 for	downstream	variant	 calling.	 	One	sample,	 STS200-017	 (Illumina)	was	of	
demonstrably	poorer	data	quality	than	the	others.		
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Figure	10:	One	Illumina	sample	shows	an	odd	bimodal	peak	when	looking	at	a	plot	of	the	
coverage.		Single	modal	peaks	without	fat	tails	are	the	best.	
Perhaps	 most	 strikingly,	 although	 most	 coverage	 plots	 depict	 a	 single,	 approximately	
normally	 distributed	 peak,	 this	 “poorer”	 STS200-017	 sample	 on	 Illumina	 produced	 a	
bimodal	peak	(Figure	10).	
Moreover,	we	also	saw	differences	when	looking	at	histograms	of	the	quality	scores	
(of	 each	 base	 of	 each	 read).	 	 This	 difference	 was	 not	 apparent	 when	 looking	 only	 at	
Illumina’s	original	quality	scores	but	was	when	using	GATK-based	tools	to	recalibrate	quality	
scores	empirically.		Virtually	all	of	the	empirically	determined	quality	scores	for	STS200-017	
were	less	than	30,	rendering	it	unsuitable	for	further	use	(Figure	11).			
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Figure	11:	Histogram	showing	frequency	of	bases	(y-axis),	with	varying	base	quality	scores	
(x-axis)	for	two	samples.		Data	on	the	top	are	the	reported	base	quality	scores	by	Illumina	
for	 the	good	sample	 (left,	 STS032-011),	and	bad	sample	 (right,	 STS200-017).	 	 These	 two	
graphs	are	nearly	identical.		When	adjusting	empirically	for	accuracy	(bottom),	the	poorer	
sample	fares	significantly	worse,	with	the	majority	of	data	falling	below	a	q-score	of	30.	
We	also	reviewed	additional	metrics	such	as	a	histogram	of	base	by	cycle,	and	base	
quality	by	cycle	 (Figure	 12).	 	Histograms	of	 these	data	comparing	STS032-011	to	STS200-
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017,	suggested	that	STS200-017	had	steep	drop-offs	in	quality	near	the	ends	of	the	reads	at	
higher	cycle	counts.	These	data	may	have	contributed	to	the	percentage	of	unmapped,	or	
singly	mapped	reads	found	in	STS200-017,	which	was	5X	higher	than	for	STS032-011.	
	
	
Figure	 12:	 Quality	 control	 of	 base	 quality	 by	 cycle	 after	 recalibration	 shows	 dramatic	
differences	between	the	good	sample	(STS032-011)	and	the	poorer	sample	(STS200-017).		
In	STS200-017	the	second	of	the	paired	reads	performs	especially	poorly,	with	empirical	
scores	being	up	to	10	worse	than	reported	score.	
	
	 29	
We	 then	 checked	 to	 see	 if	 the	 bottom-line	 was	 affected	 and	 if	 these	 apparent	
differences	in	quality	impacted	variant	calls.		Comparison	of	variant	calling	between	a	basic	
variant	calling	algorithm	setup	for	Illumina	(via	GATK,	UnifiedGenotyper	(82)),	and	Complete	
Genomics	 (Complete	 Genomics	 internal	 pipeline),	 saw	 dramatic	 differences	 when	
comparing	SNVs	for	STS200-017	(51%)	vs.	STS032-011	(85%).	
Taken	 together,	 these	 data	 suggested	 that	 the	 STS200-017	 sample	 for	 Illumina	
performed	 more	 poorly.	 	 Upon	 presentation	 to	 Illumina,	 they	 agreed	 to	 re-sequence	 a	
second	sample	from	the	same	individual	(now	on	HS2000),	and	this	second	sample	passed	
all	QC	metrics	and	was	in-line	with	the	metrics	generated	for	STS032-011	and	other	samples	
sequenced	at	the	same	time	with	Illumina.		These	data	strongly	support	the	value	of	QC	in	
sequencing	studies.	
3.1.3.4 Comparison	of	WGS	Technologies	Relative	to	Existing	Sanger	Data	
	
	 We	 next	 leveraged	 existing	 Sanger	 data	 for	 STS200-017	 that	 arose	 out	 of	 the	
functional	positional	candidate	screen.		Forty-eight	variants	in	the	Sanger	data	for	STS200-
017	 were	 identified	 using	 Mutation	 Surveyor,	 and	 were	 hand-validated	 individually	 by	
checking	the	chromatograms	for	double-peaks	in	both	the	forward	and	the	reverse	strand.		
Neither	 Illumina	 (44	 SNVs))	 nor	 Complete	 Genomics	 (45	 SNVs)	 identified	 all	 48	 SNVs;	
collectively	 they	were	able	to	 identify	46	total	SNVs.	All	“missed”	SNVs	were	homozygous	
for	the	reference	by	WGS.		The	data	suggest	that	both	Illumina	and	Complete	Genomics	are	
approximately	 equivalent;	 they	 both	 identify	 the	 majority	 of	 Sanger-ascertained	 SNVs.		
However,	assuming	Sanger	sequencing	as	the	Gold	standard,	the	data	did	suggest	that	the	
WGS	might	have	contain	some	false	negatives.		We	additionally	checked	the	other	sample,	
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STS032-011,	for	which	we	had	more	limited	Sanger	data	available,	because	it	had	a	known	
p53	mutation,	 for	 the	 expected	 variant,	 and	 confirmed	we	were	 able	 to	 identify	 the	p53	
R175H	mutation.	
3.1.4 Choosing	Illumina	as	a	Sequencing	Platform	
	
Several	 factors	 lead	 us	 to	 choose	 Illumina	 over	 Complete	 Genomics.	 	 First,	 the	
majority	of	the	Complete	Genomics	analysis	pipeline	is	not	well	understood,	and	exists	in	a	
black	 box.	 	 It	 requires	 the	 use	 of	 proprietary	 algorithms	 and	 analyses	 cannot	 be	 cross-
checked	with	 existing	 tools	 like	 BWA	 (81),	 Samtools	 (83),	 Picard	 (84),	 and	GATK	 (80,	 85).		
However,	at	the	time,	we	did	not	feel	as	 if	the	variant	calling	for	Complete	Genomics	was	
sub-par	or	compromised	due	to	these	differences.		Moreover,	although	Illumina	did	have	a	
slight	 hiccup	 during	 the	 initial	 phase	 of	 testing,	 subsequent	 resubmission	 of	 a	 different	
sample	from	the	same	individual	cleaned	up	the	data	and	QC	metrics	well.	
3.1.5 Additional	Sequencing	of	LFSL	Family	Members.			
	
Once	we	had	 selected	 Illumina	 to	move	 forward	with,	we	 sequenced	 the	proband	
STS200-000	 (HS2000).	 	 However,	 these	 data	 produced	 no	 compelling	 co-segregating	
variants	between	STS200-000	and	STS200-017.		To	better	ascertain	co-segregating	variants,	
we	 then	 sequenced	 five	 additional	 individuals	 (STS200-032,	 STS200-019,	 STS200-008,	
STS200-009,	and	STS200-001)	at	MD	Anderson	Cancer	Center	on	HS4000	at	100-bp	paired	
end	and	analyzed	according	to	the	previously	outlined	pipeline	(Figure	9)	
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3.1.6 Establishment	of	a	Variant	Prioritization	Strategy	
	
Given	 the	 STS200	 pedigree	 (Figure	 8),	 we	 expected	 that	 a	 germline	 cancer	
predisposition	 variant	 could	 be	 driving	 the	 cancer	 and	 sarcoma	 phenotypes	 seen	 in	 the	
latest	 generation.	 	 However,	 clinical	 testing	 suggested	 that	 a	 p53	 mutation	 was	 not	
responsible,	suggesting	the	presence	of	a	different,	LFSL	gene.	 	We	hypothesized	that	 the	
driver(s)	behind	LFS	and	LFSL	would	be	etiologically	similar.		
Therefore,	we	established	several	criteria	
(1) We	 expected	 the	 variant	 to	 co-segregate	 between	 affected	 individuals	
with	 cancer	 and	 obligate	 carriers	 because	 it	 resembles	 an	 inherited	
cancer	syndrome	
(2) The	variant	would	be	 in	1q23,	particularly	given	 the	relatively	high	LOD	
score	
(3) The	 mutation	 would	 be	 an	 SNV	 (70%-80%	 of	 p53	 LFS	 is	 driven	 by	
missense	mutations	
(4) The	mutation	would	be	predicted	to	be	damaging,	either	through	lack	of	
conservation,	or	through	a	big	change	in	the	amino	acid	properties	
(5) Lastly,	we	expected	the	variant	to	be	rare	because	LFS	is	rare.	
In	 summary,	 we	 initially	 focused	 on	 identifying	 co-segregating,	 rare	 (MAF<1%),	
heterozygous,	coding	SNVs	that	were	predicted	to	be	damaging	by	both	SIFT	 (<0.05),	 (86)	
and	Polyphen2	(PP2,	>0.453),	(87)	that	were	in	the	linked	region	in	1q23.			
Unfortunately,	 there	were	no	variants	 that	met	 these	 stringent	 criteria.	 	 To	better	
isolate	putative	mutations,	we	then	relaxed	the	criteria	in	several	ways	(Table	1).	
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Table	1:	Table	of	various	criteria	used	to	identify	putative	cancer	predisposition	variants	in	
1q23.	 	Under	 the	stringent	criteria,	no	putative	variants	were	 found.	 	We	 incrementally	
adjusted	criteria	to	be	more	relaxed	to	better	identify	candidate	mutations.	
		 Stringent	 More	Relaxed	
Minor	Allele	Frequency	(MAF,	1KG)	 <1%	 <5%	
SIFT/PP2	predictions	 Both	damaging	 Either	damaging	
Co-segregation	 Absolute	 FamSeq	(88)	
Variant	type	 SNV	only	 SNV	or	indels	
Location	(via	linkage	analysis)	 In	1q23	 Whole	genome	
	
3.2 Identification	of	ARHGAP30	as	an	LFSL	Predisposition	Gene	
3.2.1 Penetrance	and	Rarity	in	p53	and	LFS	
	
The	presence	of	multiple	LFS-related	criteria	suggests	uncertainty	in	the	field	about	
the	best	and	most	appropriate	definitions	for	LFS.	(60,	61,	63,	64)		Inevitably,	less	stringent	
definitions	of	LFS,	such	as	under	the	Chompret	criteria,	where	just	a	single	individual	can	be	
sufficient	 for	 an	 LFS	 diagnosis,	 imply	 that	 penetrance	 need	 not	 be	 significantly	 high	 in	
LFS/LFSL	families.		Moreover,	we	posit	that	given	the	overall	importance	and	prominence	of	
p53	in	cancer,	additional	LFSL	genes	are	likely	to	be	less	penetrant.		In	turn,	this	can	lead	to	
greater	 ambiguity	 in	 clinical	 ascertainment,	 and	 underreporting,	 such	 that	 in	 sum,	 less	
penetrant	 genes	 and	 mutations	 could	 be	 somewhat	 more	 prevalent	 in	 the	 general	
population	than	would	otherwise	be	expected	based	on	LFSL	(non-p53	LFS)	incidence.		If	we	
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do	consider	that	such	genes	may	be	 less	penetrant,	then	 it	may	make	sense	to	adjust	the	
cutoff	point	for	a	MAF-filter.		
3.2.1.1 Framework	for	Rare	Variation	
	
According	 to	several	databases,	 the	most	common	LFS	mutations	are	quite	 rare	 in	
the	 general	 population.	 	 We	 leveraged	 the	 IARC	 (89)	 database	 to	 determine	 the	 most	
frequently	mutated	codons,	and	then	looked	up	the	mutation	frequency	of	variants	in	these	
codons	 in	databases	such	as	Exome	Aggregation	Consortium	(ExAC)	 (90)	and	ESP	 (91).	 	 In	Figure	 13	we	 show	 a	 histogram	of	 the	most	 commonly	mutated	 codons	 in	 families	 that	
have	been	clinically	ascertained	as	classic	LFS	(strictest	criteria).		For	the	nine	most	common	
codons,	 I	 have	 included	 the	 codon	 number,	 and	 codon	 sequence.	 	 Above	 these,	 where	
present,	are	the	“MAF”	of	a	variant	in	that	codon	as	indicated	in	the	ExAC	database,	as	well	
as	the	incidence.		At	the	time	of	inquiry,	ExAC	contained	60,706	individuals.		Despite	the	fact	
that	 ExAC	 attempts	 to	 remove	 individuals	 affected	 by	 severe	 pediatric	 disease,	 it	 is	 clear	
that	p53	 variants	 are	occurring	 at	 some	 relative	 frequency.	Under	 the	exome	 sequencing	
project,	 which	 covered	 7,000	 individuals,	 we	 saw	 exactly	 1	 individual	 with	 a	mutation	 in	
codon	273	(0.02%),	while	we	saw	28	with	a	mutation	in	codon	337	(0.56%).	
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Figure	13:	Histogram	from	IARC	(89)	showing	hotspot	mutations	in	p53	at	the	codon	level.		
For	the	nine	most	commonly	altered	codons,	the	codon	number	is	 listed,	along	with	the	
codon	sequence.	 	Above	that	 is	a	representation	of	the	 incidence	 in	the	ExAC	database,	
either	 as	 a	 percentage	 of	 all	 samples,	 or	 as	 the	 total	 number	 of	 individuals	 with	 a	
mutation	in	that	codon	(in	parentheses),	indicating	that	these	mutations	are	very	rare	in	
the	general	population.	
In	contrast	to	this,	recent	research	supports	the	idea	that	germline	TP53	mutations	
may	be	more	common	 than	previously	appreciated	based	on	LFS	 incidence.	 	A	perusal	of	
exome	 databases	 found	 131	 individuals	 (0.2%	 of	 samples)	 with	 TP53	 mutations.	 	 These	
mutations	largely	fell	in	the	DNA	binding	domain	(~80%),	and	included	some	that	are	known	
to	 cause	 LFS,	 suggesting	 that	 numerous	 individuals	 may	 be	 carrying	 a	 non-penetrant	
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deleterious	 p53	 allele	 (92).	 Overall	 penetrance	 through	 close	 examination	 of	 the	 IARC	
database	was	 found	 to	 be	 ~80%	 (tumors	 before	 the	 age	 of	 70),	with	 varying	 penetrance	
based	on	sex,	age,	and	which	p53	allele	was	mutated	(93).	
3.2.2 Allowing	for	more	common	variants	identifies	two	variants	that	co-segregate	
	
Given	these	emerging	data,	particularly	that	p53	variants	may	occur	as	much	as	0.2%	
in	the	general	population,	may	mean	that	a	MAF	threshold	of	1%	is	too	conservative	(92).	In	
order	 to	 cast	 a	wider	 net,	 and	 account	 for	 the	 possibility	 that	 variable	 penetrance	 could	
partially	explain	the	results,	we	opened	our	MAF	filter	to	account	for	variants	with	a	MAF	
less	 than	 5%.	 	 Although	 this	 could	 potentially	 lead	 to	 the	 identification	 of	 a	multitude	of	
variants,	 in	practice	maintaining	 the	absolute	 co-segregation	criterion	 is	highly	 restrictive.		
There	are	exactly	two	variants	that	both	co-segregate	with	a	MAF	threshold	of	less	than	5%,	
and	are	predicted	to	be	damaging	by	both	SIFT	and	Polyphen2	(Table	2).	
Table	2:	Table	 showing	all	 variants	 in	1q23	which	both	co-segregate,	have	a	MAF	<	5%,	
and	are	predicted	to	be	damaging	by	both	SIFT	and	Polyphen2	(PP2).	
	
SLAMF1	encodes	signaling	lymphocytic	activation	molecule	1.		It	is	involved	in	the	activation	
and	 differentiation	 of	 immune	 cells	 and	 has	 roles	 in	 both	 innate	 and	 adaptive	 immune	
response.	 	As	noted	 in	Table	 2,	although	the	SIFT	and	PP2	scores	are	both	promising	(i.e.	
predicted	to	be	deleterious	–	scores	are	close	to	0	and	1	respectively),	the	MAF	is	quite	high	
(close	 to	 4%	 in	 the	 1000	 genomes	 project	 (94),	 1KG)).	 	When	 considered	 under	 the	 ESP	
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(adjusted	 for	 ethnicity	 -	 the	 STS200	 family	 is	 of	Caucasian	descent),	 this	 number	 is	 about	
twice	as	high,	8.9%.		Such	a	high	MAF	is	perhaps	more	common	than	we	would	prefer	for	
what	 is	 theoretically	a	 rare	disease.	 	 SLAMF1	has	not	yet	been	associated	with	a	disease.		
Nevertheless,	the	role	of	the	immune	system	in	cancer	is	becoming	increasingly	apparent;	it	
is	a	new	hallmark	in	the	“Hallmarks	of	Cancer”	v2.	(2),	thus	making	it	a	plausible	functional	
candidate.	
NDUFS2	 encodes	NADH	dehydrogenase	ubiquinone	 iron-sulfur	protein	2.	 	NDUFS2	
catalyzes	 NADH	 oxidation	 within	 the	 mitochondria	 (including	 ubiquinone	 reduction	 and	
proton	 ejection).	 	 Much	 like	 SLAMF1,	 the	 MAF	 in	 both	 the	 1KG	 and	 ESP	 (for	 European	
Americans)	are	quite	high	for	what	is	understood	to	be	a	relatively	rare	disease.		Mutations	
in	 the	gene	NDUFS2	have	been	associated	with	Mitochondrial	Complex	 I	Deficiency.	 	This	
mitochondrial	 disorder	 has	 heterogeneous	 presentation,	 including	 macrocephaly	 (large	
head)	 and	 myopathies.	 	 However,	 cancer	 has	 never	 been	 associated	 with	 this	 disease,	
suggesting	that	NDUFS2	may	not	be	a	strong	candidate	for	additional	follow-up.	
To	 best	 determine	 if	 these	 variants	were	 viable	 candidates,	we	 performed	 Sanger	
sequencing	to	(a)	confirm	the	variant	in	the	7	individuals	with	WGS,	and	(b)	to	test	for	co-
segregation	 in	 additional	 members	 of	 the	 pedigree.	 	 In	 SLAMF1,	 the	 married-in	 founder	
turned	 out	 to	 have	 the	 mutation	 of	 interest.	 	 In	 NDUFS2,	 two	 obligate	 carriers	 and	 an	
affected	were	WT	for	 the	variant.	 	Thus,	neither	of	 these	variants	 is	of	significant	 interest	
moving	forward.	
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3.2.3 Less	stringency	in	SIFT/PP2	finds	four	new	variants	for	consideration	
	
A	 second	 possibility	 is	 that	 SIFT	 (86)	 and	 PP2	 (87)	 are	 imperfect	 prediction	
algorithms	and	that	requiring	a	mutation	to	be	“damaging”	across	both	algorithms	may	lead	
to	premature	exclusion	of	variants.		SIFT	predictions	are	based	on	amino	acid	conservation	
in	 closely	 related	 sequences.	 	 In	 contrast,	 PP2	 emphasizes	 the	 impact	 of	 the	 change	 on	
protein	structures.		In	practice,	SIFT	and	PP2	do	not	always	agree	with	one	another,	and	it	
may	 be	more	worthwhile	 to	 consider	 variants	 predicted	 to	 be	 damaging	 by	 one	or	more	
algorithm(s).	 	 Moreover,	 known	 LFS	 variants	 such	 as	 p53	 M133T	 sometimes	 may	 be	
predicted	to	be	relatively	benign	(initially	 the	variant	had	a	PP2	score	of	0.148,	but	under	
the	most	recent	iteration,	it	is	now	0.858).		For	example,	if	a	cancer	predisposing	germline	
mutation	 is	 human-specific;	 in	 this	 case,	 we	 would	 expect	 a	 SIFT	 score,	 which	 is	 based	
primarily	on	conservation	to	be	relatively	high	(i.e.	benign).		To	cast	the	widest	possible	net,	
we	then	changed	the	stringency	in	SIFT/PP2	to	not	require	any	thresholds,	although	we	did	
still	 require	 the	 variant	 to	be	exonic.	 	 In	 combination	with	 the	higher	MAF	 threshold,	we	
found	6	total	variants	(Table	3),	two	of	which	were	the	same	as	in	3.2.2.	
Table	3:	Table	of	all	variants	meeting	meeting	the	stringent	criteria,	except	for	rarity,	and	
SIFT/PP2	scores.		All	6	variants	are	relatively	common,	and	two	are	synonymous	SNVs.	
	
	 38	
Of	 these,	 there	were	 three	 new	 genes,	 IFI16,	 ADAMTS4	 and	OLFML2B.	 ADAMTS4	
encodes	disintegrin	and	metalloproteinase	with	thrombospondin	motifs	4	and	is	known	to	
degrade	 aggrecan	 in	 cartilage	 and	 brevican	 in	 the	 brain	 and	 has	 a	 thrombospondin	 type	
motif	(TSR)	that	binds	to	the	ECM.	(95)	ADAMTS4	is	thought	to	possibly	play	roles	in	arthritis	
(96)	 and	 potentially	 in	 glioma	 progression.	 (95)	 Similar	 to	 previous	 candidates,	 MAF	 for	
these	genes	are	comparatively	high,	around	5%	and	10%	for	1KG	and	ESP	respectively,	and	
make	the	variant	less	compelling.	
The	variant	in	Interferon	Gamma	Inducible	Protein	16	(IFI16)	is	synonymous,	and	like	
the	other	variants	considered	so	 far,	 is	 reasonably	polymorphic,	but	 is	actually	one	of	 the	
candidate	 genes	 previously	 identified.	 	 IFI16	 is	 a	 member	 of	 the	 p200	 family,	 known	 to	
inhibit	cell	cycle	progression.		Moreover,	loss	of	IFI16	has	been	associated	with	breast	and	
prostate	cancers	(97).			
There	 have	 been	 no	 papers	 published	 on	 Olfactomedlin-like	 2B	 (OLFML2B),	 but	
olfactomedlins	 have	 been	 implicated	 in	 development	 and	 organization	 of	 the	 nervous	
system,	 and	 are	 generally	 thought	 to	 facilitate	 protein-protein	 interactions	 and	 cell	
adhesion	(98).	Given	the	lack	of	immediately	compelling	candidates,	we	pushed	forward	to	
consider	additional	variants	rather	than	immediately	jump	to	consider	Sanger	sequencing.		
3.2.4 FamSeq	identifies	ARHGAP30	as	an	LFSL	candidate	gene	
	
Without	 any	 particularly	 strong	 candidates	 so	 far	 identified	 in	 1q23,	 we	 next	
implemented	 FamSeq	 (88)	 to	 help	 identify	 additional	 co-segregating	 variants	 and	 reduce	
the	risk	of	false	negatives.	FamSeq	leverages	pedigree	information	to	make	more	informed	
decisions	about	variant	zygosity.	Effectively,	FamSeq	places	a	probability	on	a	given	variant	
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call,	including	how	likely	it	is	to	be	heterozygous.		If	one	or	more	individuals	have	the	same	
weak(er)	 variant	 call,	 FamSeq	 helps	 to	 isolate	 that	 variant	 and	 flag	 it	 for	 additional	
consideration.	
We	then	used	FamSeq	on	the	six	affecteds/obligate	carriers,	requiring	complete	co-
segregation	of	the	same	heterozygous	mutation	of	interest.		At	this	time,	we	did	not	use	the	
married-in	control	as	a	negative	filter	since	this	could	be	crosschecked	later,	and	it	appeared	
the	filtering	criteria	were	already	particularly	stringent.	 	However,	under	these	conditions,	
we	found	no	new	rare,	or	semi-rare	coding	mutations	in	1q23,	even	when	considering	the	
more	lenient	parameters	discussed	in	3.2.2	and	3.2.3.			
One	other	possibility	 is	 that	 the	 family	 contains	 a(nother)	 phenocopy,	 or	 that	one	
affected	individual	could	be	homozygous,	or	even	hemizygous	for	the	mutation	of	interest.		
It	 would	 be	 unlikely,	 but	 not	 impossible,	 for	 example,	 for	 both	 parents	 to	 have	 the	
mutation,	 or	 for	 there	 to	 have	 been	 a	 gene	 conversion	 event	 prior	 to	 DNA	 sampling.		
Instead	 then	 of	 asking	 FamSeq	 to	 identify	 all	 variants	 that	 had	 possible	 heterozygous	
mutations	 in	 6	 of	 6	 affected/obligate	 carriers,	 we	 instead	 asked	 FamSeq	 to	 identify	 all	
variants	 that	 seemed	 to	 be	 heterozygous	 in	 5	 of	 6	 individuals.	 Under	 the	 more	 relaxed	
criteria	 listed	 above,	 we	 generated	 another	 list	 of	 candidate	 variants,	 with	 one	 notable	
addition,	a	mutation	in	ARHGAP30	(Table	4).	
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Table	 4:	 Table	 of	 FamSeq-derived	 variants	 that	 are	 semi-rare,	 and	meet	 strict	 SIFT/PP2	
requirements.	
	
The	ARHGAP30	variant	was	found	to	be	heterozygous	in	5	of	6	affecteds/obligate	carriers,	
but	in	the	sixth	sample,	the	variant	was	found	to	be	homozygous	mutant	(Figure	14).			
	
Figure	14:	Depiction	of	STS200	and	WGS	data,	showing	co-segregation	of	the	ARHGAP30	
mutation.		One	individual	is	homozygous	(STS032-011)	
ARHGAP30	encodes	a	RhoGTPase	that	has	been	linked	to	cancer	and	cell	migration	
(99,	 100),	with	 research	 indicating	 it	 acts	 like	a	 tumor	 suppressor	 gene,	making	 it	 a	 good	
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candidate	for	LFSL.	Although	the	MAF	was	somewhat	higher	than	initially	desired,	the	fact	
that	 it	was	a	tumor	suppressor	gene,	and	was	predicted	to	be	damaging	(coding),	and	co-
segregates	implicates	it	as	the	most	promising	candidate	identified.		We	then	confirmed	the	
results,	including	the	homozygous	result	by	Sanger	sequencing	for	these	seven	individuals,	
indicating	this	mutation	did	co-segregate	for	these	seven	individuals.		Subsequent	follow-up	
to	 sequence	 additional	 members	 of	 the	 pedigree	 confirmed	 that	 co-segregation	 was	
otherwise	 complete.	 	 There	 was	 one	 seeming	 outlier:	 a	 bladder	 cancer	 patient	 (STS200-
102),	who	was	WT	for	the	mutation.		However,	based	on	the	linkage,	he	shared	very	little	of	
the	 1q23	 haplotype	 and	 was	 expected	 to	 be	 a	 phenocopy,	 (i.e.	WT	 for	 the	 mutation	 of	
interest).	Thus,	these	data	further	cemented	ARHGAP30	as	a	candidate	for	future	studies.		
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Figure	 15:	 Sanger	 sequencing	 of	 additional	 members	 of	 the	 pedigree	 confirms	 co-
segregation	of	 the	mutation	 in	ARHGAP30,	 including	 the	homozygous	result	 for	STS200-
032.	 	 Based	 on	 the	 linkage,	 we	 expected	 one	 of	 STS200-108	 or	 STS200-109	 to	 be	 a	
phenocopy,	 of	 which	 STS200-108	 appears	 to	 be.	 	 Individuals	 with	WGS	 are	marked	 by	
green	boxes.	
3.2.5 Co-segregation	over	the	whole	genome	
	
In	 order	 to	 rule	 out	 the	 unlikely	 possibility	 that	 the	 linkage	 was	 incorrect,	 we	
expanded	 the	 search	 to	 include	 variants	over	 the	entire	 genome.	 	 This	 time,	 because	we	
were	not	in	the	linked	region,	we	changed	the	parameters	to	exclude	STS200-019,	because	
she	 was	 a	 probable	 carrier	 based	 on	 linkage,	 but	 has	 not	 yet	 developed	 cancer.	 	 We	
continued	to	leverage	FamSeq	to	reduce	the	risk	of	false-positives,	but	decided	to	be	more	
restrictive	using	FamSeq	by	not	allowing	any	phenocopies	or	homozygous	alternate	alleles,	
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and	requiring	five	of	five	individuals	to	carry	the	putative	mutation.		However,	we	continued	
to	use	the	less	stringent	criteria	(MAF	<	5%,	SIFT	or	PP2	predicted	to	be	damaging).	
We	 found	 seven	 coding	 variants	 that	 met	 these	 criteria	 over	 the	 whole	 genome,	
including	the	aforementioned	SLAMF1	and	NDUFS2,	as	well	as	 two	non-coding	variants	 in	
F11R	and	ARHGAP30	that	were	within	1q23.	
Table	5:	Table	of	variants	that	appear	to	completely	co-segregate	using	FamSeq	over	the	
entire	genome.	
	
To	 definitively	 determine	 if	 any	 of	 these	 variants	 were	 also	 candidate	 germline	 cancer	
predisposition	 variants,	 we	 tested	 additional	 samples	 from	 the	 pedigree	 to	 see	 if	 they	
maintained	co-segregation.			
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Table	 6:	 Table	 showing	 that	 additional	 variants	 elsewhere	 in	 the	 genome	 identified	 by	
FamSeq	largely	do	not	co-segregate	when	tested	by	Sanger	sequencing.	
	
Of	these,	only	the	variant	in	PKLR	was	found	to	completely	co-segregate	across	the	rest	of	
the	 STS200	 pedigree.	 	 However,	 this	 exact	 variant	 is	 annotated	 in	 the	 ClinVar	 database	
(101),	 as	 being	 associated	 with	 pyruvate	 kinase	 deficiency	 (PKD).	 	 PKD	 is	 an	 autosomal	
recessive	disease	in	which	red	blood	cells	break	down	too	easily	due	to	the	lack	of	pyruvate	
kinase.		It	has	never	been	associated	with	a	cancer	phenotype.		
3.2.6 No	non-coding	variants	are	immediately	compelling	
	
Next,	we	considered	variants	that	were	in	1q23,	but	were	not	in	coding	regions,	such	
as	those	 in	UTRs,	 introns,	or	that	were	upstream	or	downstream	of	the	gene	(with	2,500-
bp),	in	potential	regulatory	regions.		There	were	203	such	variants	that	were	not	considered	
to	be	polymorphic,	 the	majority	of	which	were	 intronic.	 	However,	we	note	 that	 some	of	
these	 are	 likely	 to	 be	 false	 positives	 because	 they	 existed	 in	 near	 regions	 that	 were	
homopolymers.	
We	then	applied	FunSeq2	(102),	to	better	narrow	down	the	 list.	 	FunSeq2	is	a	tool	
that	can	help	prioritize	non-coding	regions	by	looking	at	how	often	variants	appear	in	them.		
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The	 authors	 hypothesize	 that	 regions	 that	 almost	 never	 have	 a	 variant	 are	 somehow	
protected	 and	 therefore	 may	 be	 functionally	 important.	 	 However,	 we	 didn’t	 find	 any	
variants	in	these	so-called	ultra-conservative	regions.	
3.3 Cross-check	of	p53	confirms	that	p53	is	not	a	genetic	driver	in	STS200	
We	also	exhaustively	reviewed	p53	to	confirm	it	had	no	mutations,	or	copy-number	
loss	and	was	definitively	WT.		Moreover,	as	discussed	in	2.3.2,	recent	research	has	identified	
a	p53	UTR-variant	 that	 co-segregated	with	disease	 in	an	LFSL	 family	where	p53	had	been	
previously	 ruled	 out	 (77).	 	 To	 check	 to	 see	 if	 the	 STS200	 family	 contained	 this	mutation	
(rs78378222),	 we	 checked	 the	 WGS	 data,	 and	 used	 Sanger	 sequencing,	 finding	 that	 all	
tested	individuals	were	WT	for	the	UTR-variant.			
3.4 More	in-depth	investigation	of	“known”	sarcoma	risk	factors		
Several	 genes	 have	 been	 associated	 with	 sarcomas,	 either	 through	 a	 study	 of	
individual	 subtypes,	 or	 through	 broader	 analysis	 of	 targeted	 sequencing.	 When	 they	
analyzed	1,162	sarcoma	probands,	Ballinger	et	al.	found	that,	overall,	probands	were	more	
likely	 to	 have	multiple	 pathogenic	 variants	 relative	 to	 controls,	 and	 that	 these	were	 best	
clustered	 in	 TP53,	 ATM,	 ATR,	 BRCA2,	 and	 ERCC2	 (16).	 	 To	 supplement	 these	 data,	 we	
generated	a	genome-wide	list	of	genes	that	have	been	previously	associated	with	sarcomas	
through	both	a	literature	search,	and	a	perusal	of	the	data	put	together	by	the	WHO,	across	
both	CN	data	and	mutational	data	(11).	
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Table	 7:	 List	 of	 genes	 associated	 with	 sarcomas,	 either	 through	 hereditary	 cancer	
syndromes,	CN	changes,	or	as	fusion	transcripts.	
ACP5	 COL1A1	 GLMN	 NFATc2	 SMARCA4	
ACTB	 COL1A2	 GNAS	 NFIB	 SMARCA5	
ACVR1	 COL6A3	 H19	 NR4A3	 SMARCB1	
AIP	 CREB1	 HAS2	 NTRK3	 SOS1	
AKT1	 CREB3L1	 HEY1	 PATZ1	 SP3	
ALK	 CREBBP	 HMGA2	 PBX1	 SQSTM1	
ANTXR1	 CSF1	 HRAS	 PDGFB	 SS18	
ANTXR2	 CTNNB1	 IDH1	 PDGFRA	 SSX1	
APC	 CXCR7	 IDH2	 PIK3CA	 SSX2	
ASPSCR1	 DDIT3	 IGF1R	 PLAG1	 SSX4	
ATF1	 DICER1	 IGF2	 PMS2	 STARD13	
ATIC	 DUX4	 INI1	 PORCN	 T	
BCL2	 EBF1	 KCNQ1OT1	 POU5F1	 TAF15	
BCOR	 ERCC2	 KDR	 PRKAR1A	 TEK	
BLM	 ERG	 KIT	 PTCH1	 TFE3	
BRAF	 ETV1	 KRAS	 PTEN	 TIE1	
BUB1B	 ETV4	 LEMD3	 PTEN		 TNFRSF11A	
C11orf95	 ETV6	 LHFP	 PTH1R	 TNFRSF1A	
CAMTA1	 EWSR1	 MAP2K1	 PTPN11	 TP53	
CCNB3	 EXT1	 MDM2	 RANBP2	 TPM3	
CCND1	 EXT2	 MEN1	 RB1	 TPM4	
CCNE1	 FEV	 MID1	 RECQL3	 TSC1	
CDH11	 FGFR4	 MKL2	 RECQL4	 TSC2	
CDK4	 FH	 MTAP	 RET	 USP6	
CDKN1C	 FLI1	 MYH9	 ROR2	 VGLL3	
CDKN2A	 FLT1	 MYOCD	 SDD	 VHL	
CDKN2B	 FOSL1	 NBN	 SDHB	 WRN	
CHEK2	 FOXO1	 NCOA2	 SDHC	 WT1	
CIC	 FUS	 NF1	 SDHD	 WWTR1	
CLTC	 GLI1	 NF2	 SH3BP2	 		
	
However,	we	did	not	find	any	other	pathogenic	variants	in	the	germline	in	these	sarcoma-
related	genes	in	any	of	the	STS200	family	members.		It	is	possible	that	some	of	this	is	driven	
by	the	fact	that	many	of	the	listed	genes	are	part	of	fusion	transcripts.	
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3.5 STS200	has	no	co-segregating	indels	or	deletions	anywhere	in	the	genome	
Lastly,	LFS	can	be	caused	not	only	by	SNVs	in	p53,	but	also	by	indels	and	CN	changes	
(56).		To	best	determine	if	LFSL	in	the	STS200	family	could	also	be	caused	by	either	of	these,	
we	 leveraged	 both	 GATK	 and	 pindel	 (103)	 for	 calling	 indels,	 and	 ERDS	 (104)	 for	 CNVs.	
However,	we	found	no	recurrent	indels	or	CN	changes	suggesting	that	neither	indels	of	CN	
changes	were	responsible	for	LFSL	in	STS200.	
3.6 Sequencing	of	additional	LFSL	pedigrees	finds	three	other	cases	with	the	exact	same	
variant	
To	 next	 determine	 if	 this	 variant	 was	 more	 widely	 relevant,	 we	 used	 Sanger	
sequencing	to	test	probands	from	other	LFSL	pedigrees	(where	p53	was	ruled	out)	to	see	if	
they	had	 the	exact	 same	mutation	 in	ARHGAP30.	 	We	 tested	6	probands	 from	Creighton	
University,	27	probands	 from	MD	Anderson	Cancer	Center	 (including	STS200),	9	probands	
from	Ohio	State	University,	and	6	probands	from	the	National	Cancer	 Institute	 (NCI)	 for	a	
total	 of	 48	 probands.	 	 Of	 these,	 three	 additional	 probands	 contained	 the	 exact	 same	
mutation	in	ARHGAP30,	for	a	total	of	4	of	48	(8.4%),	suggesting	that	this	mutation	could	be	
a	potential	hotspot.			
Interestingly,	this	mutation	is	somewhat	analogous	to	hotspot	mutations	in	p53.		In	
p53,	 several	hotspot	mutations	occur	 in	CpG	sites,	 such	as	 those	at	codons	175,	248,	and	
273,	 with	 deamination	 and	 G!A	 transitions	 being	 common	 (105).	 	 Our	 variant	 in	
ARHGAP30,	 GTTCGGC[G/A]AACCCAG,	 also	 occurs	 in	 a	 CpG	 site	 and	 may	 arise	 due	 to	
deamination.	 	 This	 may,	 at	 least	 in	 part,	 explain	 why	 the	 mutation	 could	 be	 a	 hotspot,	
and/or	why	the	mutation	is	relatively	common	in	the	general	population.	
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3.6.1 Statistical	case	for	enrichment	of	ARHGAP30	R806Q/R1017Q	
To	 test	 statistically	 if	 these	 LFSL	 families	 were	 enriched	 for	 the	 mutation	 of	
ARHGAP30,	we	used	to	a	Poisson	approximation	based	on	two	reported	allele	frequencies.		
The	 dbSNP	 database	 contained	 the	 lowest	 reported	 MAF	 (0.86%),	 while	 the	 ESP	 (for	
European	 Americans)	 contained	 the	 highest	 MAF	 (2.72%).	 	 Using	 this	 information,	 we	
counted	 the	 number	 of	 cases	 we	 would	 expect	 to	 see	 on	 average,	 for	 48	 samples,	 and	
computed	a	one-sided	p-value	 to	determine	 the	 likelihood	 that	we	 saw	4	or	more	 cases.		
For	dbSNP,	this	corresponds	to	a	p-value	of	8.7e-4,	and	for	4.4e-2	for	ESP,	suggesting	that	
these	LFSL	pedigrees	are	enriched	for	the	mutation	in	ARHGAP30.	
The	 result	 of	 having	 multiple	 families	 with	 the	 same	 exact	 mutation	 in	 a	 tumor	
suppressor	 gene	 is	 unexpected,	 but	 not	 impossible.	 	 The	majority	 of	 well-studied	 tumor	
suppressor	 genes	 and	 oncogenes	 follow	 a	 specific	 pattern.	 	 Oncogenes	 are	 typically	
recurrently	 mutated	 at	 specific	 amino	 acids,	 while	 tumor	 suppressor	 genes	 have	 flatter	
mutational	 profiles,	 with	 mutations,	 especially	 protein-truncation	 mutations,	 occurring	
throughout	 the	 length	 of	 the	 gene	 (54).	 	 However,	p53	 is	 a	 notable	 exception	 for	 tumor	
suppressor	genes	where	hotspots	for	cancer	predisposition	are	observed	(1.3.4).			
3.6.2 Co-segregation	in	non-STS200	families	
Subsequent	testing	of	these	families	was	somewhat	limited.		Of	the	two	other	LFSL	
families	from	MDACC,	we	had	additional	DNA	from	only	one	of	the	families	(just	the	parents	
of	the	proband).		In	this	family,	of	which	the	proband	had	a	Wilms’	tumor,	one	parent	did	
contain	the	variant	of	interest	but	had	not	(yet)	developed	cancer.		The	other	was	wild-type.	
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3.6.3 Co-segregation	is	almost	complete	in	the	Creighton	pedigree	
The	pedigree	we	received	from	Creighton	University	is	substantial.	We	received	both	
DNA	 and	 formalin-fixed	 paraffin-embedded	 (FFPE)	 blocks	 from	 Dr.	 Lynch	 to	 test	 for	 co-
segregation	 in	 this	 family.	 	For	 the	DNA	samples,	we	used	Sanger	sequencing,	but	 for	 the	
FFPE	 blocks,	 we	 used	 pyrosequencing.	 	 Samples	 from	 this	 pedigree	 included	 FFPE	 blocks	
from	before	1972,	and	contained	highly	cross-linked	and	fragmented	DNA,	making	Sanger	
sequencing	 difficult.	 	 Therefore,	 using	 pyrosequencing,	 which	 amplifies	 a	 much	 smaller	
fragment	 (~100-bp	 vs.	 500-800-bp)	 was	 advantageous.	 	 Even	 with	 the	 use	 of	
pyrosequencing,	we	found	that	we	needed	to	use	a	nested	PCR	in	a	clean	room	to	generate	
sufficient	 DNA	 from	 these	 samples	 and	 additional	 optimizations	 for	 FFPE	 samples	 as	
described	by	Doyle	et	al.	(106),	including	enrichment	of	the	polymerase	(106).	
These	data	showed	that	co-segregation	was	almost	complete	in	this	family.		Three	of	
four	tested	family	members	contained	the	exact	same	mutation,	including	two	with	cancer.		
The	fourth	is	a	theoretical	obligate	carrier.		She	has	not	yet	developed	cancer,	but	had	two	
children	with	breast	cancer	 (F,	diagnosed	at	35	y.o.,	dead	at	36	y.o.)	and	 lung	cancer	 (M,	
diagnosed	 at	 32	 y.o.	 dead	 at	 32	 y.o.).	 	 We	 have	 requested	 a	 second	 sample	 from	 this	
individual	for	retesting,	but	have	not	yet	received	it.			
We	 received	 one	 FFPE	 tumor	 sample	 from	Creighton	University;	when	 tested	 this	
tumor	had	retention	of	heterozygosity	(ROH).		However,	we	note	that	loss	of	heterozygosity	
(LOH)	may	not	be	required	for	tumorigenesis.		First,	given	the	limited	number	of	studies	on	
ARHGAP30,	 it	 is	not	 clear	 if	 the	gene	could	be	haploinsufficient.	 	 Secondly,	 in	 sequencing	
both	 human	 and	mouse	 LFS	 tumors	 with	 p53	mutations,	 it	 is	 clear	 that	 p53	 LOH	 is	 less	
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common	 than	 otherwise	 appreciated.	 	 Therefore,	 we	 do	 not	 consider	 this	 single	 result	
showing	ROH	to	rule	out	ARHGAP30	from	additional	consideration.	
To	 summarize,	 the	 same	 ARHGAP30	 mutation	 is	 found	 across	 multiple	 LFSL	
pedigrees,	and	appears	to	be	enriched	in	LFSL	families	over	the	general	population.	For	the	
most	part	co-segregation	is	complete	in	the	families	we	have	tested	so	far.		Taken	together	
these	 data	 suggest	 that	 this	 specific	 variant	 in	 ARHGAP30	 is	 a	 strong	 candidate	 for	 a	
putative	 cancer	 predisposition	 mutation,	 or	 at	 the	 very	 least,	 a	 modifier	 for	 cancer	
predisposition.	
3.7 Structure	of	ARHGAP30	
	
ARHGAP30	has	one	canonical	domain,	a	RhoGAP	domain	towards	the	5’	end	of	the	
gene	(codons	34-182),	and	two	primary	isoforms,	dubbed	here	as	a	long	isoform	(L-
ARHGAP30)	and	a	short	isoform	(S-ARHGAP30).		The	two	isoforms	differ	from	each	other	
only	by	a	glutamic	acid-rich	repeat.		The	ARHGAP30	mutation	is	marked	by	an	asterisk,	and	
lies	just	outside	this	region	(at	R806Q	in	the	short	isoform	and	at	R1017Q	in	the	long-
isoform).		
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Figure	16:	Depiction	of	important	elements	of	ARHGAP30	in	relation	to	the	mutation.		
ARHGAP30	has	only	one	known	domain.		The	long	and	short	isoforms	differ	only	by	a	
glutamic	acid	(E)	rich	element.		However,	the	putative	cancer	predisposing	mutation	
(marked	by	an	asterisk)	lies	outside	this	element.	
	
3.8 ARHGAP30	acts	like	a	tumor	suppressor	gene	
	
There	have	been	exactly	two	papers	published	on	ARHGAP30	to	date.		Both	papers	
suggest	that	ARHGAP30	 is	a	tumor	suppressor	gene	with	roles	consistent	with	cancer	(99,	
100).		In	the	first	paper,	the	majority	of	figures	lacked	controls,	and	few	conclusions	can	be	
drawn	 from	 it.	 	 However,	 data	 with	 controls	 indicate	 that	 when	WT	 ARHGAP30	 (short	
isoform)	 is	overexpressed,	PAE/PDGFRb	cells	are	 less	 spread	out,	and	more	 rounded,	and	
therefore	may	have	more	migratory	potential.	
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Figure	 17:	 Figure	 3a	 from	Naji	 et	 al.	 2011.	 	 In	 the	 presence	 of	 the	 overexpressed	 short	
isoform	of	WT	ARHGAP30,	cells	appear	significantly	more	rounded	relative	to	untreated	
controls,	 and	 may	 have	 more	 migratory	 capacity.	 	 Used	 with	 permission:	 Naji,	 L.,	 D.	
Pacholsky,	and	P.	Aspenstrom.	2011.	ARHGAP30	is	a	Wrch-1-interacting	protein	involved	
in	 actin	 dynamics	 and	 cell	 adhesion.	 Biochemical	 and	 biophysical	 research	
communications	409:	96-102.	L/N	4294720235318.	
The	 second	paper,	by	Wang	et	 al.	 is	 significantly	more	 comprehensive	 (100).	 They	
showed	 that	 ARHGAP30	 was	 significantly	 downregulated	 in	 colorectal	 cancer	 vs.	 normal	
tissues,	 and	 that	 it	was	 consistently	 associated	with	 poorer	 prognosis,	 having	both	 larger	
tumors	and	more	advanced	stages	of	cancer	on	average,	ARHGAP30	was	initially	identified	
via	a	microarray	analysis	of	TCGA	data	in	colorectal	cancer.	
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Figure	 18:	 Figure	 1a,c	 from	 Wang	 et	 al.	 2014.	 	 a)	 qRT-PCR	 data	 showing	 ARHGAP30	
expression	was	downregulated	 in	 colorectal	 cancer	 vs.	normal	 tissues.	 	 c)	Kaplan-Meier	
curve	 showing	 that	 higher	 ARHGAP30	 expression	 levels	 was	 correlated	 with	 survival.		
Used	with	permission:	Wang,	J.,	J.	Qian,	Y.	Hu,	X.	Kong,	H.	Chen,	Q.	Shi,	L.	Jiang,	C.	Wu,	W.	
Zou,	Y.	Chen,	J.	Xu,	and	J.	Y.	Fang.	2014.	ArhGAP30	promotes	p53	acetylation	and	function	
in	colorectal	cancer.	Nat	Commun	5:	4735.	L/N	4294720087364.	
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Importantly,	we	note	that	ARHGAP30	and	p53	mutations	should	not	be	considered	
to	be	mutually	exclusive.		Under	cBio	(22),	multiple	tumors	appear	to	have	alterations	in	
both	genes	(Figure	19),	including	a	very	small	subset	of	samples	that	have	truncating	
mutations	in	both	ARHGAP30	and	p53.
	
Figure	19:	ARHGAP30	and	p53	are	not	mutually	exclusive	according	to	data	from	cBio	
Oncoprint	(22).		Only	a	close	up	of	the	data	is	presented.	
	
3.8.1 ARHGAP30	has	a	role	in	cell	proliferation	and	migration	
	
Wang	 et	 al.	 tested	 the	 impact	 of	 stable	 overexpression	 of	 ARHGAP30	 across	 three	main	
ideas:	cell	proliferation,	cell	migration,	and	apoptosis,	finding	that	cells	transfected	with	WT	
ARHGAP30	 grew	 more	 slowly,	 moved	 less	 relative	 to	 controls,	 and	 promoted	 apoptosis	
(100).	
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Figure	20:	Figure	4a,b,c,e	from	Wang	et	al.	2014.	(100)	a)	MTT	assay	showing	proliferation	
of	 LoVo	 cells	 is	 decreased	 when	 ARHGAP30	 is	 over-expressed.	 	 Moreover	 this	
functionality	 seems	 to	be	 independent	of	 the	GAP	domain	 since	 the	effect	 in	 the	R55A	
mutant,	which	has	no	GAP-relation	functionality.		b)	HCT116	cells	also	grow	more	slowly	
in	 a	 GAP-independent	 manner.	 c)	 Both	 LoVo	 and	 HCT116	 cells	 showed	 increased	
apoptotic	activity	when	overexpressed,	and	e)	decreased	capacity	to	migrate	relative	to	
controls.		Used	with	permission:	Wang,	J.,	J.	Qian,	Y.	Hu,	X.	Kong,	H.	Chen,	Q.	Shi,	L.	Jiang,	
C.	Wu,	W.	Zou,	Y.	Chen,	J.	Xu,	and	J.	Y.	Fang.	2014.	ArhGAP30	promotes	p53	acetylation	
and	function	in	colorectal	cancer.	Nat	Commun	5:	4735.	L/N	4294720087364.	
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3.8.2 ARHGAP30	has	a	p53-dependent	role	in	cell	proliferation	and	migration	
	
The	authors	also	find	that	ARHGAP30	has	p53-dependent	effects.	Ectopic	expression	of	
WT	ARHGAP30	significantly	upregulates	p53-target	genes	like	p21,	NOXA,	BAX,	and	PUMA,	
an	effect	that	was	also	RhoGAP	domain-independent	in	HCT116	cells.		Moreover,	when	p53-
null	 HCT116	 cells	 were	 used,	 this	 effect	 was	 abrogated,	 and	 p53	 target	 genes	 were	 not	
upregulated.	 	 These	 effects	 extended	 to	 proliferation	 (Figure	 21j)	 and	 apoptosis	 assays	
(Figure	21k)	with	no	significant	effects	observed,	thus	suggesting	that	ARHGAP30	has	p53-
dependent	effects.	
	
Figure	21:	Figure	4.j,k	from	Wang	et	al.	2014	(100).	J;	 In	contrast	to	Figure	20b,	 in	a	p53	
null	HCT116	line,	ARHGAP30	overexpression	does	not	suppress	growth.		k;	similarly,	they	
observe	no	changes	in	apoptosis	in	a	p53	null	context.	Used	with	permission:	Wang,	J.,	J.	
Qian,	Y.	Hu,	X.	Kong,	H.	Chen,	Q.	Shi,	L.	Jiang,	C.	Wu,	W.	Zou,	Y.	Chen,	J.	Xu,	and	J.	Y.	Fang.	
2014.	ArhGAP30	promotes	p53	acetylation	and	function	in	colorectal	cancer.	Nat	Commun	
5:	4735.	L/N	4294740034573.	
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These	data	persisted	in	the	context	of	DNA	damage.	qRT-PCR	data	showed	that	cells	
treated	 with	 etoposide	 had	 upregulation	 of	 p53	 target	 genes,	 and	 that	 this	 effect	 was	
attenuated	 by	 knockdown	of	WT	ARHGAP30.	 	Moreover,	 chromatin	 immunoprecipitation	
(ChIP)	analysis	of	cells	with	ARHGAP30	knockdown	and	etoposide	treatment	found	reduced	
binding	 of	 p53	 to	 p21,	 BAX,	 NOXA,	 and	 PUMA.	 This	 effect	 seemed	 to	 be	 driven	 by	
acetylation	 of	 p53	 at	 Lys382	 (K382),	 which	 is	 known	 to	 activate	 p53.	 	 	 Additional	
experimentation	 found	 that	 this	 effect	 was	 abrogated	 by	 knockdown	 of	 p300,	 and	 that	
under	 co-immunoprecipitation,	 ARHGAP30	 can	 pull	 down	 both	p53	and	p300.	 	 However,	
these	p53-dependent	effects	were	found	to	be	long-isoform	specific,	rather	than	the	short-
isoform	of	ARHGAP30,	suggesting	a	functional	role	for	the	glutamic	acid	rich	element	in	the	
carboxy	terminus	of	the	gene.	
3.9 ARHGAP30		c.G161,017,761A/p.R>Q	has	cancer-like	functions	for	both	the	
long	isoform	(p.R1017Q)	and	the	short	isoform	(p.R806Q)	
	
Given	 our	 strong	 genetic	 evidence,	 including	 co-segregation	 and	 recurrence,	
implicating	ARHGAP30	R1017Q/R806Q	as	a	putative	cancer	predisposition	mutation,	as	well	
as	 the	 functional	 data	 presented	 by	 Wang	 et	 al.	 (100),	 we	 next	 tested	 if	 our	 mutation	
conferred	 any	 cancer-like	 advantages	 when	 transfected	 in	 vitro.	 	 In	 line	 with	 previous	
experiments,	we	first	sought	to	test	cell	migration	and	cell	proliferation.	
We	assayed	several	 sarcoma	cell	 lines,	plus	 the	HEK293T	cell	 line	as	a	 transfection	
control.		In	addition,	we	perused	the	Cancer	Cell	Line	Encyclopedia	(CCLE)	(107)	to	look	for	
cell	lines	with	no,	or	low	expression	of	ARHGAP30	to	better	test	the	potential	effects	of	the	
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mutation,	 but	weren’t	 able	 to	 find	 any.	 	Therefore,	we	 picked	 the	 cell	 line	with	 sarcoma	
lineage,	 and	 lowest	 expressing	 ARHGAP30,	 Hs	 863.T.	 	 No	 CCLE	 cell	 lines	 had	 reported	
mutations,	truncating,	missense,	or	otherwise	in	ARHGAP30.	
	
Table	8:	Table	of	sarcoma	cells	lines	used	for	transfection,	with	p53	status	and	ARHGAP30	
status	included.	
Cell	Line	 Tissue	 p53	status	 ARHGAP30	status	
HEK293T	 Kidney	 p53	R280S	(108)w	 WT,	Norm.	Expr.	
U-2	OS	 Osteosarcoma	 p53	WT	 WT,	Norm.	Expr.	
Saos-2	 Osteosarcoma	 p53	deletion	homozygous;	
c.1-1182del1182	(ATCC)	
WT,	Norm.	Expr.	
HT-1080	 Fibrosarcoma	 p53	WT	 WT,	High	Expr.	
Hs.	863T	 Ewing	Sarcoma	 p53	WT	 WT,	Low	Expr.	
	
Given	that	LFSL	arises	out	of	a	p53	WT	background,	we	would	certainly	expect	to	see	
an	effect	 in	cell	 lines	with	WT	p53.	 	However,	because	p53	mutations	are	so	 important	 in	
the	context	of	LFS,	and	because	ARHGAP30	has	been	demonstrated	to	interact	with	p53,	we	
felt	it	valuable	to	concurrently	consider	the	potential	ramifications	of	cooperativity	between	
the	two	genes.		Moreover,	p53	null	mice	seemed	to	abolish	the	effect	of	ARHGAP30	across	
several	phenotypes	(100).	
	 59	
To	generate	the	appropriate	mutant	plasmids,	we	acquired	expression	constructs	for	
the	short-	and	long-	isoforms	from	Origene	and	used	site-directed	mutagenesis	to	introduce	
our	putative	LFSL	mutation.	 	After	sequencing	the	WT	and	mutant	plasmids	to	ensure	the	
appropriate	sequence	and	mutation	were	present,	we	next	tested	transfection	across	both	
Lipofectamine	3000	(LPF)	and	FuGene	6	(FG6),	finding	overall	better	results	for	FG6	(FG6),	
especially	 for	 Saos-2.	 Indeed	 for	 Saos-2,	 when	 staining	 for	 ARHGAP30,	 we	 observed	
practically	no	transfection	when	using	LPF.		For	two	other	cell	lines	(HT-1080,	293T),	we	also	
observed	that	FG6	appeared	to	transfect	at	higher	efficiencies.		However,	for	the	fourth	cell	
line,	U-2	OS,	we	observed	the	reverse;	LPF	appeared	to	perform	better	(Figure	22).		For	the	
fifth	 cell	 line,	 with	 low-expressing	 ARHGAP30	 (Hs	 863.T),	 the	 cells	 did	 not	 survive	
transfection	with	either	FG6	or	LPF	and	therefore	could	not	be	pursued	further.		Given	that	
we	did	see	successful	transfection	with	FG6	for	U-2	OS	though,	to	best	include	Saos-2,	we	
decided	to	use	FG6	moving	forward.			
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Figure	 22:	 Western	 Blot	 performed	 in	 conjunction	 with	 Kevin	 Tracy	 (CPRIT	 summer	
student)	 comparing	 the	 efficacy	 of	 transfecting	 U-2	 OS,	 HT-1080,	 HEK293T,	 and	 Saos-2	
with	 either	 Lipofectamine	 3000,	 or	 FuGene	 6,	 across	 both	 wild-type	 and	 mutant	
ARHGAP30	(long-isoform).		Stained	with	an	ARHGAP30	antibody	specific	for	long-isoform.		
Control	was	selected	from	a	previous	experiment	with	positive	staining.		The	data	suggest	
that	overall,	cells	transfected	with	FuGene	6	appear	to	uptake	more	of	the	plasmid	and/or	
produce	 more	 protein.	 	 This	 is	 especially	 true	 for	 Saos-2	 (left	 edge	 of	 figure),	 where	
transfection	was	almost	non-existent	when	using	lipofectamine.	
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3.10 ARHGAP30	R806Q/R1017Q	have	increased	migratory	potential	
To	test	migratory	potential,	we	used	a	scratch	assay.			
3.10.1 HEK293T	
In	HEK293T	cells,	we	observed	that	cells	 transfected	with	mutant	ARHGAP30	appeared	to	
show	increased	migratory	capability.	 	Due	to	the	nature	of	the	cell	 line,	during	scratching,	
cells	 came	 off	 in	 sheets,	 and	 were	 unable	 to	 limit	 the	 scratch	 to	 a	 single	 field-of-view.	
	
Figure	 23:	 Scratch	 assay	 of	 HEK293T	 cells,	 transfected	 with	 either	 WT	 or	 mutant	 L-
ARHGAP30.		Cells	transfected	with	mutant	ARGHAP30	had	increased	migratory	potential.	
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3.10.2 U-2	OS	
U-2	OS	cells	are	WT	for	p53	and	therefore	fall	best	in	line	with	what	we	would	expect	to	see	
in	 an	 LFSL	 patient	 without	 inherited	 TP53	 mutations.	 	 In	 these	 cells,	 we	 see	 the	 most	
dramatic	 change	 of	 all	 tested	 cell	 lines	 when	 comparing	 the	 wound	 healing	 capability	
between	transfection	with	WT	and	mutant	plasmids.		Cells	transiently	transfected	with	WT	
ARHGAP30	 (both	 long-	 and	 short-isoforms)	 show	 limited	 ability	 to	 close	 the	 wound.	 	 In	
contrast,	 the	 mutant	 L-ARHGAP30	 shows	 pronounced	 ability	 to	 close	 the	 gap	 with	 the	
shorter	 isoform	 showing	more	 limited,	 but	 still	 significant	 ability	 to	 close	 the	 intervening	
space	(Figure	24).			Given	that	U-2	OS	cells	are	WT	for	p53,	these	data	demonstrate	that	the	
ARHGAP30	 mutation	 is	 sufficient	 to	 generate	 an	 effect	 even	 when	 p53	 is	 not	 disrupted,	
including	in	an	LFSL	patient-related	context.	
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Figure	24:	Scratch	assay	of	U-2	OS	cells	shows	dramatically	improved	ability	to	close	the	
gap	when	transfected	with	mutant	ARHGAP30,	particularly	for	the	long-isoform	compared	
to	WT-transfections.	
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3.10.3 Saos-2	
Saos-2	cells	are	p53-null,	but	we	again	see	increased	ability	of	the	cells	to	close	the	wound	
under	 transient	 transfection	of	 the	mutant	 relative	 to	WT	controls,	although	 this	effect	 is	
not	as	dramatic	as	in	U-2	OS.		One	distinct	difference	here	though	is	that	the	short-isoform	
shows	 increased	closure	 relative	 to	 the	 long-isoform	 (Figure	 25).	 	Given	 that	Saos-2	cells	
are	null	 for	p53,	these	data	suggest	that	the	effect	 is	present	even	 in	the	absence	of	p53.	
Although	 the	 result	 is	 not	 as	 accelerated	 as	 in	 U-2	 OS	 cells,	 taken	 together	 these	 data	
continue	to	point	towards	a	p53-independent	mechanism.	
	
Figure	25:	Scratch	assay	of	Saos-2	cells.		Mutant	ARHGAP30	was	not	able	to	close	the	gap	
entirely	 over	 48	 hours,	 but	 did	 show	 increased	movement	 relative	 to	 cells	 transfected	
with	WT	ARHGAP30.	 	
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3.10.4 HT-1080	
Similar	 to	U-2	OS	 cells,	 HT-1080	 cells	 are	WT	 for	p53	 (53,	 107).	 	 However,	 in	 contrast	 to	
previous	data,	the	endogenously	high	ARHGAP30	HT-1080	cells	closed	remarkably	quickly,	
including	when	the	WT-ARHGAP30	plasmids	are	overexpressed,	having	closed	after	just	24-
hours	 (Figure	 26).	 	 Notably,	 even	 the	 untreated	 (?)	 control	 (with	 endogenously	 high	
ARHGAP30	 levels)	 is	 able	 to	 somewhat	 close	 the	wound	 (though	not	 completely).	 	Again,	
mutant	 ARHGAP30	 shows	 increased	 ability	 to	 close	 relative	 to	WT	 transfections,	 but	 this	
effect	is	somewhat	muted	given	the	rapid	closing.	
	
Figure	26:	Scratch	assay	of	HT-1080	data.		Both	WT	ARHGAP30	and	mutant	ARHGAP30	are	
able	to	close	the	wound	over	30	hours.	Mutant	ARHGAP30	does	lead	to	marginally	faster	
wound	closure	relative	to	WT	ARHGAP30.	
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3.10.5 Summary	of	wound	healing	experiments	
	
These	data	can	be	summarized	either	qualitatively	(as	shown	in	Figure	27)	or	
quantitatively.			
	
Figure	27:	Qualitative	description	of	the	closure	results	across	the	four	cell	lines,	and	
various	transfection	conditions.		More	“+”,	implies	a	faster	closure	rate.	
Quantitative	representation	can	be	done	in	two	ways.		First,	we	can	try	to	find	the	size	
of	the	wound	by	finding	the	leading	edges	of	the	wound	and	using	a	lasso-type	tool	to	try	to	
determine	the	most	appropriate	area.		This	approach	has	challenges	when	the	leading	edge	
is	not	well	defined	–	either	from	being	slightly	out	of	focus,	or	from	live	cells	which	are	
migrating,	but	not	part	of	a	distinct	edge.		It	also	has	the	potential	to	be	subjective.		The	
second	approach	uses	a	threshold	tool;	since	cells	are	often	darker	than	the	unclosed	
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wound,	this	fact	can	be	used	to	identify	the	percentage	of	the	field	of	view	that	is	covered	
by	cells.		This	has	the	advantage	of	perhaps	being	more	unbiased,	and	is	better	at	picking	up	
lone	cells	in	the	middle	of	the	wound,	or	at	correcting	for	cases	where	cells	may	be	
migrating	more	than	proliferating	(leaving	some	areas	as	being	less	dense).	
We	have	used	the	first	method,	measuring	the	area	every	three	hours,	because	we	
found	it	to	be	less	error	prone	given	the	quality	of	pictures	that	we	obtained,	but	
quantification	makes	one	simple	fact	clear.		Despite	efforts	to	the	contrary,	it	is	difficult	to	
create	single	scratches	with	the	same	exact	width	–	see	different	starting	points	for	%	
Covered	for	various	treatments	(Figure	28).	
	
Figure	28:	Quantification	of	wound	closure	in	HT-1080	cells.			
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3.11 ARHGAP30	R806/1017Q	proteins	show	increased	proliferative	capacity	
3.11.1 HEK293T	
Consistent	with	ARHGAP30’s	status	as	a	tumor	suppressor	gene,	in	293T	cells	we	observed	
suppression	of	growth	when	cells	were	treated	with	WT	ARHGAP30,	but	when	treated	with	
mutant	ARHGAP30	we	saw	although	they	did	not	confer	a	proliferative	advantage	relative	
to	 a	 control,	 they	 did	 appear	 to	 abolish	 the	 slower	 growth	 rates	 observed	 when	
overexpressing	WT	ARHGAP30.	
	
Figure	 29:	 Proliferation	 assay	 of	 HEK293T	 cells	 showing	 reduced	 growth	 rates	 in	
conjunction	with	WT	ARHGAP30	transfection.	 	Cells	transfected	with	mutant	ARHGAP30	
in	contrast	show	increased	proliferation.	
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3.11.2 U-2	OS	
In	 contrast,	 in	 U-2	 OS	 cells,	 we	 saw	 a	much	more	muted	 response,	 although	 the	 overall		
phenotype	 is	 similar	 to	 293T	 cells.	 	 Cells	 transfected	with	WT	ARHGAP30	 did	 grow	more	
slowly	 relative	 to	 a	 control,	 and	 cells	 transfected	 with	 mutant	 ARHGAP30	 appeared	 to	
abrogate	some	of	that	response	bringing	it	nearly	in	line	with	the	control,	but	not	above	the	
control.	
	
Figure	 30:	 Proliferation	 assay	 of	 U-2	OS	 has	minimal	 differences	 between	 the	 different	
conditions.		However,	there	do	appear	to	be	slight	differences	consistent	with	ARHGAP30	
being	a	tumor	suppressor	gene,	and	the	mutant	abrogating	some	tumor	suppressor-like	
behavior	via	increased	growth	rates.	
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3.11.3 Saos-2	
Data	for	Saos-2	appears	to	run	somewhat	counter	to	the	previous	data.		We	saw	a	trend	for	
the	 long	 isoform	that	seems	to	be	similar	to	that	observed	for	293T	and	U-2	OS	cells,	but	
not	 for	 the	 short	 isoform.	 	 Namely	 transfection	 with	WT	ARHGAP30	 suppresses	 growth,	
while	 transfection	with	mutant	ARHGAP30	 leads	 to	higher	growth	 rates	more	 in	 line	with	
the	control.		However,	we	note	that	making	this	assumption	assumes	that	cells	were	seeded	
at	the	same	initial	concentration	at	time	of	zero	hours.	
	
Figure	31:	Proliferation	assay	of	Saos-2	showing	that	mutant	ARHGAP30	appears	to	have	
an	effect	in	the	long-isoform,	but	not	the	short-isoform.	
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3.11.4 HT-1080	
Similar	 to	 the	 scratch	 assay,	 in	 HT-1080	 cells,	 it	 is	 difficult	 to	 tease	 out	 a	 difference	 in	
proliferation	rates	between	transfecting	with	WT	or	mutant	ARHGAP30	 for	both	the	short	
and	long	isoforms.			
	
Figure	 32:	 Proliferation	 assay	 for	 HT-1080s	 showing	 minimal	 differences	 between	 the	
various	transfections.	
4 Discussion	
	
Co-segregation	 analysis	 was	 used	 to	 isolate	 a	 plausible	 LFSL	 gene.	 	We	 identify	 a	
reasonably	 rare,	 co-segregating	 mutation	 in	 1q23	 that	 is	 recurrent	 across	 multiple	 LFSL	
pedigrees.	 	Moreover,	 this	gene	has	demonstrated	significance	 in	colorectal	 cancer	 in	 the	
literature	(100),	and	our	functional	evidence	shows	the	mutation	itself	appears	capable	of	
inducing	cancer-like	phenotypes	such	as	proliferation	and	migration.	
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	 The	 functional	 data	 presents	 an	 interesting	 picture	 when	 juxtaposed	 against	 the	
results	from	Wang	et	al.	(100).	Previously,	these	authors	showed	ARHGAP30	overexpression	
was	found	to	have	no	effect	on	apoptosis,	proliferation,	and	expression	of	p53	target	genes	
in	p53	null	HCT116	cells	(100).		This	left	one	big	arm	of	their	functional	work	unexplored	–	
what	 happens	 to	migration	 in	 an	 ARHGAP30	 overexpression/p53	 null	 background.	 If	 cell	
migration	is	abrogated	alongside	apoptosis	and	proliferation	in	p53	null	HCT116	cells,	it	runs	
in	 direct	 contrast	 to	 what	 we	 observe	 in	 Saos-2	 cells.	 	 In	 Saos-2	 cells	 with	 the	 cancer	
predisposing	 mutation,	 cells	 are	 able	 to	 close	 the	 cap	 relative	 to	 overexpression	 of	 WT	
ARHGAP30.	 	This	suggests	 that	not	only	does	 the	ARHGAP30	p.R>Q	mutation	have	a	p53-
independent	means	of	 impacting	tumorigenesis,	but	also	that	 it	may	be	a	gain-of-function	
mutation.				
	 Consistent	 with	 this	 interpretation,	 we	 observe	 wound	 healing	 and	 proliferation	
phenotypes	 across	 both	 S-ARHGAP30	 and	 L-ARHGAP30,	 where	 as	 data	 from	Wang	 et	 al.	
(100)	suggest	that	p53	acetylation	is	L-ARHGAP30	specific.		If	our	mutation	were	to	impact	
phenotypes	through	acetylation,	we	would	not	expect	to	see	differences	in	S-ARHGAP30.	
Interestingly,	the	effect	on	wound	healing	is	greatest	in	WT	p53	U-2	OS	cells,	placing	
further	 weight	 on	 a	 p53-independent	 mechanism	 for	 mutant	 ARHGAP30.	 	 However,	 we	
acknowledge	 that	 some	of	 this	difference	could	be	due	 to	 reduced	 transfection	efficiency	
(Figure	22),	and/or	cell	properties.		Gaps	in	wound	healing	are	typically	closed	through	cell	
proliferation	and/or	cell	migration	and	of	the	cells	cultured,	Saos-2	cells	grew	the	slowest.	
Our	data	from	HT-1080	are	curious.	 	ARHGAP30	expression	is	constitutively	high	in	
this	 cell	 line	 relative	 to	 other	 cell	 lines	 that	 we	 used	 (Figure	 33),	 and	 has	 no	 known	
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mutation	 in	ARHGAP30	 according	 to	 the	 CCLE	 (107).	 Given	 that	ARHGAP30	 is	 a	 putative	
tumor	suppressor	gene,	and	the	previous	establishment	that	WT	ARHGAP30	can	negatively	
impact	cell	motility	(99,	100),	we	might	expect	these	cells	to	have	the	most	limited	response	
to	the	wound	healing	assay.		Instead,	they	have	the	most	pronounced	effect,	closing	within	
30	 hours,	 perhaps	 suggesting	 that	 these	 cells	 have	 acquired	 some	 sort	 of	 escape	
mechanism.	 	Moreover,	 additional	WT	ARHGAP30	exacerbates	 the	 closure	 relative	 to	no-
treatment	controls,	which,	on	its	own,	implies	ARHGAP30	acts	more	like	an	oncogene	in	this	
cell	 line.	 	Data	from	the	wound	healing	assay	 indicates	that	overexpression	of	the	mutant	
construct	slightly	improves	closure	relative	to	WT	ARHGAP30,	but	overall	these	data	suggest	
that	the	contribution	of	ARHGAP30	to	tumor	etiology	in	HT-1080	may	be	considerably	more	
complex	than	first	expected.	
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Figure	33:	qPCR	data	for	several	cell	lines,	showing	that	ARHGAP30	expression	in	HT-1080	
cells	 are	 significantly	 higher	 than	 healthy	 skin	 fibroblasts,	 a	 colorectal	 cancer	 cell	 line	
(HCT116)	osteoblasts	(hOB),	or	two	osteosarcoma	lines	(U2OS,	Saos-2).	
In	addition,	we	had	previously	begun	to	look	at	the	potential	effect	of	ARHGAP30	
mutations	on	downstream	effectors	of	p53	(Figure	34).		These	data	were	generated	by	Dr.	
Yu	Deng	in	the	Krahe	Lab.			She	used	lymphoblastoid	cell	lines	(LBCLs)	from	STS200,	three	
with	the	ARHGAP30	p.R>Q	mutation,	and	one	with	WT	ARHGAP30	(“009”).		She	cultured	all	
four	lines,	and	then	treated	each	with	and	without	radiation.		Focusing	only	on	the	
untreated	samples,	we	see	that	as	expected,	levels	of	p53	are	about	the	same	across	all	
individuals.		However,	the	levels	of	p21	are	not	the	same.		In	patient-derived	LBCLs	with	the	
mutant	ARHGAP30,	we	saw	lower	levels	of	p21.		Thus,	it	is	possible	that	ARHGAP30,	in	
addition	to	interacting	with	p53,	may	also	be	part	of	a	p21,	p53-independent.	
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Figure	34:	Western	blot	of	p53	and	p21.	Data	generated	by	Yu	Deng,	Ph.D.	 (A)	Western	
blot	 showing	protein	 levels	of	p53	and	p21	 in	 STS200-derived	 cells.	 	 LBCLs	 from	STS200	
were	 untreated	 (-)	 or	 irradiated	 (+)	 to	 check	 for	 p53	 acetylation	 in	 response	 to	 the	
stressor.		Concomitantly,	we	checked	for	a	response	in	a	p53	downstream	target,	p21.	(B)	
Quantification	of	the	protein	levels	of	p53	and	p21	in	non-irradiated	cells	shows	reduced	
p21	levels	in	cancer	patients.	ARHGAP30	genotypes	are	provided	above/below	patient	IDs	
to	aid	interpretation:	AA	–	homozygous	WT,	AB	–	heterozygous	mutant,	BB	–	homozygous	
mutant.	
We	 next	 considered	 potential	 relevance	 to	 sporadic	 sarcomas.	 	 Under	 cBio,	
ARHGAP30	 is	 recurrently	 mutated	 in	 just	 0.7%	 of	 all	 samples,	 and	 our	 specific	 germline	
variant	 has	 not	 yet	 been	 called	 in	 publicly	 available	 somatic	mutation	 data.	 	 However,	 it	
turns	out	that	our	mutation	is	assayed	by	SNP	arrays.	 	We	worked	with	Dr.	Keith	Baggerly	
and	 Dr.	 Ying	 Wang	 to	 acquire	 these	 data	 and	 to	 generate	 a	 list	 of	 tumors	 and	 their	
genotypes.		We	sorted	by	genotype,	letting	the	A-allele	stand	for	the	WT-allele,	and	the	B-
allele	 for	 the	mutant-allele.	 	We	 then	 counted	 total	 alleles,	 and	 ran	 a	 one-sided	 Poisson	
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approximation	 to	 see	 how	 likely	we	were	 to	 uncover	 at	 least	 that	many	 alleles.	 	We	 ran	
these	 data	 under	 two	 conditions,	 once	 for	 the	 lowest	 reported	MAF	 (0.86%,	 dbSNP)	 and	
once	 for	 the	 highest	 (2.72%,	 ESP-EA).	 	 At	 the	 lower	 allele	 frequency,	 multiple	 cancers	
appear	to	be	enriched	for	the	mutation,	but	when	using	the	ESP	as	a	baseline,	there	is	just	
one	 showing	 statistical	 significance,	 colorectal	 adenocarcinoma	 (COAD).	 	We	 further	note	
that	 for	 COAD	 tumors,	 there	 are	 seven	 tumors	with	 a	 “BB”	 genotype,	 versus	 six	with	 an	
“AB”	genotype	–	 these	data	 imply	 that	LOH	may	be	a	 reasonably	common	event	 in	 these	
tumors.	
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Table	 9:	 Table	 showing	 allele	 incidence	 of	ARHGAP30	 c.G>A,	 p.R>Q	 in	 TCGA	 SNP	 array	
data	 (data	 generated	 by	 the	 TCGA:	 “http://cancergenome.nih.gov”).	 	 p-values	 are	
calculated	 via	 a	 Poisson	 approximation	 to	 determine	 if	 we	 saw	 enrichment	 for	 the	
number	 of	 mutant	 alleles	 relative	 to	 expectation	 based	 on	 MAF	 (dbSNP,	 0.86%;	 ESP,	
2.72%).		Data	highlighted	in	red	have	p-values	less	than	0.05.	
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Despite	 these	 data,	 there	 are	 a	 couple	 of	 mitigating	 questions	 remaining	 to	 be	
answered.	 	 First,	 the	 co-segregation	 analyses	 suggest	 that	 co-segregation	 may	 not	 be	
canonically	complete.		However,	we	believe	there	are	plausible,	if	rare,	scenarios	that	could	
explain	these	seemingly	“outlying”	individuals.			
First,	 for	 the	 one	 individual	 in	 STS200	 that	 is	 homozygous	 for	 the	 mutation	 of	
interest	 (STS200-032),	 it	 is	 unlikely,	 but	 not	 impossible	 that	 she	 received	 a	mutant	 allele	
from	 both	 parents.	 	 Alternatively,	 she	 could	 have	 experienced	 an	 extremely	 early	 gene	
conversion	event	that	resulted	in	an	extended	stretch	of	LOH.		To	address	this	possibility	we	
used	our	WGS	data	and	looked	in	the	region	near	ARHGAP30	and	plotted	whether	variants	
were	 homozygous	 for	 the	 alternate	 allele	 (blue),	 or	 heterozygous	 for	 the	 alternate	 allele	
(red).	 	 If	 the	 sample	was	 homozygous	WT,	we	 left	 it	white/blank.	 	 In	 this	 region,	 it	 does	
appear	 as	 if	 the	 STS200-032	 sample	 is	 on	 average	more	 homozygous	 for	 the	 SNVs/SNPs	
interrogated	(Figure	35),	though	it	impossible	to	say	for	sure.		A	third,	related	possibility	is	
uniparental	 disomy	 (UPD),	 in	which	 two	 copies	 of	 the	 chromosome	 come	 from	 the	 same	
parent.		This	may	also	help	explain	some	of	the	other	heterozygous	mutations	in	this	region	
in	 STS200-032,	 the	majority	 of	 which	 are	 rare.	 	 Unfortunately,	 to	 definitively	 distinguish	
between	all	possibilities	is	 impossible	in	the	absence	of	an	available	DNA	sample	from	the	
mother.	
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Figure	35:	CIRCOS	plot	showing	possible	gene	conversion	event.		Homozygous	events	are	
in	 blue	 and	white/blank.	 	 Heterozygous	 events	 are	 red.	 	 The	majority	 of	 samples	 have	
significant	 heterozygous	 variants	 in	 this	 region,	with	 the	 exception	 of	 STS200-032.	 	We	
feel	that	this	data	could	be	consistent	with	a	gene	conversion	event.	
In	 addition	 to	 STS200,	 one	 other	 co-segregation	 question	 remains	 under	
investigation.	 	One	theoretical	obligate	carrier	 in	 the	Creighton	pedigree	did	not	have	the	
ARHGAP30	mutation.	 	She	had	two	children	with	LFSL-associated	cancers	(breast	and	lung	
cancer,	 both	 before	 the	 age	 of	 40).	 	 However,	 she	 is	 in	 a	 more	 distant	 branch	 of	 the	
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pedigree,	 and	 it	 is	 possible	 that	 she	 has	 a	 second,	 non-ARGHAP30	 cancer	 predisposition	
gene.	 	 Alternatively,	 it	 is	 possible	 that	 the	 father	may	have	 carried	 a	 cancer-predisposing	
mutation;	however,	no	information	is	known	about	his	family.	
	 However,	 we	 do	 not	 consider	 the	 MAF	 a	 major	 sticking	 point.	 	 As	 previously	
discussed,	 emerging	 research	 suggests	 that	 germline	p53	variants	may	 be	more	 common	
than	previously	expected.	 	Thus,	 it	may	be	perfectly	 reasonable	to	have	a	more	common,	
less	 penetrant	 allele	 (p53	 or	 non-p53),	 even	 for	 a	 rare	 disease.	 	 Interestingly,	we	 do	 not	
observe	any	variants	 in	known	cancer	genes	–	 this	 implies	either	 that	ARHGAP30	has	 the	
potential	 to	 have	 a	 strong	 monogenic	 effect,	 or	 that	 there	 are	 additional	 yet	 to	 be	
uncovered	polygenic	or	modifier	genes	that	further	modulate	sarcomagenesis.		For	example	
MDM2	SNP309,	with	a	high	MAF,	affects	tumorigenesis	(1.3.1).	
	
5 Future	Directions	in	ARHGAP30	R806Q/R1017Q	
	
Our	evidence	strongly	supports	that	ARHGAP30	and	the	p.R806/1017Q	mutation	is	a	
recurrent,	 co-segregating,	 cancer	predisposition	gene	 in	 LFSL	 families.	 	However,	we	note	
that	 these	 data	 do	have	 some	mitigating	 question	marks.	 	 The	 variant	 is	 not	 overly	 rare,	
putting	it	in	line	with	a	previous	purported	LFSL	gene/mutation	CHEK2	1100delC,	and	in	the	
STS200	pedigree	has	an	unexpected	outlier,	 a	 single	homozygous	 case.	 	Moreover,	 in	 the	
one	tumor	we	have	been	able	to	sequence,	we	were	not	able	to	detect	LOH.		However,	we	
feel	that	there	are	plausible	explanations	for	each	of	these	scenarios	and	thus	do	not	derail	
the	 underlying	 genetic	 and	 functional	 evidence	 presented.	 	 We	 further	 note	 functional	
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experiments	would	best	be	done	in	backgrounds	of	null	ARHGAP30	to	determine	if	this	was	
a	GOF	mutation.	
We	 propose	 two	 fundamental	 ways	 to	 move	 forward	 with	 this	 project:	 First,	
sequence	 (non-p53)	 LFSL	 pedigrees	 lacking	 p.R806/1017Q	 mutations	 for	 additional	
mutations	 elsewhere	 in	 ARHGAP30.	 	 If	 ARHGAP30	 follows	 the	 pattern	 of	 other	 tumor	
suppressor	genes,	including	p53,	 it	should	have	mutations	elsewhere	in	the	gene	that	also	
give	rise	to	LFSL.		Identification	of	further	families	with	additional	mutations	would	greatly	
strengthen	the	argument	that	ARHGAP30	is	an	LFSL,	cancer-predisposition	gene.		Secondly,	
explore	 the	 functional	 implications	 in	 vivo	 through	 the	 use	 of	 a	 mouse	 model.	 	 CRISPR	
technology	 has	 greatly	 impacted	 the	 ease	 and	 feasibility	 of	 generating	 mice	 with	 single	
point	mutations	such	as	in	the	ARHGAP30	RQ	variant.		Following	generation	of	appropriate	
mouse	model	 and	 cohort	with	 the	mutation(s)	 of	 interest,	we	 can	 the	 track	 and	observe	
tumor	 formation	 in	 the	mice.	 	Moreover,	 in	 conjunction	with	 this,	 it	will	 be	 important	 to	
check	 for	 LOH	 in	 tumors,	 both	 in	 the	 mice,	 or	 in	 humans,	 where	 tumor	 samples	 are	
available,	to	look	for	characteristic	LOH.	
We	note	that	there	are	many	other	possible	in	vitro	experiments	that	could	be	run,	
to	explore	other	potential	functional	implications.		For	example,	we	have	not	yet	looked	at	
apoptosis,	in	which	ARHGAP30	plays	a	known	role.	(100)		More	to	the	point,	we	have	so	far	
focused	on	overexpression	of	ARHGAP30	in	cells	with	endogenous	ARHGAP30;	therefore,	it	
may	 be	 worth	 interrogating	 the	 results	 in	 an	 ARHGAP30	 null	 background,	 or	 comparing	
results	against	the	cell	lines	when	ARHGAP30	has	been	silenced.		
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6 Introduction:	Sarcomagenesis	and	Somatic	Mutations	
6.1 LFS	is	a	model	for	identifying	acquired	somatic	mutations	in	sarcomagenesis	
Cancer	 has	 been	 attributed	 to	 a	 variety	 of	 factors,	 including	 germline	 cancer	
predisposition	 mutations,	 as	 well	 as	 somatic	 alterations.	 	 In	 the	 first	 portion	 of	 the	
dissertation,	we	leveraged	LFSL	to	identify	a	novel	germline	cancer	predisposition	mutation	
in	ARGHAP30.	 	 In	 the	second	portion,	we	 leverage	 tumors	 from	LFS	patients,	with	known	
p53	mutations,	 to	address	 the	potential	 contributions	of	 somatic	alterations.	 	Despite	 the	
ubiquity	of	p53	mutations	 in	human	cancers,	 some	 individuals	 in	 LFS	pedigrees	 (with	p53	
mutations)	do	not	develop	cancer	(56,	93),	or	develop	cancer	very	late,	suggesting	that	the	
p53	mutation	alone	 is	 insufficient	 for	 tumorigenesis	and	that	additional,	acquired	somatic	
changes	are	necessary.	 	Thus,	we	propose	to	use	p53-LFS	as	a	model	for	 identifying	these	
changes,	particularly	those	involved	in	sarcomagenesis.	
6.2 Sarcomas	are	incredibly	diverse	
The	 rarity,	 heterogeneous	 composition,	 and	numerous	 subtypes	of	 sarcomas	have	
complicated	 elucidation	 of	 genetic	 risk	 factors	 and	 driver	 mutations.	 	 A	 recent	 study	
implicates	ATM	and	ATR	as	risk	factors	(16),	but	lacked	the	statistical	power	to	definitively	
determine	one	way	or	the	other.		Moreover,	sequencing	done	by	the	TCGA	has	shown	that	
different	 sarcoma	 subtypes	 tend	 to	 have	 distinct	mutational	 profiles	 across	 the	 genome,	
methylome,	 transcriptome,	 and	 proteome	 (10),	 implying	 sample	 selection	 is	 critical	 to	
achieve	statistical	power.		Thus,	researchers	are	faced	with	a	conundrum	–	sequence	many	
more	disparate	sarcomas,	and	try	to	work	around	confounding	from	multiple	subtypes,	or	
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attempt	to	acquire	additional	sarcomas	of	more	similar	subtypes,	of	which	samples	may	be	
limited,	even	in	large	consortiums.	
6.3 Benefits	and	Disadvantages	of	working	with	Human-LFS	sarcomas		
Under	 LFS,	 sarcomas	 are	 a	 fairly	 common	 cancer,	 representing	 about	 25%	 of	 all	
tumors	 (13%	STS	 and	10%	OS,	Figure	 6)	 (53),	 suggesting	 perhaps	 that	 sarcomagenesis	 is	
largely	 driven	 by	 p53.	 	 However,	 p53	
alterations	 are	 present	 in	 only	 about	 half	 of	
all	sporadic	sarcomas	(10),	and	data	from	cBio	
seems	to	suggest	that	even	this	50%	number	
may	 be	 somewhat	 of	 an	 overestimate	
(depending	on	ascertainment)	(Figure	36).			
	
Figure	 36:	 Five	 sarcoma	 studies	 have	 been	
recorded	 in	 cBio,	 covering	 bone	 sarcomas	 (Ewing),	 and	 soft	 tissue	 sarcomas	 (mostly	
liposarcomas	 and	 leiomyosarcomas).	 	 From	 left	 to	 right,	 these	 comprise	 249,	 265,	 207,		
107,	 and	 43	 samples.	 	 These	 data	 suggest	 that	 alterations	 in	 p53	 are	 not	 particularly	
common	in	sarcomas,	topping	out	at	~60%.	
We	also	leveraged	cBio	to	check	for	tumors	with	alterations	in	any	of	MDM2,	MDM4,	and	
TP53	with	 about	 45%	 of	 sarcomas	 having	 an	 alteration	 in	 at	 least	 one	 of	 these	 genes,	
including	 a	 high	 percentage	with	MDM2	 amplification	 (Figure	 37).	 	 Taken	 together,	 and	
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considering	 the	 prevalence	 of	 sarcomas	 in	 LFS-patients/pedigrees,	 these	 data	 seem	 to	
indicate	a	role	for	p53	in	sarcomagenesis.	
	
	
Figure	37:	cBio	Oncoprint	plot	showing	distribution	of	MDM2/MDM4/TP53	alterations	in	
sarcomas,	covering	45%	of	tumors.		
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Figure	38:	IARC	data.	(89)		Histogram	of	p53	mutations	that	have	reported	families	
meeting	the	classical	criteria	for	LFS	(n=442).		Of	these,	mutations	in	codon	248	(~14%)	are	
the	most	common,	followed	by	mutations	in	codon	175	(~8%),	analogous	to	codon	172	in	
the	mouse.	
Working	with	LFS-sarcomas	may	harbor	one	distinct	advantage	over	that	of	sporadic	
sarcomas	alone;	they	all	involve	disruption	of	the	tumor	suppressor	gene	p53	increasing	the	
likelihood	that	these	sarcomas	arise	out	of	a	p53-dependent	manner.		However,	aside	from	
rarity,	 it	 is	not	clear	if	all	p53	alterations	should	be	treated	equivalently	–	indeed	different	
p53	alleles	have	different	penetrance	(93).		It	remains	to	be	seen	if	tumor	etiology	is	similar	
for	 mutations	 in	 p53	 that	 are	 LOF	 (either	 by	 deletion,	 or	 point	 mutation)	 vs.	 GOF	 p53	
mutations.	 	Despite	 these	potential	 issues,	 it	 is	our	 long-term	hope	 that	 identifying	genes	
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associated	 with	 sarcomagenesis	 in	 LFS	 patients,	 will	 also	 have	 relevance	 to	 sporadic	
sarcomas,	and	other	cancer	types.	
6.4 A	Mouse	Model	of	LFS	May	Help	Identify	Important	Sarcomagenesis	Genes	
To	 overcome	 some	 of	 the	 limitations	 associated	 with	 sequencing	 only	 human	
tumors,	we	elected	to	pursue	and	take	advantage	of	a	mouse	model	of	LFS.		Several	mouse	
models	exist,	 including	p53-/-	mice	in	which	cancer	penetrance	is	100%,	with	most	cancers	
occurring	before	6	months.	 	These	mice	had	tumor	profiles	similar	 to	 that	of	LFS-patients	
(109).		However,	since	the	majority	of	LFS	patients	have	heterozygous	point	mutations,	we	
instead	elected	to	pursue	a	different	mouse	model.		This	model,	from	Dr.	Lozano,	contains	
the	 Trp53	 R172H	 mutation	 that	 is	 analogous	 to	 the	 TP53	 R175H	 hotspot	 mutation	 in	
humans	((51)		Of	the	p53	mutations	associated	with	classical	LFS,	the	TP53	R175H	mutation	
is	the	second-most	common	(Figure	38),	and	is	known	to	be	a	GOF	mutation).		This	mouse	
model	was	also	known	to	develop	sarcomas	(53%),	particularly	osteosarcomas	(28%,	most	
frequent	tumor	type	reported)	(51).	
The	overall	relevance	of	modeling	the	human	TP53	R175H	mutation	can	be	further	
emphasized	with	 the	use	of	 a	downloaded	copy	of	 the	 IARC	database	 (53)	 for	additional,	
more	granular	analysis.		These	data	include	a	“topography”	column,	which	contains	the	site	
of	 the	original	neoplasm,	as	well	as	 the	 type	and/or	codon	of	 the	p53	mutation.	 	We	can	
generate	similar	histograms	as	to	Figure	38,	except	selected	for	tumors	arising	out	of	“soft	
tissue”	 and	 “bone”	 –	 the	 majority	 of	 which	 are	 sarcomas,	 to	 see	 if	 germline	 R175H	
mutations	are	prominent	in	these	tumors.		Although	the	overall	mutation	profile	is	different	
than	 compared	 to	 all	 tumors	 (Figure	 38),	 the	 histograms	 in	 Figure	 39	 indicate	 that	
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alterations	at	codon	175	are	still	prominent	 in	both	osteosarcomas	 (Figure	 39A)	and	soft	
tissue	sarcomas	(Figure	39B).	
	
Figure	 39:	 Histogram	 of	 p53	 mutations	 based	 on	 IARC	 data	 (53)	 and	 split	 by	 tumor	
pathology	(soft	tissue	and	bone).	
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6.4.1 Comparative	approaches	to	identifying	sarcoma	drivers	
One	accepted	approach	to	identifying	drivers	is	to	look	for	recurrent	changes,	either	
through	gains	or	 losses,	due	to	gross	amplifications	or	deletions,	or	SNVs	 in	critical	genes.		
These	 ideas	 underlie	 several	 efforts,	 including	 COSMIC,	 and	 TCGA	 to	 catalog	 somatic	
variation	across	a	wide-range	of	tumors	(5,	110(111).	
However,	recurrence	alone	may	be	a	poor	metric.		Some	genes	or	genomic	regions	
may	be,	or	appear	 to	be,	hypermutable,	but	may	have	 little	 functional	 consequence.	 	For	
example,	olfactory	genes	and	large	muscle	genes	(e.g.	TTN)	often	appear	to	be	represented	
in	 lists	of	significantly	 recurrently	mutated	genes	 in	cancer	 (112,	113).	Respectively,	 these	
gene	 families	 are	 either	 not	 expressed	 in	 tumors,	 or	 due	 to	 their	 size	 are	 likely	 to	 have	
acquired	somatic	changes	by	chance	alone,	suggesting	that	recurrence	alone	is	insufficient	
or	 that	 it	 may	 misclassify	 some	 genes.	 	 Thus,	 separating	 out	 drivers	 from	 passengers	
remains	a	key	challenge.	
Therefore,	 to	 better	 assist	 in	 separating	 passengers	 from	 drivers,	 we	 used	 a	
comparative	genomics	approach,	leveraging	a	mouse	model	of	LFS	(6.4).	We	hypothesized	
that	recurrent	alterations	in	key	genes	and	pathways,	across	both	humans	and	mice,	were	
more	likely	to	be	functionally	important	drivers	of	sarcomagenesis.	
Using	the	mouse	model	confers	several	advantages.		First,	it	provides	an	avenue	to	
more	 readily	 generate	 LFS-associated	 sarcomas.	 	 Secondly,	 the	 mice	 will	 all	 have	 been	
raised	 in	 the	 same,	 shared	 environment,	 the	mouse	 facility.	 	 Thirdly,	 the	mice	will	 come	
from	 reasonably	 similar	 backgrounds,	 and	 have	 the	 same	 exact	 cancer	 predisposition	
mutation,	potentially	improving	the	ability	to	identify	recurrent	changes.		Fourthly,	by	using	
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humans	and	mice,	 it	provides	additional	context	for	recurrent	variation	such	as	CNVs	that	
arise	 out	 of	 species-specific	 genomic	 context.	Moreover,	 this	 comparative	 approach	 was	
previously	 successful	 in	 acute	 promyelocytic	 leukemia,	where	 authors	 also	 used	 a	mouse	
model	to	help	implicate	JAK1	V657F	as	being	important	in	disease	progression	(114).	
6.5 Complete	tumor	profiling	as	a	goal	
Although	many	sequencing	studies	have	focused	on	looking	at	genomic	information	
via	 WGS	 or	 WES,	 it	 is	 clear	 that	 other	 changes,	 such	 as	 those	 in	 the	 transcriptome	 or	
methylome	 may	 significantly	 contribute	 to	 cancer	 (5,	 6,	 115).	 	 In	 fact,	 these	 data	 can	
support	each	other	when	done	 in	concert,	 to	provide	a	more	 layered,	nuanced	picture	of	
the	tumor	by	testing,	such	as	by	testing	to	see	 if	mutations	are	being	expressed	(114).	 	 In	
addition,	fusion	proteins	have	been	implicated	in	several	types	of	sarcomas,	such	as	Ewing	
sarcomas	(116),	suggesting	that	sequencing	DNA	alone	may	miss	key	drivers.	Transcriptomic	
sequencing	may	be	particularly	key	for	identifying	these	fusion	proteins.	
6.6 Open-ended	Expectations	for	Sequencing	Sarcomas	
For	most	cancers	the	number	of	driver	mutations	is	thought	to	be	between	1-10	(19,	
54),	 occurring	 in	 a	 subset	 of	 reasonably	 predictable	 genes	 (e.g.	 TP53,	 NF1,	 RB1,	 PTEN,	
BRCA1,	BRAF,	and	so	on).		However,	there	is	considerable	ambiguity	regarding	the	expected	
mutational	profile	of	LFS	sarcomas.	 	Many	LFS-associated	soft	 sarcomas	appear	 to	exhibit	
chromothripsis	and	CNAs,	particularly	soft	tissue	sarcomas	(10,	15),	and	exome	sequencing	
of	osteosarcomas	also	reveals	CNAs	to	be	common	(117,	118).		On	the	other	hand,	several	
genes	 with	 SNVs	 that	may	 impact	 osteosarcomagenesis	 have	 been	 identified	 (117,	 118).	
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Other	papers	have	 identified	point	mutations	and	deletions	 in	genes	 such	as	NF1,	ERCC2,	
and	PTEN	that	should	be	associated	with	sarcomas	(119,	120),	further	cementing	the	need	
for	a	multi-omics	approach.	
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However,	 in	 many	 p53-associated	 non-sarcoma	 tumors,	 we	 observe	 a	 mutator	
phenotype,	related	to	p53’s	function	as	the	guardian	of	the	genome,	in	which	these	tumors	
appear	 to	 acquire	 a	 plethora	 of	 variants,	 some	 of	 which	
	
Figure	40:	Tumor-free	survival	curve	of	p53+/H	(n=50)	and	p53+/+	 (n=20)	mice	from	our	
cohort,	 showing	 that	 that	 p53H/+	mice	 were	 more	 prone	 to	 develop	 tumors	 (p-value:	
6.37-e7).		Some	p53+/+	mice	developed	lymphomas,	particularly	in	the	thymus.	
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may	only	be	passengers	 (121,	122).	 	Thus	 it	may	be	unclear	what	we	should	expect	when	
looking	 at	 p53-LFS	 sarcomas,	 chromothripsis,	 characteristic	 of	 sarcomas,	 or	 a	 mutator	
phenotype	consistent	with	p53	mutations,	or	some	mixture	of	the	two.	
7 Results		
7.1 Description	of	Mouse	Cohort	Results	
	 Our	original	cohort	consisted	of	50	mice	with	the	p53	R172H	mutation,	and	20	mice	
that	 were	 p53	 WT.	 	 These	 mice	 were	 followed	 for	 a	 period	 of	 up	 to	 two	 years,	 with	
euthanasia	 performed	 for	 tumors,	 or	 other	 health	 conditions	 as	 needed.	 	 We	 collected	
multiple	 tissues	 from	 every	 mouse	 for	 pathology	 (including	 vastus	 lateralis,	 duodenum,	
pectoral	 and	 stomach	 muscles,	 diaphragm,	 kidney,	 spleen,	 heart,	 lung,	 liver,	 femur,	 and	
spine),	 thus	 allowing	 us	 to	 interrogate	 tumors	 that	may	 not	 have	 been	 obvious	 to	 gross	
observation.			
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Figure	41:	Pie	graph	of	 tumor	distribution	 in	 the	p53	R172H	 cohort	 (n=50)	shows	a	high	
prevalence	of	lymphoma,	with	a	variety	of	sarcoma	types.	
Overall,	 mice	 with	 the	 LFS	 cancer-predisposition	 did	 develop	 tumors	 and	 had	
reduced	survival	 relative	 to	control	mice.	 	However,	we	did	observe	several	p53	WT	mice	
that	had	to	be	sacrificed	due	to	hyperpnea.		In	all	such	cases,	mice	were	visibly	hunched	and	
had	 lymphoma	 in	 the	 thymus	upon	dissection,	 suggesting	 that	 the	p53	WT	 C57BL/6	mice	
might	 have	 a	 predilection	 towards	 lymphomas,	 consistent	 with	 published	 results	 by	
Donehower	et	al.	(123).	
7.1.1 Lymphomas	and	sarcomas	were	the	most	common	tumor	types	
	 We	 sent	 all	 our	 tissues	 to	 Dr.	 Elizabeth	 Whitley	 (Pathogenesis,	 LCC)	 for	 full	
pathology.		The	majority	of	tumors	that	we	observed	in	our	mice	were	lymphoma	(including	
	 94	
in	 some	p53-WT	mice),	 or	 sarcoma,	with	 the	majority	 of	 these	 being	 osteosarcomas	 and	
histiocytic	 sarcomas.	 	Consistent	with	 the	notion	 that	 sarcoma	 types	 could	have	different	
etiologies,	we	 attempted	 to	minimize	 the	 types	 of	 sarcomas	we	 observed	 during	 sample	
selection.	
7.1.2 Choice	of	sarcoma	type	for	sequencing	
The	most	common	sarcoma	type	we	observed	in	the	mice	was	histiocytic	sarcomas,	
a	 neoplasia	 composed	 of	 hematopoietic	 cells,	 that	 has	 historically	 been	 classified	 as	
lymphoma,	 and	 is	 typically	 ascertained	 only	 after	 extensive	 immunophenotypic	
characterization	 (124),	 making	 it	 a	 less	 compelling	 candidate.	 	 In	 addition,	 histiocytic	
sarcomas	are	not	considered	to	be	among	the	most	common	tumor	types	associated	with	
LFS	 in	 humans;	 in	 fact,	 in	 the	 IARC	 TP53	 database,	 there	 are	 no	 germline	 p53	 variants	
associated	 with	 histiocytic	 sarcomas.	 	 Therefore,	 we	 instead	 chose	 to	 sequence	
osteosarcomas	 and	 fibrosarcomas,	 leveraging	 additional	 samples	 that	 were	 previously	
generated	 in	 the	 Krahe	 Lab	 with	 a	 p53	 R172H	 mutation.	 	 In	 total,	 these	 comprised	 two	
additional	osteosarcomas,	and	four	additional	fibrosarcomas,	for	eight	osteosarcomas,	and	
six	fibrosarcomas	in	total	for	omics	analysis.	
7.1.3 List	of	mouse	sarcomas	for	sequencing	
The	table	below	(Table	 10)	 contains	a	 list	of	 samples,	 their	ages,	gender,	 types	of	
tissue	sequenced,	and	whether	or	not	the	mouse	was	also	diagnosed	with	lymphoma.	
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Table	 10:	 Table	 of	 Mouse	 Sarcomas	 for	 NGS.	 	 VL	 –	 vastus	 lateralis,	 FR	 –	 femur,	 FS	 –	
fibrosarcoma,	OS	–	osteosarcoma.	 	 Several	mice	were	 found	 to	 also	have	 lymphoma	 in	
addition	to	sarcomas	–	these	are	noted	in	the	table.	
Sample	 Age	(mo)	 Sex	 Normal	Type	 Tumor	Type	 Lymphoma	
F8-23	 13.0	 M	 VL	 FS	 Yes	
F1-13	 11.8	 M	 VL	 FS	 No	
F2-3	 9.1	 M	 VL	 FS	 No	
F8-17	 14.2	 M	 VL	 FS	 No	
F3-8	 15.5	 F	 VL	 FS	 No	
F2-4	 16.1	 M	 VL	 FS	 Yes	
F8-70	 10.9	 F	 FR	 OS	 No	
F8-51	 13.4	 F	 FR	 OS	 Yes	
F3-20	 14.3	 F	 FR	 OS	 No	
F7-12	 17.3	 F	 FR	 OS	 Yes	
F3-98	 16.5	 F	 FR	 OS	 No	
F8-49	 13.0	 M	 FR	 OS	 Yes	
F7-2	 19.1	 F	 FR	 OS	 Yes	
F3-35	 13.5	 F	 FR	 OS	 No	
	
These	data	show	one	remarkable	trend.		The	majority	of	fibrosarcomas	were	found	in	male	
mice	(5:1	male	to	female),	while	the	majority	of	osteosarcomas	were	found	in	female	mice	
(7:1	 female	 to	 male).	 	 We	 have	 no	 reason	 to	 believe	 that	 this	 is	 anything	 more	 than	 a	
statistical	 anomaly,	 but	 may	 be	 worth	 continuing	 to	 monitor	 in	 future	 cohorts.	 	 We	
otherwise	found	no	distinct	trends	for	age	and/or	lymphomas	
7.2 Mouse-specific	variation	necessitates	the	use	of	N/T	pairs	
Initially,	 we	 had	 hoped	 to	 use	 a	 pool	 of	 normal	mice	 to	 serve	 as	 control	 tissues,	
under	the	assumption	that	the	mice	were	isogenic.	 	However,	during	initial	analysis	of	the	
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normal	pool,	we	found	these	mice	had	pockets	of	variation	that	were	typically	unique	to	a	
given	mouse,	 and	 could	 be	 due	 to	 being	 on	 a	 mixed	 background.	 	 These	 patterns	 were	
visible	 grossly,	 at	 the	 chromosome	 level	 when	 looking	 at	 variant	 density	 plots,	 and	 by	 a	
background	check	of	the	mouse.	
When	 generating	mouse	models,	 there	 is	 risk	 for	 introducing	 additional	 variation	
during	the	process,	particularly	when	using	embryonic	stem	cells	(ESC)	for	targeting	(125).	
In	 this	 case,	 especially	 in	 early	 generations,	 the	 flanking	 regions	 around	 the	mutation	 (or	
gene)	often	come	from	the	ESC,	rather	than	the	original	mouse	strain.		This	flanking	region	
can	be	reduced	through	backcrossing,	but	even	after	10	successive	backcrosses,	as	much	as	
1	 cM	 on	 either	 side	 of	 the	 target	 (~40	 genes	 on	 average)	 is	 likely	 to	 retain	 donor	
sequence(125)	(125),	leading	to	the	presence	of	passenger	mutations	around	the	region	of	
interest,	particularly	since	variation	is	generally	called	against	the	background	of	the	original	
mouse	 strain.	 	 Thus,	 it	 is	 possible,	 if	 unlikely,	 that	 germline	 variation	 in	 these	 flanking	
regions	may	contribute	to	the	outcome,	and	strictly	considering	only	somatic	variation	may	
be	somewhat	of	an	oversimplification	when	trying	to	uncover	genetic	contributions	towards	
sarcomagenesis.	
In	fact,	in	sequencing	normal	controls	from	our	p53	mice,	we	seemed	to	observe	this	
phenomenon.	 When	 we	 looked	 at	 overall	 variant	 density	 profiles	 for	 some	 mice	 in	 our	
cohort	(called	against	the	reference,	a	C57BL/6	mouse),	we	found	variation	in	the	flanking	
regions	on	chr11	(Figure	42)	that	was	present	in	mice	with	a	p53+/H	background	(red,	blue),	
but	not	WT-controls	with	wild-type	p53	(orange,	yellow,	purple).			
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Figure	42:	Variant	density	plot	(#	of	variants/100kb)	from	a	pilot	study	designed	to	
determine	if	using	a	normal	pool	was	reasonable	under	the	hypothesis	that	the	mice	were	
sufficiently	isogenic.		We	sequenced	two	tissues	from	a	p53+/H	mouse,	and	three	femurs	
from	three	other	mice	with	WT	p53.		These	data	show	distinctly	different	variant	profiles	
for	the	p53H/+	mice	vs.	the	p53	WT	mice,	and	even	hints	that	the	p53	WT	mice	may	not	be	
isogenic	with	each	other		
7.2.1 Multiple	chromosomes	appear	to	have	non-C57BL6	background	
Moreover,	we	found	potentially	confounding	background	from	the	129-mouse	in	other	
chromosomes	as	well.		We	worked	with	Dr.	Benavides	(MDACC	–	Smithville,	TX;	Research	
Animal	Support	Facility	–	Smithville),	to	characterize	the	mouse	background	using	strain-
specific	SNPs.		A	subset	of	chromosomes	in	the	mice	we	tested	had	no	129-alleles,	but	a	
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subset	of	chromosomes,	such	as	13,	and	14	had	fairly	extensive	contamination.		Overall,	the	
data	seemed	to	indicate	that	just	over	80%	of	the	alleles	were	from	the	C57BL/6	
background.	
	
	
Figure	 43:	 SNP	 data	 checking	 the	 background	 of	 the	 p53	 R172H	 mice	 showing	 that	
although	 the	majority	 of	 the	 alleles	 were	 from	 the	 C57BL/6	 background	 (>80%),	 there	
were	some	chromosomes	that	had	extensive	heterozygous	alleles.		The	data	also	strongly	
suggest	that	these	mice	should	not	be	considered	isogenic.	
Consistent	with	these	data,	we	also	looked	at	variant	density	plots	(line	graph	of	
variants/100	kb)	across	other	chromosomes	across	five	tissues	from	different	mice	(Figure	44),	finding	that	mice	appeared	to	be	less	isogenic	than	originally	expected.		Several	mice	
had	unique	variation/variant	profiles,	such	as	“GL_1_N…”	(grey)	on	chromosomes	1,	7,	11,	
and	13,	or	“GL_7_N…”	(orange)	on	chromosome	11.	
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Figure	 44:	 Variant	 density	 plots	 (#	 variants/100	 kb	windows),	 continue	 to	 support	 that	
these	mice	are	should	not	be	considered	isogenic.	
These	data	support	the	previous	evidence	from	the	background	check	that	these	mice	were	
not	isogenic,	and	necessitated	the	switch	from	a	normal	pool	to	only	sequencing	matched	
normal/tumor	pairs	to	better	ascertain	somatic	risk	factors.		
For	 fibrosarcomas,	 we	 elected	 to	 use	 the	 vastus	 lateralis	 (VL,	 muscle)	 and	 for	
osteosarcomas	 (OS),	we	used	a	 femur	 (FR,	bone)	as	a	normal	 control.	 	We	expected	 that	
such	 considerations	matter	 less	 for	 the	 genomic	 analysis,	 but	more	 for	 transcriptomic	 or	
epigenetic	analyses	where	tissue	specificity	matters	more	(126).	 	 In	all	cases,	we	chose	to	
sequence	normal	tissue	that	was	distal	 to	the	tumor	to	better	delineate	acquired	somatic	
changes.	
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7.3 LOH	and	Pyrosequencing	
7.3.1 Initial	WGS	data	suggests	not	all	sarcomas	have	LOH	
	
The	general	consensus	in	the	field	is	that	the	majority	of	p53-tumors	have	eventual	
LOH	 (127).	 However,	 in	 our	 pilot	 study,	 in	which	we	 sequenced	 2	 human	 tumors,	 and	 2	
mouse	 tumors	 by	 WGS,	 we	 observed	 one	 tumor	 with	 LOH	 and	 one	 with	 ROH	 for	 each	
organism.	 	 Alerted	 to	 the	 possibility	 that	 LOH	might	 not	 be	 as	 common	 as	 expected,	we	
used	pyrosequencing	 to	quantitatively	determine	 the	extent	of	 LOH	 in	our	mouse	 tumors	
and	 found	 two	 initially	 unexpected	 results.	 	 First,	 we	 saw	 LOH	 in	 some	 normal	 tissues.		
Secondly,	in	contrast	to	the	general	consensus	described	in	Rivlin	et	al.	(127)	of	the	majority	
of	tumors	having	eventual,	we	saw	LOH	in	p53	in	mouse	sarcomas	only	about	half	the	time.		
However,	we	acknowledge	that	previously	published	LOH	data	by	Lang	et	al.	is	also	around	
50%	(51).	
7.3.2 Some	normal	tissues	appear	to	have	LOH	
	
In	 addition	 to	 pyrosequencing	 tumor	 tissues,	 we	 also	 sequenced	 the	 matching	
constitutive	tissues	from	the	same	mouse	as	controls,	finding	two	outliers.		We	found	two	
femurs	that	appeared	to	be	normal	at	gross	observation,	but	had	relatively	advanced	LOH	
by	 pyrosequencing	 (Figure	 45).	 In	 both	 cases,	 LOH	was	more	 pronounced	 in	 the	 tumor,	
relative	to	the	supposedly	normal	femur.	Moreover,	these	femurs	were	not	adjacent	to	the	
osteosarcoma.	 	One	osteosarcoma	was	 located	 in	 the	 ribs,	while	 the	other	osteosarcoma	
was	in	the	left	leg	(with	the	femur	being	from	the	right	leg).	
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Figure	 45:	 Pyrograms	with	 peak	heights.	 	 These	 data	 suggest	 that	we	had	 LOH	 in	what	
appeared	 to	 be	 normal	 femurs	 upon	 gross	 observation.	 	Moreover,	 these	 femurs	were	
distal	 from	 the	 primary	 tumor	 site,	 suggesting	 that	 LOH	 may	 not	 be	 sufficient	 for	
tumorigenesis.	
To	 rule	 out	 the	 possibility	 that	 all	 constitutive	 tissues	 had	 this	 same	 behavior,	 we	
pyrosequenced	 additional	 tissues	 from	 the	 same	mouse,	 including	 the	 pectoralis	muscle.		
These	other	tissues	all	had	ROH,	suggesting	that	the	LOH	was	relatively	unique	to	the	femur	
(Figure	46).	
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Figure	46:	Graphical	depiction	of	pyrosequencing	data	of	additional	constitutive	tissues	in	
mice	with	LOH	in	the	femur.		On	the	x-axis	is	a	number-scale	representing	the	%H-allele,	
with	circles	trending	towards	the	left	side	of	the	graph	having	greater	LOH.		Circles	near	
50%	 have	 ROH	 (i.e.	 have	 retained	 the	WT-allele).	 	 These	 data	 suggest	 the	 majority	 of	
normal	(N)	samples	have	ROH,	with	the	exception	of	these	two	FR	samples,	which	show	
relatively	advanced	LOH,	though	not	exceeding	the	tumors.	 	
These	data	are	consistent	with	the	idea	that	p53	LOH	at	the	Trp53	R172H	locus	is	not	
sufficient	for	tumorigenesis.		However,	because	we	typically	send	one	femur	for	pathology,	
and	 reserve	 the	 other	 for	 experiments,	 such	 DNA	 extractions,	 it	 is	 possible	 that	 the	
sequenced	 femur	 had	 cancerous	 or	 pre-cancerous	 lesions	 that	 were	 not	 visible	 at	 gross	
observation.	 	We	did	not	observe	such	a	pattern	to	be	the	case	for	any	VL/FS	pairs;	no	VL	
samples	had	LOH.	
These	 data	 are	 juxtaposed	 against	 p53-/-	 and	 p53+/-	mice.	 	 In	 p53-/-	 null	 mice,	 the	
penetrance	 of	 tumors	 is	 100%,	 suggesting	 that	 LOH	 alone	 would	 be	 sufficient	 for	
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tumorigenesis.	 	 In	 p53+/-	 mice,	 the	 data	 indicate	 p53	 should	 be	 considered	 to	 be	
haploinsufficient.		Only	half	of	all	tumors	in	mice	under	the	age	of	18	months	had	LOH,	and	
this	 number	 dropped	 to	 just	 15%	 in	 tumors	 over	 18	 months.	 (128)	 However,	 no	 such	
comprehensive	analysis	of	LOH	has	been	done	 in	p53H/+	mice	and	 it	 is	not	clear	 if,	or	how	
the	GOF	mutation	may	impact	such	behavior.	
7.3.3 Use	of	toe	tissue	as	normal	controls	
	
Due	to	observations	that	some	tissues,	which	on	gross	observation	appeared	to	be	
normal,	had	LOH,	we	wanted	to	find	better	control	tissues	to	best	determine	a	baseline	that	
represented	 ROH.	 	 We	 elected	 to	 use	 toe	 tissue,	 originally	 collected	 for	 genotyping,	
between	days	7-10	when	it	is	still	cartilaginous.		Theoretically,	these	tissues	should	have	had	
minimal	 time	 to	 acquire	 additional	 somatic	 changes	 and	 therefore	 serve	 as	 a	 more	
appropriate	benchmark	than	constitutive	tissues	collected	at	time	of	sacrifice.	
Data	from	toe	tissue	collected	across	our	mouse	tumors	suggests	that	the	totality	of	
the	experiment	and	analysis	has	a	slight	bias	for	the	mutant	A-allele.		Whether	this	occurs	
during	the	PCR	amplification,	or	as	part	of	the	pyrosequencing	process,	which	is	known	to	
favor	 the	 A-allele	 is	 unknowable.	 	 Using	 the	 toe	 data	 as	 a	 whole,	 we	 set	 up	 our	 own	
classification	 scheme.	 	 We	 averaged	 the	 allele	 %	 from	 all	 toes,	 and	 then	 calculated	 a	
standard	 deviation.	 	 Anything	 within	 two	 standard	 deviations	 from	 the	 average	 was	
considered	ROH.			
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7.3.4 Pyrosequencing	shows	that	LOH	occurs	in	only	about	50%	of	mouse	LFS-sarcomas	
	
Pyrosequencing	of	all	tumors	and	matched	normals	suggested	that	LOH	was	present	only	
in	 about	 half	 of	 all	 sarcomas	 (Figure	 47),	 indicating	 the	 LOH	 (at	 the	 R172H	 locus)	 is	 not	
required	for	sarcomagenesis.		These	data	are	also	somewhat	consistent	with	previous	data	
suggesting	that	LOH	is	less	common	in	older	tumors.		Using	an	arbitrary	cutoff	point	of	15	
months,	this	provides	a	clear	delineation	 in	fibrosarcomas.	 	For	osteosarcomas	the	data	 is	
less	clear.		There	are	two	osteosarcomas	(F8-49	and	F3-35)	at	about	13	months	that	did	not	
appear	to	have	LOH,	and	two	older	ones	with	more	pronounced	LOH	(F7-12	and	F3-98).		We	
also	did	not	observe	any	trends	for	LOH	as	it	relates	to	lymphoma	status.	
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Figure	 47:	 Depiction	 of	 pyrosequencing	 results	 plotted	 against	 %	 of	 mutant	 and	 WT	
alleles.	 	Mouse	 name,	 tumor	 type	 (fibrosarcoma	 –	 FS,	 osteosarcoma	 –	 OS)	 sex,	 age	 at	
sacrifice,	and	 lymphoma	status	are	 listed	at	 left-hand	column.	 	Data	 indicate	where	 the	
matching	normal	 is	 (always	 femur,	or	vastus	 lateralis	 for	 corresponding	 tumors),	with	a	
solid	line	indicating	the	extent	of	LOH	in	the	tumor.		Additional	dashed	lines	account	for	
tumor	purity	as	indicated	by	the	pathologist	where	available.		The	black,	solid	vertical	line	
indicates	 ROH.	 	 Black	 dot-dash	 line	 bisecting	 graph	 in	 two	 separates	 out	 fibrosarcomas	
from	osteosarcomas.		Table	at	top	provides	summary	based	on	tumor	type	and	ROH/LOH	
status.	
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8 Results:	Sequencing	of	Mouse	Samples	
	
We	then	looked	at	several	different	kinds	of	sequencing.	For	DNA,	we	looked	at	WES	
(at	40X/80X	N/T	coverage,	Nimblegen	2.0,	capture	region	54.3	Mb)	and	low-coverage	WGS.		
For	RNA,	we	were	unable	to	isolate	high-quality	RNA	from	fresh	frozen	tissues.		Despite	our	
best	 attempts	 to	 snap	 freeze,	 RNA	 appeared	 degraded	 after	 isolation.	 	 For	 methylation	
data,	we	used	reduce	representation	bisulfite	sequencing	(Illumina).			
	
8.1 WES	variant	calling	pipeline	
We	did	all	WES	and	somatic	variant	calling	 in-house	according	 to	best	practices	as	
outlined	by	GATK.	(80)	We	additionally	used	five	different	somatic	variant	callers,	MuTect,	
(129)	MuTect2,	(80)	VarScan2,	(130)	Somatic	Sniper	(131)	and	MuSE,	(132)	again	using	the	
default	recommended	settings.		Historically,	somatic	variant	callers	have	generally	showed	
poor	agreement	with	one	another,	and	are	continuing	to	undergo	refinement.	(133)	(134)	
(135)	
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Figure	 48:	 Krahe	 lab	 pipeline	 for	 identification	 of	 somatic	 variation	 in	 WES	 data.	 	 We	
found	somatic	variant	callers	to	produce	widely	disparate	calls	–	to	compensate	for	this,	
we	 looked	 at	 all	 somatic	 variants	 that	 were	 found	 by	 at	 least	 two	 algorithms	 to	 best	
balance	false	positives	and	false	negatives.	
8.1.1 Filtering	for	high-quality	somatic	variants	
In	 our	 pipeline,	 using	 the	 recommended	 best	 practices,	 and	 selecting	 only	 for	
variants	 each	 considered	 to	 be	 high	 confidence,	 we	 saw	 poor	 agreement	 between	 the	
samples	when	looking	at	somatic	SNVs	(Figure	 49).	A	significant	proportion	of	the	 lack	of	
agreement	 seems	 to	 be	 due	 to	 the	 high	 number	 of	 variants	 found	 by	 both	mutect1	 and	
Varscan2,	which	call	the	most	variants.		Of	all	the	variant	callers,	MuSE	shows	the	greatest	
overlap	with	other	algorithms.		
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Figure	 49:	 Representative	 Venn	 diagram	 of	 agreement	 between	 five	 different	 somatic	
variant	callers	in	our	mouse	samples.		All	variants	were	called	according	to	best	practices	
as	 outlined	 in	 the	 documentation	 and	 were	 considered	 to	 be	 high	 confidence	 by	 the	
individual	variant	caller.	 	Overall,	the	key	data	trends	that	we	observe	are	that	Mutect1	
and	Varscan2	call	the	most	variants,	and	that	MuSE	shows	the	most	agreement	with	other	
somatic	variant	callers.	
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The	lack	of	agreement	underlies	a	key	question:	which	somatic	variant	calls	are	true	
positives?	 How	 should	 researchers	 balance	 retaining	 false	 positives,	 with	 true	 positives	
occurring	at	lower	allele	frequencies	(e.g.	arising	by	tissue	heterogeneity).	Consideration	of	
variants	 found	 by	 all	 algorithms	 is	 almost	 certainly	 too	 restrictive	 –	 they	 represent,	 on	
average,	just	0.1%	of	all	somatic	variant	calls	(by	any	algorithm).		In	contrast,	consideration	
of	 variants	 found	 in	 any	 one	 algorithm	 may	 lead	 to	 spurious	 association.	 	 Brief	 visual	
inspection	indicates	that	these	one-algorithm	mutations	contain	a	mix	of	plausibly	true	and	
likely	to	be	false	variants.			
To	get	a	sense	for	an	appropriate	cutoff,	we	counted	the	number	of	variants	found	
by	 exactly	 one	 algorithm,	 by	 exactly	 two	 algorithms	 (any	 pair	 was	 fine),	 by	 any	 three	
algorithms,	and	so	on.		On	average,	about	5%	of	total	somatic	variants	are	called	are	found	
by	3+	algorithms,	and	about	10-15%	of	 total	 somatic	 variants	are	 found	by	2+	algorithms	
(Table	11).	
Table	 11:	 Table	 showing	 overlap	 of	 five	 different	 somatic	 variant	 callers.	 	 The	 top	 half	
counts	the	number	found	by	exactly	1,	2,	3,	4,	or	5	algorithms	for	16	N/T	pairs	across	14	
mice.	The	second	half	translates	these	into	percentages.	
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8.1.2 Somatic	mutation	burden	in	sporadic	sarcomas	
The	most	 recent	 reported	 overall	 somatic	 mutation	 burden	 for	 human	 adult	 soft	
tissue	sarcomas	is,	on	average,	1.06	per	Mb,	with	the	highest	reported	being	33.5	mutations	
per	 Mb,	 where	 mutations	 are	 considered	 to	 be	 non-synonymous	 SNVs	 (10).	 Back	
referencing	the	data	against	the	cBio	portal	reveals	that	the	samples	with	the	three	highest	
mutation	 loads	 (>350	 total	 mutations)	 have	 somatically	 acquired	 likely	 loss-of-function	
mutations	 in	p53:	 TCGA-DX-AB2E-01	 (R342*,	 age	 53,	myxofibrosarcoma),	 TCGA-3B-A9HT-
01(W91*,	 age	 53,	 leiomyosarcoma),	 and	 TCGA-DX-AB32-01	 (L252del,	 age	 62,	
undifferentiated	 pleomorphic	 sarcoma),	 consistent	 with	 the	 possibility	 that	 p53	 LOF	
alterations	 can	 increase	 mutational	 load.	 	 Four	 patients	 had	 somatic	 mutations	 at	 p53	
R175H,	analogous	to	the	mouse	model;	these	had	36,	59,	62,	and	101	mutations,	at	ages	44,	
73,	64,	and	62	respectively	(10,	22).			
We	 then	 took	 variants	 that	 had	 been	 identified	 by	 two	 or	 more	 algorithms,	 and	
annotated	with	ANNOVAR	 (136),	 SIFT,	 (86)	 and	PROVEAN	 (137)	 to	 further	 select	 for	non-
synonymous	variants	to	see	if	our	mice	were	in	line	with	these	data	(Table	12).	
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Table	12:	Table	 showing	 the	number	of	non-synonymous	SNVs	 found	 in	each	mouse	by	
two	 or	 more	 algorithms	 (2+),	 or	 three	 or	 more	 algorithms	 (3+).	 	 Results	 are	 roughly	
consistent	 with	 published	 data	 on	 mutation	 rates	 (by	 non-synonymous	 SNVs)	 in	 soft	
tissue	sarcomas.	
	
At	a	capture	region	of	54.3	Mb	in	the	mouse,	if	the	same	mutation	rates	hold	in	the	
mice,	we	would	expect	to	see	an	average	of	58	mutations.		To	estimate	an	upper	bound,	we	
took	 the	highest	mutational	burden	 in	an	adult	 soft	 tissue	 sarcoma	 from	the	TCGA	paper		
(10),	33.5	mutations	per	Mb.	 	Applying	this	rate	to	the	mouse	exome	(33.5	mutations	per	
Mb	*	54.3	Mb),	gives	an	upper	bound	of	1,819	somatic	mutations.		Choosing	either	2+	or	3+	
is	therefore	roughly	within	the	same	order	of	magnitude.			
Because	we	were	unsure	of	how	a	germline	GOF	p53	mutation	in	the	mouse	could	
contribute	 to	 somatic	 mutation	 rates,	 we	 decided	 that	 it	 was	 worthwhile	 to	 at	 least	
consider	somatic	variants	 identified	by	2+	algorithms,	especially	when	using	recurrence	as	
an	endpoint.		
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8.2 Whole	Exome	Sequencing	Results	
8.2.1 Recurrence	in	Somatic	SNV	Data	
We	 initially	 looked	 at	 recurrence	 of	 SNVs	 across	 all	 mouse	 tumors,	 finding	 one	
recurrent	 SNV,	 in	 Mroh2a.	 	 This	 variant	 (c.C4088T,	 p.T1363M)	 was	 predicted	 to	 be	
damaging	 (PROVEAN=-4.02,	 threshold	 <	 -2.5;	 SIFT=0.046,	 threshold	 <	 0.05)	 but	 may	 be	
polymorphic;	it	has	an	rsID	but	no	reported	allele	frequencies.		Secondly,	we	looked	to	see	if	
there	were	any	genes	 that	were	 recurrently	mutated	 (using	only	variants	predicted	 to	be	
deleterious).		There	were	nine	genes	that	recurred	across	three	or	more	tumors	(Table	13).	
	
Table	13:	Table	of	recurrent	somatically	mutated	genes	in	mouse	tumors	(three	or	more	
tumors).		For	a	gene	to	be	considered,	it	had	to	have	a	mutation	predicted	to	have	
functional	consequence.			Shading	indicates	where	two	comparisons	for	the	same	tumor	
were	made,	one	to	a	femur	(FR),	and	one	to	a	muscle	(VL).	
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With	the	exception	of	Arid1A,	 these	recurrently	somatically	mutated	genes	do	not	appear	
be	well-known	players	in	cancer.		They	are	not	found	in	any	of	our	human-based	gene	lists	
(covering	cancer,	the	p53	network,	and	sarcomas).	 	Therefore,	these	genes	may	represent	
either	 good	 novel	 candidates	 to	 pursue	 further,	 or	 false-positives,	 arising	 perhaps	 out	 of	
multiple	testing	of	the	entire	exome.	
8.2.1.1 Arid1a	
ARID1A	 (in	 humans)	 is	 known	 to	 be	 a	 haploinsufficient	 tumor	 suppressor	 and	 is	 a	
SWI/SNF	 chromatin	 remodeling	 gene	 that	 has	 been	 linked	 to	 several	 cancers,	 including	
ovarian,	gastric,	and	breast	tumors,	but	not	including	sarcomas.		In	fact,	in	one	paper	by	Wu	
et	 al.	 the	 authors	 specifically	 claim	 they	 are	 not	 aware	 of	 any	 ARID1A	 mutations	 being	
detected	in	human	sarcomas	(138).		Moreover,	the	majority	of	cancer-causing	mutations	in	
ARID1A	 that	 have	 so	 far	 been	 identified	 are	 stopgain	 or	 frameshift	 mutations	 (138),	 as	
opposed	 to	 the	 non-synonymous	 SNVs	 we	 identified	 in	 Arid1a	 in	 the	 mouse.	 	 Taken	
together,	these	data	raise	some	doubt	as	to	whether	or	not	these	mutations	could	impact	
sarcomagenesis,	 but	 do	 allow	 that	 ARID1A	 may	 be	 an	 intriguing,	 if	 not	 immediately	
compelling,	candidate	for	follow-up.	
8.2.1.2 Mroh2a	
Mroh2a	 is	 the	most	common	somatically	mutated	gene	across	our	mouse	 tumors.		
These	comprise	seven	non-synonymous	variants,	and	one	stop	gain	variant,	some	that	have	
been	flagged	as	potentially	being	polymorphic.	
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Table	14:	Table	of	somatic	variants	in	Mroh2a	across	all	mice.		Mice	not	listed	here	do	not	
have	somatic	alterations	predicted	to	be	damaging.	
	
The	function	of	MROH2A	in	humans	has	not	been	characterized	and	there	have	been	no	
published	papers	on	the	gene	(https://www.ncbi.nlm.nih.gov/gene/339766).		By	cBio,	
MROH2A	has	a	somatic	mutation	frequency	of	just	0.1%,	suggesting	it’s	not	a	superb	
candidate	for	follow-up.		But,	examination	of	recently	added	TCGA	sarcoma	data	finds	that	
MROH2A	has	a	deep	deletion	in	more	than	5%	of	sarcomas	(22).	
	
Figure	50:	cBio	data	for	MROH2A	(22).		Most	notably,	sarcomas	are	the	fourth	most	
common	tumor	with	MROH2A	alterations,	with	the	majority	of	these	being	deletions.	
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We	also	note	that	MROH2A	is	a	relatively	large	gene,	spanning	almost	60	kb,	and		
1,800	codons.		Therefore,	it	may	not	be	unexpected	to	have	acquired	somatic	variants	by	
chance	alone.		Despite	this,	the	combination	of	it	being	the	most	recurrently	mutated	gene,	
and	recent	CN	data	as	seen	in	cBio	make	it	an	interesting	candidate	for	additional	functional	
follow-up.	
8.2.2 Inspection	of	multiple	hits	in	the	p53	pathway	may	be	meaningful	
	
Disruption	 of	 key	 pathways	 is	 often	 considered	 to	 be	 a	 hallmark	 of	 cancer	 (2,	 54,	
139).		However,	pathways	often	have	built-in	redundancies,	and	a	single	alteration	may	be	
insufficient	for	tumorigenesis	(140).		For	example,	in	renal	carcinoma,	loss	of	VHL	or	PBRM	
alone	 are	 not	 sufficient	 for	 tumorigenesis,	 but	 co-occurring	 VHL,	 PBRM1,	 and	 SETD2	
mutations	are	observed,	the	latter	two	of	which	are	both	involved	in	chromatin	remodeling	
via	the	SWI/SNF	complex	(141,	142).	
This	 runs	 counter	 to	 the	 classic	 idea	 that	 mutations	 in	 the	 same	 pathway	 are	
redundant	and	therefore	unlikely,	and	the	concept	of	mutual	exclusivity	for	some	gene	pairs	
(139).		For	example,	in	glioblastoma,	TP53	and	MDM2	were	found	to	be	mutually	exclusive	
(143).			
Emerging	data	from	melanoma	presents	a	more	nuanced	picture.		Classically,	NRAS	
hot-spot	mutations	are	 known	 to	be	mutually	exclusive	 from	BRAF	 hot-spot	mutations	at	
codons	600	and	601.	 	That	 is,	each	 is	 strong	enough	on	 its	own	to	 lead	to	 tumorigenesis.		
However,	 some	 hotspot	 NRAS/KRAS/HRAS	 mutations	 have	 been	 shown	 to	 appear	
concomitantly	with	 recurring	mutations	 in	BRAF	 (not	at	 codons	600/601),	 suggesting	 that	
two	 alterations	 in	 the	 same	 pathway	 are	 possible	 or	 even	 required	 (144).	 	 These	
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observations	 indicate	 that	 two	 variants,	 with	 possibly	 weaker	 effects,	 could	 combine	 to	
create	a	similar	effect	as	one	strong	mutation.	
Moreover,	 in	 malignant	 peripheral	 nerve	 sheath	 tumors	 (MPNST),	 a	 soft	 tissue	
sarcoma,	 evidence	 suggests	 that	 activation	 of	 the	 Ras	 pathway	 takes	 multiple	 hits.	 	 In	
addition	to	a	germline	mutation	 in	NF1	 (coupled	with	somatic	 loss),	multiple	MPNSTs	had	
additional	 somatic	 variants,	 predicted	 to	 be	 pathogenic	 (e.g.	 PIK3CA,	 KIT,	 PTPN11,	 and	
FGFR1,	 among	 others)	 (145).	 	 However,	 no	 single	 gene	 has	 emerged	 as	 being	 highly	
recurrent	in	conjunction	with	mutant	NF1.	(145).	 	Taken	together,	these	data	suggest	that	
looking	 for	multiple	 hits	 in	 the	p53	 pathway	 (or	 any	 cancer	 pathway)	 has	 intrinsic	 value,	
although	 this	would	best	be	done	with	a	high	number	of	 samples	 to	allow	 for	potentially	
weaker	effects	to	be	more	evident.	
8.2.3 Notable	somatic	variants	in	individual	tumors	
To	better	ascertain	variants	more	likely	to	be	true	somatic	mutations,	we	increased	
the	threshold	for	inclusion	to	require	three	or	more	algorithms.		We	took	the	following	lists:	
1. Krahe	Lab	p53	network	genes	(n	=	131	genes)	
2. Krahe	Lab	Sarcoma	gene	list	(Table	7)	(n	=	147	genes)	
3. 	Cancer	Gene	Census	(146)	(n	=	609	genes)	
	to	 prioritize	 our	 search	 for	 known	 additional	 genetic	 risk	 factors.	 	 These	 lists	 are	 not	
redundant	with	each	other	 (Figure	 51),	with	at	 least	some	of	the	differences	due	to	how	
the	 lists	were	curated.	 	For	example,	some	genes	on	the	sarcoma	 list	are	based	on	only	a	
few	case	reports.	
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Figure	51:	Venn	diagram	of	overlap	of	three	gene	lists:	Cancer	Gene	Census,	Krahe	Lab	p53	
network,	and	Krahe	lab	sarcoma	list.		Figure	not	to	scale.	
Several	mouse	sarcomas	had	somatic	mutations	in	known	sarcoma-	or	cancer-risk	
genes	(Table	15).		Investigation	of	p53	network	genes	found	potentially	deleterious	alleles	
in	about	half	of	tumors	(Table	15),	suggesting	that	the	p53	network	does	not	need	to	be	
compromised	in	multiple	places	in	the	context	of	the	Trp53R172H	mutation.	
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Table	15:	Partial	table	of	hits	in	known	sarcoma,	cancer	or	p53	network	genes.	
	
8.2.4 Notable	germline	variation	in	sarcoma-related	genes	
Given	 previous	 reports	 that	 some	 LFS	 patients	 may	 have	 multiple	 cancer-
predisposing	 mutations	 or	 that	 differing	 p53	 alleles	 have	 different	 penetrance	 (6.3),	 we	
looked	 at	 the	 germline	 mutation	 profiles	 for	 each	 of	 the	 mice	 using	 variants	 called	 by	
HaploCaller.	 	We	 took	 the	 lists	 (146)	 previously	 outlined	 in	 8.2.3	 to	 prioritize	 looking	 for	
known	additional	risk	factors.	
The	majority	of	mice	contain	germline	variants	(non-synonymous,	non-frameshift,	or	
frameshift)	 across	 three	genes	associated	with	 sarcomas,	Cdk4,	Blm,	and,	Myocd	 the	 first	
two	of	which	are	associated	with	osteosarcomas,	the	 last	of	which	 is	associated	with	LMS	
(11).		
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Figure	 52:	 Germline	 variants	 in	 sarcoma	 predisposition	 genes	 in	mice.	 	 These	 data	 are	
compressed;	all	variants	indicated	are	predicted	to	be	damaging,	but	may	not	necessarily	
be	the	same	between	mice.		These	data	raise	the	possibility	that	they	could	contribute	to	
tumorigenesis.	 	However,	we	observe	no	LOH	of	these	variants	 in	the	tumor,	suggesting	
they	may	 be	 haploinsufficient	 (in	 conjunction	with	mutated	p53,	 or	 passengers.	 	 Key	 –	
“0/1”	 indicates	 a	 heterozygous	 variant,	 with	 the	 reference	 allele	 (“0”)	 and	 the	 most	
common	minor	allele	(“1”).		“./.”	indicates	insufficient	data	to	make	a	genotype	call,	often	
due	to	insufficient	coverage.		“0/0”	indicates	a	homozygous	reference/WT	genotype.	
The	overall	 relevance	of	 these	mutations	 is	difficult	 to	determine.	 	 It	 is	possible	 that	such	
germline	variants	contribute	to	the	osteosarcomas	observed	in	the	R172H	mouse	(51),	but	
we	do	not	see	LOH	at	these	positions	in	the	tumor,	suggesting	that	these	mutations	may	be	
haploinsufficient	(in	conjunction	with	mutant	p53),	or	that	they	could	be	merely	passengers.		
We	 also	 do	 not	 observe	 any	 strong	 predilection	 for	 mice	 in	 our	 cohort	 with	 germline	
variants	 in	Blm	and	Cdk4	 to	develop	osteosarcomas	over	 fibrosarcomas,	suggesting	at	 the	
very	least	they	are	not	driving	the	sarcoma	spectrum	towards	osteosarcomas.	
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Table	16:	Distribution	of	germline	variants	 in	Blm	and	Cdk4	by	 tumor	 type.	 	Both	genes	
have	 been	 previously	 associated	 with	 osteosarcomas,	 but	 in	 our	 mice,	 show	 no	
predilection	towards	OS	over	FS.	
	
Moreover,	 it	 is	 not	 known	 if	 these	 variants	may	 be	 polymorphisms	 (though	 they	 do	 not	
carry	dbSNP	IDs).	
We	 also	 examined	 our	mouse	 cohort	 for	 non-recurrent	 variation,	 looking	 at	 each	
mouse	individually	for	mutations	in	key	genes.		Three	mice	from	our	cohort	have	germline	
variants	 in	 sarcoma	 predisposition	 genes,	 and	 LOH	 in	 the	 tumor.	 	 RsH-F7-2	 (OS)	 has	 a	
nonsynonymous	SNV	in	Chek2	that	is	predicted	to	be	damaging	(p.G263C,	SIFT=0.04).		Both	
RsH-F7-12	 (OS)	 and	RsH-F8-70	 (OS)	 have	 the	 same	germline	mutation	 in	Bub1b,	 (p.L726I,	
SIFT=0.033),	 a	 gene	 associated	 with	 embryonal	 rhabdomyosarcoma	 and	 aneuploidy	 in	
humans	 (147),	 and	 LOH	 in	 the	 tumor.	 	 Interestingly,	 in	 humans,	 both	CHEK2	 and	BUB1B	
have	been	associated	with	chromosomal	 instability	(147-150).	 	Although	alterations	 in	the	
two	 genes	 are	 not	 considered	 sufficient	 for	 chromosomal	 instability	 (CIN)	 on	 their	 own	
(151),	these	mice	all	have	the	germline	mutation	in	p53	(and	LOH	in	the	tumor).	Thus,	it	is	
probable	that	some	germline	variants	in	these	genes	contributed	to	tumorigenesis	in	these	
mice,	 especially	 given	 their	 LOH	 in	 the	 tumors.	 	 While	 an	 accurate	 estimation	 of	 the	
penetrance	 of	 these	 germline	mutations	 in	 the	 context	 of	 an	 underlying	p53	mutation	 is	
preliminary,	 given	 the	 small	 sample	 size,	 no	 other	mice	 had	 these	 exact	 same	mutations	
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(including	as	a	germline	mutation	with	ROH	in	the	tumor),	suggesting	100%	penetrance	for	
these	specific	variants.				
8.3 RNA-seq	
Unfortunately,	 RNA	 extractions	 from	 fresh	 frozen	 tissues	 in	 the	 mouse	 produced	
sub-par	 RNA	 for	 the	 majority	 of	 tumors	 and	 could	 not	 be	 subjected	 to	 RNA-seq	
transcriptome	profiling.	
8.4 RRBS/Methylation	data	
RRBS	data	was	analyzed	in	conjunction	with	Dr.	Yue	Lu.	 	Data	for	RRBS	was	largely	
high	quality,	but	two	samples	did	not	pass	QC	(RsH-F2-4	FS,	RsH-F1-13	VL).		Therefore,	these	
were	eliminated	from	further	analyses.	
8.4.1 Principal	Components	Analysis	
Principal	components	analysis	(PCA)	of	top	1%	most	variable	sites,	across	all	
samples,	showed	roughly	three	distinct	groups	(Figure	53).		There	was	good	separation	
between	normal	femur	(FR)	and	muscle	(VL)	samples,	consistent	with	tissue-specific	
methylation.		Meanwhile,	the	majority	of	tumors	(FS,	OS)	seem	to	coalesce	into	a	third	
group	(towards	the	bottom	of	the	plot).		The	OS	that	are	not	part	of	this	third	group	do	
group	with	their	matched	tissues,	normal	femurs.	
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Figure	 53:	 PCA	 of	 RRBS	 methylation	 data.	 	 Samples	 cluster	 into	 three	 distinct	 groups,	
generally	comprised	of	FRs,	VLs,	and	tumors	(OS	and	FS).	 	A	couple	of	OS	do	group	with	
the	FR	samples.	
When	we	further	plotted	this	PCA	data	against	p53	LOH	status	from	the	
pyrosequencing	data,	we	do	not	see	much	additional	granularity	in	separating	the	tumor	
samples	(Figure	54).			Tumors	with	more	moderate	LOH	did	seem	to	group	together,	but	
there	continued	to	be	several	tumors	that	appeared	to	have	more	significant	LOH	that	
speckle	the	left	side	of	the	plot	and	were	grouped	with	the	femurs.		These	data	also	make	
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clear	that	two	presumably	normal	FRs	that	previously	showed	LOH	by	pyrosequencing	still	
appeared	to	group	with	normal	FRs	by	methylation,	suggesting	that	changes	to	the	
methylome	did	not	act	as	a	precursor	to	tumorigenesis.		
	
Figure	 54:	 PCA	 analysis	with	 the	 pyrosequencing	 LOH	 data	 laid	 over	 the	 top.	 	 There	 is	
some	modicum	of	 grouping	 of	 the	 samples	with	 pLOH	 that	 indicate	 the	 possibility	 of	 a	
dosage	effect,	but	one	FS	and	three	OS	sarcoma	samples	dot	the	left	side.	
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8.4.2 Recurrence	in	the	methylation	data	
Unlike	for	somatic	SNV	data,	we	see	many	of	the	same	changes	across	different	
mouse	tumors	from	a	methylation	perspective.		Due	to	tissue-specific	differences,	we	
considered	genes	that	were	differentially	methylated	across	all	tumors,	or	across	each	of	
FR/OS	and	VL/FS	pairs.		Multiple	genes	show	significant	hypermethylation	across	all	tumors,	
including	Hic1	(hypermethylated	in	cancer,	Table	17).		However,	of	more	immediate	note	is	
that	we	observed	substantial	hypermethylation	of	Mir219a-2	across	all	mouse	tumors.			
Table	17:	Methylation	data	in	the	mice	shows	significant	recurrence.		Overall,	recurrence	
was	much	higher	via	for	hypermethylation	vs.	hypomethylation.	Key:	NS	–	not	significant.	
	
There	have	been	no	published	studies	on	Mir219a2.		However,	in	human	cancers,	a	type	of	
sarcoma,	malignant	peripheral	nerve	sheath	tumors	(MPNST)	are	frequently	associated	with	
deep	deletions	(>6%,	Figure	55).		Therefore,	loss	of	Mir219a-2/MIR219A2	may	represent	a	
novel	key	player	in	sarcomagenesis.	
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Figure	55:	cBio	data	of	MIR219A2	(22).		Although	alterations	are	not	particularly	common	
across	all	tumor	types	and	studies	(partially	due	to	not	being	assayed),	deep	deletions	of	
MIR219A2	occur	in	almost	7%	of	MPNSTs,	a	type	of	sarcoma	and	mesenchymal	tumor.	
	 Several	other	genes	also	show	hypermethylation	across	multiple	tumors,	including	
Klf14,	Cdx1	and	Tcf15.			
8.4.2.1 KLF14	
KLF14	(Kruppel-like	factor	14)	has	been	identified	as	a	tumor	suppressor	gene.		In	
mice,	disruption	of	the	gene	leads	to	aneuploidy	and	spontaneous	tumorigenesis,	
particularly	via	centrosome	amplification,	a	common	event	in	cancer	resulting	the	presence	
of	extra	centrosomes.		Klf14	directly	targets	Polo-like	kinase	4	(Plk4),	considered	to	be	a	
master	regulator	of	centriole	replication.		In	MEFs,	Fan	et	al.	found	that	loss	of	KLF14	led	to	
genome	instability,	and	tumorigenesis,	while	gain	of	KLF14	led	to	cell	cycle	arrest	(152).		In	
contrast	to	published	work	on	KLF14,	a	big-picture	view	taken	from	the	cBio	database,	
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suggests	a	different	role.		Instead,	KLF14	appears	to	be	amplified	in	the	majority	of	cancers,	
including	sarcomas	(Figure	56).
	
Figure	56:	Alteration	frequency	of	KLF14	in	the	top	35	tumor	studies	in	cBio	((22)).	Contrary	
to	published	experiments,	suggesting	that	KLF14	acts	like	a	tumor	suppressor	gene,	multiple	
tumors	have	amplifications.	
Therefore,	given	recurrence	in	our	mouse	data,	and	strong,	published	functional	evidence	
indicating	a	role	in	genome	instability,	considered	a	hallmark	of	many	sarcomas,	KLF14	may	
be	particularly	interesting	for	additional	follow-up.	
8.4.2.2 Cdx1	
CDX1	has	a	known	role	in	gut	homeostasis	and	induction	of	Cdx1	speeds	up	cell	
proliferation	in	colon	cells,	suggesting	an	in	vitro	oncogenic	role.		Consistent	with	this,	the	
majority	of	colon	cancer	polyps	have	highly	expressed	CDX1	(153).		Moreover,	CDX1	is	a	
target	of	the	oncogenic	pathways	Ras	and	Wnt/β-catenin	pathway	as	well	as	being	a	known	
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regulator	of	the	Rho,	Ras,	and	PI3-Kinase	pathways	(153).		However,	our	data,	which	
indicate	Cdx1	is	hypermethylated	across	our	mouse	tumors,	is	not	consistent	with	this	view.	
Recent	research	indicates	the	role	of	Cdx1	may	be	considerably	more	complex.		For	
example,	although	the	majority	of	colon	polyps	have	highly	expressed	Cdx1,	about	20%	
have	lower	expression	of	Cdx1	(154).		Moreover,	in	mice	without	both	Cdx1	and	Cdx2,	
tumors	were	found	to	be	less	invasive,	and	less	differentiated	(154).		Coupled	with	LOF	
function	mutations	also	being	found	in	other	tumor	types,	such	as	carcinomas,	this	suggests	
that	CDX1	has	a	complex	role	in	tumorigenesis,	with	both	tumor	suppressive	and	oncogenic	
effects.			
8.4.2.3 TCF15	
_TCF15	(transcription	factor	15)	is	found	to	be	altered	in	about	1%	of	all	tumors	
catalogued	by	cBio	(22).		However,	the	available	data	somewhat	contradicts	each	other	–	in	
MPNSTs	(a	mesenchymal	tumor/sarcoma),	6.2%	harbor	deletions.		In	contrast,	in	the	TCGA	
sarcoma	(mostly	adult	STS)	study,	2%	of	cases	show	amplification	(5	cases),	while	0.5%	(1	
case)	show	deletions.		Additional	data	from	a	Memorial	Sloan	Kettering	Cancer	Center	
(MSKCC)	sarcoma	study	aligns	with	the	TCGA	data	(1.2%	(4	cases)	have	amplification,	0.3%	
(1	case)	has	a	deletion),	potentially	implying	that	TCF15	has	tumor	subtype	specific	
relevance.		Given	that	we	observe	hypermethylation	in	our	mice,	our	data	most	closely	line	
up	with	the	MPNST	data.		However,	this	runs	contrast	to	expectation	relative	to	known	
function.		Previously,	TCF15	has	been	associated	with	priming	and	accelerating	pluripotent	
cells	for	differentiation	through	repression	of	NANOG		(155).		Thus,	a	lack	of	TCF15,	such	as	
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via	hypermethylation	could	promote	tumorigenesis	through	evasion	of	a	more	limited	
replicative	potential	associated	with	differentiated	cells.	
9 Results:	Sequencing	of	Human	Samples	
	
We	received	several	human	sarcomas	from	Dr.	Strong,	spanning	a	variety	of	p53	mutations	
and	tumor	types	(Table	18).	
Table	18:	Table	of	human	LFS	sarcomas	and	omics	analyses	performed.	 	The	majority	of	
WGS/WES	data	was	generated	on	Illumina,	except	for	STS170-038	(Complete	Genomics).	
	
We	then	looked	at	several	different	kinds	of	next	generation	sequencing	(NGS).		For	
DNA,	 we	 looked	 at	 either	 at	 WGS,	 or	 at	 WES	 in	 conjunction	 with	 low-coverage	 WGS	
(lcWGS).	 	 The	 majority	 of	 the	 normal/tumor	 pairs	 were	 assayed	 on	 Illumina	 at	 40X/80X	
coverage	 respectively.	 	 One	 sample	 was	 assayed	 on	 the	 Complete	 Genomics	 platform	
(STS170-038).	Analysis	 for	 Illumina	samples	was	done	with	the	pipeline	outlined	 in	Figure	48.	
For	RNA,	we	were	unable	to	isolate	high-quality	RNA	from	fresh	tissues,	presumably	
due	 to	handling	at	 the	 time	of	 tumor	extraction	 (and	understandable	prioritization	of	 the	
patient),	 but	we	were	able	 to	 leverage	FFPE	 tissues	 instead	 to	acquire	 suitable	RNA.	 	 For	
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methylation	 data,	 we	 used	 the	 EPIC	 array	 (Illumina),	 and	 analyzed	 the	 data	 via	 the	 R-
package	minfi	 (156).	 	 Although	we	 still	 considered	 recurrence	 as	 an	 endpoint,	 analysis	 of	
both	RNA	and	methylation	data	is	further	complicated	by	sample	availability.		For	example,	
for	osteosarcomas,	we	would	ideally	sequence	a	tissue-matched	normal	bone,	rather	than	
the	muscle,	due	 to	 tissue	 specificity	 in	RNA	and	methylation.	 	We	can	get	around	 this	by	
sequencing	more	appropriate	 tissue	 controls	 (e.g.	 a	normal	osteoblast	 cell	 line),	but	 then	
these	normal	cell	line	controls	lack	the	underlying	p53	mutations	present	in	the	constitutive	
tissue.		Moreover,	recurrence	analysis	is	potentially	confounded	by	the	variety	of	underling	
tumor	 types	 and	 germline	 p53	 mutations,	 making	 it	 more	 likely	 that	 they	 could	 have	
different	underlying	mechanisms	of	sarcomagenesis.		Thus,	it	was	also	essential	to	consider	
individual	tumor	analysis	(6.2	&	6.3).	
9.1 Analysis	of	human	tumors	alone	reveals	minimal	recurrence	in	somatic	mutations	
Similar	 to	mouse	 samples,	we	 saw	 little	 overlap	 between	 the	 five	 somatic	 variant	
callers.		Using	similar	reasoning	as	8.1.1,	we	used	variants	that	were	found	by	two	or	more	
somatic	variant	callers.	
Table	19:	Table	showing	agreement	between	variant	callers	on	the	WES	human	data.	
	
	 130	
Initial	 analysis	 of	 the	 human	 tumors	 for	 recurrent	 somatic	 changes	 in	 the	DNA	 found	 no	
overlap,	either	at	the	mutation	or	gene	level,	with	the	exception	of	p53.				
The	 lack	of	overlap	could	arise	out	of	 several	 scenarios.	 	First,	given	 the	variety	of	
germline	mutations	and	tumor	types,	these	tumors	may	have	distinct	etiologies	from	each	
other.	 	 Secondly,	 tumor	 heterogeneity,	 clonality,	 and	 contamination	 from	 normal	 tissue	
may	obfuscate	variant	calling.	 	 Such	mutations,	occurring	 in	 just	a	 fraction	of	 the	sample,	
could	be	missed	without	using	deep	sequencing.	 	Thirdly,	 tumorigenesis	 in	 these	patients	
may	be	driven	by	something	other	than	somatically	acquired	SNVs	or	indels,	such	as	CNAs	
or	epigenetic	changes.	
Therefore,	 to	work	around	the	 fact	 that	 these	potentially	confounding	variables	as	
best	 as	 possible,	 we	 examined	 each	 of	 the	 tumors	 individually	 for	 both	 germline	 and	
somatic	variants.			
9.2 Some	human	tumors	had	additional	germline	variants	in	cancer	genes	
Analysis	 of	 germline	 variation	 did	 find	 two	 individuals	 with	 rare	mutations	 in	 key	
cancer-related	 genes.	 	 MGC900-001	 (p53	 R273H,	 breast	 cancer)	 had	 a	 mutation	 in	 the	
breast	cancer	predisposition	gene	CHEK2	(p.R180C,	MAF	<0.01%)	that	was	predicted	to	be	
damaging	 (SIFT=0.18,	 PP2=1).	 	 Notably,	 CHEK2	 had	 previously	 been	 associated	 with	 LFS	
(2.3.1).		A	second,	different	individual	(SMN119-000,	p53	del	ex	1-9)	had	a	mutation	in	the	
DNA	 repair	 gene	 MLH3	 (p.V741F),	 that	 was	 also	 relatively	 rare	 (MAF	 ~2%),	 and	 also	
predicted	to	be	deleterious	(SIFT=0.38,	PP2=0.933).		Although	neither	tumor	showed	of	the	
remaining	WT	allele,	they	may	still	contribute	to	the	overall	risk	profile	of	the	individuals	on	
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a	mutant	TP53	germline	background.		These	data	demonstrate	the	utility	in	looking	not	only	
at	acquired	somatic	mutations,	but	also	at	germline	variation.	
9.3 Individual	human	tumors	had	mutations	in	known	sarcoma	genes	
Individual	analysis	of	human	tumors	was	useful	not	only	at	 the	germline	 level,	but	
also	at	 the	somatic	 level.	 	 Individual	 sarcomas	had	notable	 somatic	mutations	 in	 sarcoma	
related	genes.		One	tumor	had	an	early,	heterozygous,	somatic	stop-gain	mutation	in	PTEN	
(p.G20X).		Given	that	PTEN	is	a	haploinsufficient	TSG	(157,	158),	such	a	mutation	would	be	
expected	 to	have	 functional	 consequences.	 	A	 second	 tumor	had	a	 stop-gain	mutation	 in	
NOTCH1.	 	 NOTCH1	 is	 a	 transmembrane	 receptor	 that	 is	 typically	 considered	 to	 be	 an	
oncogene,	 having	 been	 found	 to	 be	 up-regulated	 in	 synovial	 sarcomas	 and	
rhabdomyosarcomas	 (159)	 and	 abnormalities	 in	 Notch	 signaling	 have	 been	 linked	 with	
pediatric	sarcomas	(159).	
However,	in	the	majority	of	solid	tumors,	genetic	alterations	are	rare	in	any	member	
of	the	Notch	signaling	pathway.		Instead,	deregulation	of	Notch	signaling	may	play	a	larger	
role	 in	 tumor	 maintenance	 (159).	 	 Indeed,	 the	 role	 of	 Notch	 signaling	 is	 becoming	
considerably	more	complex	than	initially	suspected.		For	example,	NOTCH1	has	been	shown	
to	be	activated	in	some	osteosarcomas	(160),	but	in	other	cases,	it	has	also	been	shown	to	
have	 tumor	 suppressive	 properties	 (161),	 suggesting	 a	 highly	 context-dependent	 role	 for	
Notch	signaling	that	may	be	either	oncogenic	or	tumor-suppressive	(161).	
Overall,	 the	 lack	 of	 consensus	 in	 the	 human	 samples,	 possibly	 due	 to	 tumor	 type	
heterogeneity,	may	argue	for	a	different	approach.		Rather	than	use	the	human	samples	as	
a	 discovery	 set,	 and	use	 the	mouse	model	 to	 confirm	 recurrent	 changes,	 do	 the	 reverse.		
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Use	tumors	from	the	mouse	model,	where	the	mutation,	tumor	types,	and	environment	are	
more	consistent,	to	look	for	recurrence,	and	follow-up	in	the	human	tumors.	
9.4 Copy	number	analysis	in	human	data	
Alternatively,	other	 types	of	 alterations	may	explain	 the	 lack	of	 consensus	 seen	 in	
somatic	mutations.		Chromosomal	instability	is	considered	to	be	hallmark	of	sarcomas	(10).		
We	 worked	 with	 Dr.	 Nicholas	 Navin	 and	 a	 graduate	 student	 of	 his,	 Naveen	 Ramesh,	 to	
generate	 copy	 number	 analyses	 using	 our	 WES	 and	 lcWGS	 data	 and	 their	 pipeline.		
Consistent	with	previously	published	data,	we	observed	copy	number	alterations,	especially	
across	our	tumors	with	point	mutations	in	p53	(Figure	57).		Our	data	is	generally	consistent	
with	 reported	 data	 for	 sarcomas	 in	 that	 deletions	 are	more	 common	 than	 amplifications	
(10).		Both	MGC900-001	and	SMN669-000	tend	to	have	more	deletions	than	amplifications,	
but	 this	was	 less	 true	 for	 SMN1012-000	 and	 STS170-000,	where	 amplifications	may	 have	
been	more	prevalent.	
This	effect	was	less	pronounced,	or	even	non-existent	in	tumors	we	sequenced	that	
had	p53	deletions	(Figure	 58).	 	These	data	may	partially	explain	the	lack	of	somatic	point	
mutations	observed	 in	our	human	tumor;	 larger	events	may	be	driving	sarcomagenesis	 in	
these	patients.	
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Figure	57:	Copy	number	analysis	of	human	tumors	with	point	mutations	in	p53	indicates	
significant	 copy	 number	 aberrations	 in	 human	 LFS	 tumors.	 	 Data	 generated	 in	
collaboration	with	Naveen	Ramesh	(Dr.	Nicholas	Navin	lab).	 	Grey	lines	represent	ploidy	
determinations,	 while	 blue	 lines	 represent	 copy	 number	 calls.	 	 Red	 horizontal	 lines	
represent	1N,	2N,	3N,	and	4N	from	bottom	to	top	respectively.	
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Figure	 58:	 Copy	 number	 analysis	 of	 human	 tumors	 with	 deletions	 in	 p53	 indicates	
relatively	 few	copy	number	aberrations	 in	 some	human	LFS	 tumors.	 	Data	generated	 in	
collaboration	with	Naveen	Ramesh	(Dr.	Nicholas	Navin	lab).	 	Grey	lines	represent	ploidy	
determinations,	 while	 blue	 lines	 represent	 copy	 number	 calls.	 	 Red	 horizontal	 lines	
represent	1N,	2N,	3N,	and	4N	from	bottom	to	top	respectively.	
	
9.5 Analysis	of	methylation	data	showed	two	distinct	profiles	
	
For	 human	 methylation	 data,	 we	 used	 Illumina’s	 HumanMethylationEPIC	 (EPIC)	
array	 on	 the	 same	 DNA	 that	 we	 used	 to	 perform	 WES	 and	 lcWGS.	 	 To	 analyze	 human	
methylation	 data,	 we	 used	 the	minfi	 R-package	 and	 ssnoob	 pre-processing,	 followed	 by	
bumphunter	 to	 find	differentially	methylated	 regions	 (DMRs)	as	described	by	Fortin	et	 al.	
(162).	
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The	method	calls	 for	a	minimum	default	 cutoff	of	0.2	 (i.e.	a	20%	difference	 in	 the	
beta-values	 between	 normal/tumor),	 but	 for	 some	 samples	 this	 led	 to	 hundreds	 of	
thousands	of	candidate	bumps	and	long	compute	times.		Since	past	a	certain	point,	results	
are	 less	 likely	 to	 be	 considered	 significant	 after	 adjusting	 for	 multiple	 testing	 and	
permutations,	the	general	consensus	is	to	increase	the	cutoff	(in	our	case	up	to	about	a	50%	
difference	 in	 beta	 values),	 in	 order	 to	 drive	 the	 number	 of	 candidate	 bumps	 (without	
consideration	of	p-value)	down	to	~30,000-40,000.	 	We	can	see	then	some	normal/tumor	
pairs	 have	 very	 few	 DMRs	 (SMN1119-000,	 and	 STS170-000),	 while	 others	 must	 have	
exceedingly	 high	 thresholds	 for	 the	 difference	 between	 beta-values	 (up	 to	 54%,	 STS170-
038),	as	seen	in	Table	20.	
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Table	20:	Table	of	human	samples	with	EPIC	array	data,	 indicating	sex,	age,	and	normal	
and	tumor	tissue	types,	and	the	number	of	bumps	and	DMRs	identified	by	the	pipeline.		
We	note	that	the	#	of	DMRs	may	be	somewhat	artificial	since	the	pipeline	uses	#	of	DMRs	
to	help	generate	appropriate	parameters.		PBL	–	peripheral	blood	leukocytes,	BR	–	breast,	
FR	–	femur,	MLPS	–	myxoid	liposarcoma,	OS	–	osteosarcoma,	SC	–	sarcomatoid	carcinoma,	
SCC	–	spindle	cell	carcinoma,	LPS	–	liposarcoma,	MFS	–	myofibrosarcoma,	RCC	–	renal	cell	
carcinoma.	
	
However,	 some	 of,	 or	 perhaps	 even	 the	 majority	 of	 these	 DMRs	 may	 be	 due	 to	 tissue-
specific	differences	(163).	 	As	an	alternative,	 it	may	be	better	to	ascertain	DMRs	against	a	
tissue-matched	control	from	a	different	person,	or	cell	line.	
9.6 Recurrence	analysis	in	human	methylation	data	
	
Confounding	 information	 aside,	 there	 did	 appear	 to	 be	 some	 recurrence	 at	 the	
methylation	level.	We	found	no	DMRs	that	were	consistent	across	all	pairs,	with	the	top	five	
hypomethylated	genes	including	LHFPL2,	PTPRN2,	NRG1,	ESR1,	and	JARID2,	and	the	top	five	
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hypermethylated	genes	including	FOXN3,	TWIST1,	TCF4,	ST7,	and	MICAL3.		However,	we	did	
not	see	any	overlap	with	the	mouse	data.			
These	methylation	data	represent	an	interesting	cross-section	of	genes	of	the	genes	
that	are	hypomethylated,	 LHFPL2	 is	a	 transmembrane	protein	 that	 is	 lightly	altered	when	
examined	 in	cBio	 (<10%	of	any	tumor	type	affected),	across	both	amplification,	deletions,	
and	mutations,	suggesting	potentially	tumor	or	environment	specific	effects.	PTPRN2	 is	an	
oncogene	that	has	been	associated	with	promoting	migration	in	breast	cancer	(164),	while	
ESR1	is	thought	to	act	as	a	tumor	suppressor	gene	(165).		NRG1	has	also	been	connected	to	
breast	cancer	where	it	has	been	shown	to	induce	stem-like	properties	(166).		Recently,	Xi	et	
al.	 demonstrated	 that	 knock	 down	 of	 JARID2	 inhibited	 invasiveness	while	 overexpression	
promoted	 in	 in	 bladder	 cancer	 cells	 (167).	 	 Thus,	 many	 of	 the	 genes	 that	 are	
hypomethylated	appear	to	have	oncogenic	functions.	
In	concert	with	this,	some	of	 the	hypermethylated	genes	generally	appear	to	have	
tumor	suppressor-like	functions.		Loss	of	FOXN3	in	colon	cancer	was	found	to	activate	beta-
catenin	signaling	and	promote	cell	growth	and	migration	(168).		ST7	has	been	identified	as	a	
tumor	 suppressor	 gene	 in	 prostate	 cancer	 (169).	 	 On	 the	 other	 hand,	 TWIST1	 is	 more	
commonly	considered	an	oncogene	that	induces	EMT	(170).		MICAL2	 is	also	considered	an	
oncogene	and	has	been	associated	with	metastatic	progression	and	a	potential	regulator	of	
EMT	(171).	
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9.7 Individual	analysis	in	human	methylation	data	
	
SMN669-000	 had	 significant	 hypermethylation	 upstream	 of	 MLH1	 (shore,	 p-
value=7.30e-4),	and	a	CpG	island	of	PTEN	that	is	upstream	of	the	transcription	start	site	by	
less	than	1,500	bp	(p-value:	5.26E-04).			
	
10 Discussion	and	Future	Directions	
Overall,	when	looking	at	the	data	we	saw	little	recurrence	between	human	samples,	
but	significant	recurrence	between	the	mouse	samples.		This	is	consistent	with	the	idea	that	
different	p53	 alleles	 have	 different	 penetrances,	 and	 considering	 that	 different	 sarcomas	
may	 have	 different	 etiologies	 (10,	 15,	 172),	 this	 may	 not	 be	 too	 surprising.	 	 An	 overall	
examination	 of	 the	most	 recurrent	 hits,	 including	 prioritizing	 for	 variation	 found	 in	 both	
humans	and	mice	emphasizes	this	(Table	21).	
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Table	21:	Recurrence	across	both	human	and	mouse	sarcomas,	across	all	data	types.	
	
Thus,	these	data	underscore	the	power	of	our	comparative	–omics	approach	–	not	
necessarily	because	of	the	ability	to	cross-compare	human	and	mouse	data	and	determine	
overlapping	recurrence	between	the	two,	but	because	the	mouse	platform	is	so	much	more	
stable.	 	 For	 rare	 diseases/tumors	 such	 as	 LFS/sarcomas,	 the	 reduction	 of	 confounding	
factors	 (e.g.	 genetic	 heterogeneity)	 can	 be	 a	 powerful	 discovery	 space.	 	 For	 example,	
MIR219A2	 is	 recurrently	 hypermethylated	 in	 all	 mouse	 tumors,	 which	 we	 then	 found	 to	
have	a	deep	deletion	in	sporadic	MPNSTs.			
In	 contrast,	 many	 tumors	 across	 mice	 and	 human	 showed	 alterations	 at	 the	
germline,	somatic	or	methylation	level	in	well–known	sarcoma	genes	like	PTEN.		If	these	are	
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sufficient	 on	 their	 own	 to	 lead	 to	 sarcomagenesis,	 it	 reduces	 the	 value	 in	 looking	 for	
recurrence	 in	 trying	 to	 identify	novel	 cancer	 genes.	 	However,	 this	 does	not	mean	 that	 a	
comparative	approach	 is	without	merit.	 	The	Cancer	Gene	Census	currently	 identifies	610	
genes	 (https://cancer.sanger.ac.uk/census),	 and	 represents	 a	 good	 baseline	 for	 the	 low-
hanging	fruit.		However,	it	is	important	to	note	that	there	likely	are	additional	undiscovered	
cancer	genes	 that	can	be	 found,	particularly	using	a	case	study	approach.	 	 Increasingly,	 it	
appears	that	cancer	subtypes	may	have	distinct	etiologies,	including	in	sarcomas	(10,	15).			
Additionally,	 one	 way	 to	 further	 identify	 novel	 cancer	 genes	 may	 be	 to	 look	 for	
genes	 that	 cooperate	 with	 known	 players	 such	 as	 p53.	 	 Previously,	 we	 discussed	 the	
possibility	 that	while	 disruption	 of	 key	 pathways	 is	 often	 considered	 to	 be	 a	 hallmark	 of	
cancer	(2,	54,	139),	pathways	often	have	built-in	redundancies,	and	a	single	alteration	may	
be	 insufficient	 for	 tumorigenesis	 (140).	 	 Alternatively,	 it	 may	 be	 that	 additional	 p53	
cooperating	mutations	may	contribute	to	tumor	type	and/or	spectrum.		Although	we	found	
no	evidence	for	this	in	our	data	–	we	had	no	mutations/alterations	that	were	found	only	in	
fibrosarcomas	vs.	osteosarcomas,	 it	 is	possible	that	a	relative	small	sample	size	somewhat	
obscures	 these	 data,	 or	 that	 considering	 multiple	 alterations	 may	 have	 more	 predictive	
power.		
Overall,	our	data	agrees	with	previously	published	data	–	sarcomas	have	relatively	
low	 point	mutation	 burdens,	 but	many	 have	 significant	 copy	 number	 aberrations	 (CNAs)	
(10,	15).	 	 Intriguingly,	 in	our	data,	patients	with	germline	point	mutations	 in	p53,	 tend	 to	
have	more	 CNAs	 than	 those	 with	 large	 deletions.	 	 It	 is	 not	 clear	 if	 this	 could	 be	 due	 to	
sample	purity,	or	if	p53-deletion	sarcomas	are	simply	more	CN-stable.		One	other	possibility	
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is	that	the	type	of	mutation	may	matter;	while	point	mutations	may	be	either	GOF	or	LOF,	
deletions	are	 LOF	only.	 	 This	 concept	 is	not	addressed	 in	 the	TCGA	paper	and	may	be	an	
interesting	point	for	follow-up.	
Overall,	the	data	from	TCGA	(10)	highlight	the	need	to	consider	tumor	subtypes	an	
important	factor	in	all	sequencing	analyses.		This	significantly	complicates	sarcoma	research	
moving	 forward,	 requiring	 expertise	 across	 a	 variety	 of	 fields,	 ranging	 from	 accurate	
sarcoma	 subtyping	 from	 the	 pathologist	 to	 doctors	 to	 comprehensive	 sequencing	 and	
analysis	by	bioinformatics	specialists.		Moreover,	our	data	and	published	TCGA	data	indicate	
that	any	of	a	number	of	factors	from	point	mutations,	to	CNAs,	to	methylation	profiles	likely	
contribute	to	sarcomagenesis.	
If	 all	 sarcoma	 subtypes	 have	 different	 drivers,	 this	may	make	 it	 a	 cost-prohibitive	
endeavor	or	time-insensitive	project,	due	to	the	need	to	acquire	dozens	of	samples	of	the	
same	type.		Our	data	indicate	a	role	for	using	a	mouse	model	to	identify	potential	sarcoma	
drivers,	but	we	have	 focused	on	osteosarcomas	and	 fibrosarcomas	–	generating	a	mouse	
model	 for	 even	 rarer	 types	 may	 not	 be	 possible.	 	 Alternatively,	 given	 sufficient	 time	
clinicians	 may	 collect	 enough	 samples	 from	 human	 patients	 to	 complete	 such	 a	 study.		
Importantly	though,	we	have	used	our	data	to	 identify	potential	 impact	players	which	are	
both	 novel	 (e.g.	 MIR219A2,	 and	 with	 known	 roles	 in	 other	 cancers	 such	 as	 PTEN	 and	
BUB1B).	 	 Some	 of	 these	 have	 appeared	 to	 be	 common	 to	 both	 osteosarcomas	 and	
fibrosarcomas,	 suggesting	 the	 potential	 that	 some	 drivers	 may	 be	 common	 to	 multiple	
sarcomas.	 	 Thus,	 a	 comparative	 omics	 approach	 gives	 tremendous	 value	 to	 focusing	 on	
sequencing	 more	 common	 sarcoma	 types	 first.	 	 Given	 that	 the	 end	 goal	 is	 to	 identify	
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important	genes,	which	in	turn	may	impact	clinical	outcomes,	this	may	be	sufficient	to	begin	
impact	treatment.	
Secondly,	 our	 data	 indicate	 that	 genetic	mutations	 even	 in	 known	 sarcoma	 genes	
such	 as	PTEN	 are	 generally	 rare	 across	 our	 samples,	 underlying	 an	 important	 point	 –	 the	
majority	 of	 sarcomas	 have	 low	 point	mutation	 loads	 and	 instead	 are	 considered	 to	 have	
significant	 copy	 number	 aberrations	 (10).	 	 In	 addition,	 some	 sarcoma	 subtypes,	 such	 as	
synovial	 sarcoma	 subtypes	 had	 relatively	 uniform	methylation	 profiles	 (10).	 	We	 noticed	
consistent	 patterns	 in	 our	 mouse	 methylation	 data,	 including	 some	 genes	 that	 were	
recurrently	 hypermethylated	 and	 a	 PCA	 analysis	 that	 grouped	 both	 osteosarcomas	 and	
fibrosarcomas	together.	 	Moreover	several	of	 the	top	hits	 in	 the	human	methylation	data	
had	known	functions	in	cancers.		We	highlighted	four	oncogenes	that	were	hypomethylated	
(e.g.,	 PTPRN2,	 JARID2),	 and	 two	 tumor	 suppressor	 genes	 were	 hypermethylated	 (e.g.,	
FOXN3,	 ST7).	 	 Thus,	 we	 feel	 that	 future	 sarcoma	 studies	 should	 consider	 focusing	 on	
methylation	data	over	genomic	sequence	analysis	of	point	mutations.	
We	continue	to	look	for	ways	to	iterate	over	this	process	to	better	understand	this	
dichotomy	of	looking	for	recurrence	first,	or	characterizing	an	individual	tumor.	
11 Conclusions	
	
In	conclusion,	we	have	identified	a	novel	germline	LFSL	mutation	in	ARHGAP30	that	co-
segregates	with	 disease	 across	multiple	 LFSL	 families	 (four	 total	 to	 date).	 	Moreover,	we	
have	demonstrated	that	this	mutation,	ARGAHP30	(c.G161,017,761A,	p.R806Q/p.R1017Q),	
has	 functional	 impact	when	 overexpressed	 in	 vitro	 for	 both	 the	 short	 and	 long	 isoforms,	
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suggesting	that	ARHGAP30	may	have	p53-independent	functions.		To	further	strengthen	our	
case,	 we	 are	 currently	 sequencing	 additional	 LFSL	 families	 to	 see	 if	 they	 contain	 other	
mutations	 in	 elsewhere	 in	ARHGAP30,	 and	 testing	 tumors	 to	 see	 if	 they	have	 LOH.	 	 Both	
results	 substantially	 strengthen	 the	 identification	 of	 ARHGAP30	 as	 an	 LFSL	 gene	 and	 an	
important	gene	for	clinical	testing	for	patients	and	families	with	LFS/LFSL	phenotypes.		Our	
hope	 and	 intention	 is	 that	 this	 will	 allow	 for	 genetic	 testing	 and	 improved	 tumor	
surveillance	in	individuals	who	have	this	genetic	germline	cancer	predisposition.		
Secondly,	 we	 have	 demonstrated	 the	 utility	 of	 a	 comparative	 –omics	 approach	 to	
identify	 potential	 key	 players	 in	 sarcomagenesis.	 	 Recent	 research	 by	 TCGA	 emphasizes	
tissue	 specificity	 in	 adult	 soft	 tissue	 sarcomas	 (10),	 and	 suggests	 significant	 value	 in	
sequencing	 similar	 sarcoma	 types.	 	We	 were	 able	 to	 leverage	 a	 mouse	model	 of	 LFS	 to	
identify	 two	novel	genes,	Mroh2a,	 and	Mir219a-2	as	potential	players	 in	 sarcomagenesis,	
the	 latter	 of	which	 has	 relevance	 to	MPNSTs	 (145).	 	 Strikingly,	 although	we	 observe	 few	
overlaps	in	somatic	mutations	(at	the	base	or	gene	level),	we	do	observe	significant	overlap	
at	 the	 methylation	 level,	 including	 between	 tumor	 types,	 suggesting	 that	 epigenetic	
instability	may	be	critically	important,	consistent	with	p53	as	the	guardian	of	the	epigenome	
(18).	 	Across	both	our	mouse	and	human	tumors,	we	see	recurrent	epigenetic	changes	 in	
both	novel,	and	known	cancer	genes.	
However,	 our	 data	 also	 indicate	 that	 all	 types	 of	 -omics	 approaches	 can	 point	 to	
alterations	 in	key	genes,	and	 that	 these	may	be	 relatively	private.	 	 In	 combination	with	a	
large	 existing	 knowledge	 base	 in	 cancer,	 these	 “private”	 alterations	 may	 be	 considered	
generally	sufficient	to	explain	tumorigenesis.		We	note	that	it	is	possible	that	these	tumors	
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have	 other	 mutations	 that	 contribute	 to	 cancer	 in	 smaller	 ways,	 or	 may	 be	 involved	 in	
cancer	 initiation	 as	 opposed	 to	 cancer	 progression.	 	 However,	 that	 these	 mutations	 are	
found	in	bulk	tumor	suggests	that	they	occur	 in	a	 large	proportion	of	sequenced	cells	and	
may	be	more	likely	to	be	key	drivers	rather	than	late-comers.		Thus,	recurrence	should	not	
be	used	as	the	only	endpoint	when	considering	sequencing	studies.	
In	 conclusion,	 based	 on	 our	 collective	 data	we	would	 argue	 that	 to	 best	 understand	
sarcomagenesis	moving	 forward,	one	 should	 focus	on	 complete	 tumor	profiling	 in	 as	 few	
subtypes	as	possible.		Furthermore,	we	would	recommend	an	emphasis	on	evaluating	CNAs	
and	methylation	profiles,	ultimately	 suggesting	 there	 is	 still	 strong	utility	 in	using	LFS	and	
LFSL	as	model	disorders	 to	 identify	 variation	 that	 is	 important	not	only	 for	 sarcomas,	but	
potentially	other	tumors	as	well.	
12 Materials	and	methods	
12.1 Subjects		
Tissues	and	genomic	DNA	were	kindly	provided	by	Dr.	Louise	Strong’s	lab	(MD	Anderson	
Cancer	Center),	Dr.	Henry	Lynch’s	lab	(Creighton	University),	Dr.	Albert	de	la	Chapelle’s	lab	
(Ohio	State	University),	and	Dr.	Mai	Phuong’s	lab	(National	Cancer	Institute).	
12.2 WGS/WES	
WGS	data	were	sequenced	at	100bp	PE	across	three	platforms	GAIIX	(STS200-017),	HS2000	
(STS200-000,	STS200-017,	STS032-011),	and	HS4000	(STS200-001,	STS200-008,	STS200-009,	
STS200-019,	STS200-108)	at	30-40X.		Remaining	normal/tumor	pairs	on	mice	were	
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sequenced	on	HS3000	at	40X/80X	respectively.	Samples	were	analyzed	according	to	best	
practices	as	described	by	GATK	or	individual	algorithms.	
12.3 Sanger	sequencing	
Primers	were	designed	in-house,	and	PCR	performed	according	to	standard	protocols	
(HotStarTaq	Master	Mix	kit,	QIAGEN).		PCR	products	were	cleaned	using	Diffinity	RapidTIps	
(Sigma)	for	small	experiments,	or	via	ethanol	precipitation	for	full	plates	before	submission	
to	the	Sequencing	and	Microarray	Facility	(SMF)	at	MD	Anderson	Cancer	Center.		
Sequencing	was	generated	in	both	directions.		Traces	were	analyzed	with	Mutation	
Surveyor.	
	
hARHGAP30	R806Q	F	CCACAGTTTGCCAAGATGCC	
hARHGAP30	R806Q	R	GGTCCTAATCACAGTCCTTCAC	
	
hARHGAP30-UTR	F	 tgtaaaacgacggccagtTCTCTTCCTTATTTCCTGACC	
hARHGAP30-UTR	R	 caggaaacagctatgaccCCCTAAGATACCTCCTGTCC	
	
hF11R	F	 	 tgtaaaacgacggccagtTCTAAGGAGGAAGTAGGAAAGG	
hF11R	R	 	 caggaaacagctatgaccTCTGCTCTTCCCAAGTTGTG	
	
hMROH9	F	 	 tgtaaaacgacggccagtATGACCAATATGAACCTCTTCC	
hMROH9	R	 	 caggaaacagctatgaccAAGACATTGTTGGACTTCCC	
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hMUC5B	F	 	 tgtaaaacgacggccagtAGTTCCAAAGCCACTTCCTC	
hMUC5B	R	 	 caggaaacagctatgaccCTGTAAAGCTGGTAGCTGTG	
	
hNDUFS2	F	 	 tgtaaaacgacggccagtAAGACTACAGGGTTTATATGGG	
hNDUFS2	R	 	 caggaaacagctatgaccCAGAAGAATTGCTTGAACCTG	
	
hPARP4	F	 	 tgtaaaacgacggccagtCCATAGAATAACAAACTCTGCGTC	
hPARP4	R	 	 caggaaacagctatgaccTCTGGATGGAGCATTGAAAGAG	
	
hPKLR	F	 	 tgtaaaacgacggccagtTGATACAAATGGTAGGAGTGG	
hPKLR	R	 	 caggaaacagctatgaccGCCCAGAGAAGTATGATGAC	
	
hRETSAT	F	 	 tgtaaaacgacggccagtCCTGTCAGATAGAGGTTGGG	
hRETSAT	R	 	 caggaaacagctatgaccTGTTTCTGCCCTTTCCTTGAG	
	
hSLAMF1	F	 	 tgtaaaacgacggccagtCAACACAAAGATGGAACGCTG	
hSLAMF1	R	 	 caggaaacagctatgaccATGCTTATGCTTGGAAGGGAG	
	
hTP53-UTR3	F		 tgtaaaacgacggccagtTTAAATCCCGTAATCCTTGGTGAG	
hTP53-UTR3	R		 caggaaacagctatgaccTTACATTCTGCAAGCACATCTG	
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12.4 Mutation	Surveyor	
We	ran	both	the	default,	recommended	settings,	as	well	as	a	set	of	hyper-relaxed	criteria	
that	picked	to	pick	some	true	positives	at	the	cost	of	a	lot	of	false	positives.	
Because	some	genes	are	highly	homologous	(e.g.	PYHIN1),	we	supplied	known	sequence	to	
the	program	for	such	genes	to	force	the	correct	mapping	and	eliminate	erroneous	variant	
calls.			
12.5 454	sequencing	
Pyrosequencing	was	performed	on	a	PSQ	96	machine,	according	to	manufacturer’s	
instructions.	20ng	of	DNA	was	amplified	by	PCR	before	use	with	pyrosequencer.	For	FFPE	
samples,	we	used	three	times	as	much	polymerase	as	we	would	for	a	normal	PCR,	and	ran	
the	annealing	step	in	the	cycle	for	two	minutes.	
	
hARHGAP30	F		TAAGACGACTCCGGGATCCAG		
hARHGAP30	R		 GACGGGACACCGCTGATCGTTTATCCCGAGCTTCTCGATCCT	 	
hARHGAP30	Seq		 TCAGTACAGGTCTGGGT	 	 	
	
mP53H	F	 	 GGCCATCTACAAGAAGTCACAGCA	
mP53H	R	 	 GACGGGACACCGCTGATCGTTTAAGGCGGTGTTGAGGGCTTA	
mP53H	Seq	 	 GACGGAGGTCGTGAGA	
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12.6 Cell	lines	
Four	cell	lines	(HEK293T,	Saos-2,	U-2	OS,	and	HT-1080)	were	acquired	from	the	
characterized	cell	line	core	facility	at	MD	Anderson	Cancer	Center.		The	core	provides	
mycoplasma-free,	and	fingerprinted	cell	lines.	
	
12.7 Mice.		
Existing	Trp53	R172H	mice	were	bred	to	create	a	total	cohort	of	50	mice	with	a	
heterozygous	background.		Twenty	WT	mice	were	kept	as	controls.		Mice	were	monitored	
continuously	for	tumors	and	other	health	issues,	and	sacrificed	when	necessary.		Original	
mice	were	received	from	Dr.	Guillermina	Lozano	and	are	on	a	predominantly	C57BL/6	
background.	
12.8 Genotyping	
Mouse	toes	are	collected	at	7-10	days	and	digested	with	KAPA	enzyme	(Sigma)	in	15uL	total	
volume.		Final	volume	is	brought	up	to	100uL.		DNA	is	then	assayed	by	PCR	and	run	on	an	
agarose	gel	to	look	for	band	separation	in	heterozygotes.	
	
mp53H	F		 ACCTGTAGCTCCAGCACTGG	
	
mp53H	R		 ACAAGCCGAGTAACGATCAGG	
	
12.9 Tissue	collection	
Mice	were	euthanized	by	cervical	dislocation	to	best	preserve	RNA	(over	CO2	inhalation).		
Tissues	were	then	immediately	collected	by	snap	freezing	in	liquid	nitrogen:	pectoralis,	
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vastus	lateralis,	femur,	gastrocnemius,	kidney,	spleen,	liver,	stomach,	duodenum	or	fixed	in	
paraformaldehyde	for	pathology:	gastrocnemius,	reproductive	organs,	digestive	tract,	
heart,	lung,	thymus,	head/brain,	kidney,	liver,	spleen,	leg,	sternum,	spine.		Lymph	nodes	
and	tumors	were	collected	where	possible.		All	tissues	were	sent	to	Elizabeth	Whitley	
(Pathogenesis	LCC)	for	pathology	
	
12.10 DNA	isolation	
DNA	was	harvested	from	fresh	frozen	tissues	using	a	mini-prep	kit	(Zymo)	according	to	
manufacturers	instruction,	with	one	exception.		Lysis	was	accomplished	through	gentle	
rotation	in	a	LabQuake	shaker	to	avoid	shearing	of	high-molecular	weight	DNA	during	
inversion,	or	vortexing.	DNA	was	assayed	for	genomic	integrity	by	agarose	gel	(0.8%,	20V),	
and	quantitated	using	PicoGreen	(Molecular	Probes)	
	
12.11 FFPE	RNA	isolation	
We	cut	10,	10um	sections	with	a	microtome.		RNA	was	isolated	according	to	kit	instructions	
for	ReliaPrepTM	FFPE	Total	RNA	Miniprep	System.	
	
12.12 Plasmids	
We	acquired	constructs	for	the	short	isoform	(NM_181720,	Origene	C/N	RC208825)	and	the	
long	isoform	(NM_0010255598,	Origene	C/N	RC217735).		Sanger	sequencing	was	used	to	
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confirm	the	appropriate	sequence	in	the	original	plasmid.			Plasmids	were	expanded	using	
Ultra	Competent	XL10	cells	(Stratagene),	and	DNA	was	isolated	using	
Maxi	kits	(QIAGEN),	as	per	kit	instructions.	
	
12.13 Site	Directed	Mutagenesis	
Plasmids	containing	the	mutant	were	generated	through	site-directed	mutagenesis	(Agilent)	
according	to	the	kit,	and	checked	for	correct	sequence	via	Sanger	sequencing.	Plasmids	
used	for	mutagenesis:		
F:	CTCAAGGAGTTCGGCGAACCCAGACCTGTAC	
R:	GTACAGGTCTGGGTTTGCCGAACTCCTTGA	
	
12.14 Scratch	Assay	
Cells	were	initially	seeded	in	12-well	plates	at	~60-70%	confluency.		Following	overnight	
attachment,	transfection	reagent	(Lipofectamine	2/3000,	or	FuGene	6)	and	plasmid	were	
added	at	3:1	ratio	according	to	kit	instructions.		24	hours	post	transfection,	cells	were	
checked	to	see	if	they	had	achieved	near	100%	confluency.		A	single	vertical	scratch	was	
made	with	a	P20	pipette	tip.		Cells	were	then	washed,	and	imaged	immediately	with	a	live-
cell	imaging	microscope	(Zeiss,	3i).		Images	were	taken	every	30	minutes	for	a	period	up	to	
48	hours.			
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12.15 Proliferation	Assay	
Cells	were	seeded	in	triplicate	in	96-well	plates	at	low	density	at	an	average	concentration	
of	approximately	10,000	cells/well.		Once	cells	attached,	we	transfected	according	to	the	kit	
instructions	(Lipfectamine	2/3000,	ThermoFisher;	FuGene6,	Promega).		Cells	were	then	
trypsinized,	and	counted	twice/well	using	a	hemacytometer	and	trypan	blue	(GIBCO).		Cells	
were	counted	approximately	every	24	hours.	
	
12.16 Western	Blots	
Protein	extracts	(30ug)	from	transfected	cells	were	run	on	pre-made	polyacrylamide	gels	
(Invitrogen),	transferred	to	nitrocellulose	(BioRad)	and	probed	with	antibodies	for	
ARHGAP30	(Abcam,	ab101965)	and	FLAG	(Sigma,	F3165).		Appropriate	secondary	antibodies	
came	from	Odyssey.		Blots	were	imaged	on	a	Li-Cor	(Odyssey).	
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